Vector constructs for delivery of nucleic acids encoding therapeutic anti-IGF-1R antibodies and methods of use thereof

Through the delivery of rAAV vector encoding anti-IGF-1R antibodies, the problem of large burden of teitumumab and low efficiency of gene therapy was solved, and long-term expression of anti-IGF-1R was achieved, significantly reducing IGF-1R expression and effectively treating Grave orbital disease and thyroid eye disease.

CN118974085APending Publication Date: 2024-11-15KRIYA THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380024990.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-09-07
Filing Date
2023-01-09
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

In the existing methods for treating Graves orbital disease and thyroid eye disease, intravenous infusion of teitumumab requires multiple times, resulting in a high burden on patients, and the inefficiency of viral vectors in gene therapy and the lack of target cell specificity. Not effectively resolved.

Method used

Developed recombinant adeno-associated virus (rAAV) vectors encoding anti-insulin-like growth factor 1 receptor (IGF-1R) antibodies or antigen-binding fragments thereof for gene therapy, delivered to target cells through vectors, expressing anti-IGF-1R antibodies to Inhibit disease-related signaling.

Benefits of technology

Long-term expression of anti-IGF-1R antibodies is achieved through a single injection, reducing the treatment burden, and improving the efficiency of gene therapy and target cell specificity, significantly reducing the expression and phosphorylation levels of IGF-1R, effectively treating Graves orbital disease and Thyroid eye disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005022576090000531
    Figure BDA0005022576090000531
  • Figure BDA0005022576090000532
    Figure BDA0005022576090000532
  • Figure BDA0005022576090000533
    Figure BDA0005022576090000533
Patent Text Reader

Abstract

The present disclosure provides gene therapy vectors, antibody expression cassettes, and vectors comprising a nucleic acid encoding a therapeutic anti-IGF-1R antibody (e.g., a monoclonal antibody), or an antigen-binding fragment thereof, delivery vectors (e.g., antibody expression cassettes, and vectors comprising a gene therapy construct having a nucleic acid encoding a therapeutic anti-IGF-1R antibody (e.g., a monoclonal antibody), or an antigen-binding fragment thereof, and delivery vectors (e.g., delivery cassettes) comprising a gene therapy construct having a nucleic acid encoding a therapeutic anti-IGF-1R antibody (e.g., a monoclonal antibody), or an antigen-binding fragment thereof. Viral vectors), compositions comprising the same, and methods of using the same. Some aspects of the present disclosure relate to recombinant adenoviral vector (rAAV) particles for delivery of nucleic acids encoding therapeutic anti-IGF-1R antibodies (e.g., monoclonal antibodies), or antigen binding fragments thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application No. 63 / 297,787, filed on January 9, 2022, and U.S. Provisional Application No. 63 / 374,878, filed on September 7, 2022, each of which is incorporated herein by reference in its entirety.

[0003] References to sequence listings submitted electronically

[0004] The contents of the electronically submitted sequence listing (Name: 4525_074PC02_Seqlisting_ST26.xml; Size: 214,621 bytes; Creation Date: January 9, 2023) submitted with this application are incorporated herein by reference in its entirety.

[0005] Public domain

[0006] The present disclosure relates to the field of medicine, including AAV gene therapy. Background Art

[0007] Autoimmune diseases are the third most common human pathology after cancer and cardiovascular disease. The cause of autoimmune diseases is multifactorial, in which genetic and environmental triggers are derived from severe defects in immune regulation. Autoimmune diseases Graves' disease and Hashimoto's thyroiditis are the most common autoimmune diseases in the Western world. In Graves' disease, hyperthyroidism is due to the activation of the thyroid gland by agonistic antibodies against thyroid stimulating hormone receptors (TSHR). TSHR is also expressed by orbital fibroblasts, and the combination of TSHR antibodies with orbital fibroblasts causes hyaluronic acid to produce and differentiate into adipocytes and myofibroblasts (Eckstein et al., Endocrine 68:265-70,2020). The result is increased orbital fat and orbital connective tissue fibrosis, especially in the extraocular muscles, which leads to thyroid eye disease (TED), also known as Graves' orbitopathy (GO) (Eckstein et al., Endocrine 68:265-70,2020). Overexpression of insulin-like growth factor 1 receptor (IGF-1R) and its interaction with thyroid-stimulating hormone receptor (TSH-R) are key pathogenic features of the disease.

[0008] IGF-1R can be inhibited using anti-IGF-1R monoclonal antibodies such as teprotumumab (also known as teprotumumab-trbw; RG-1507), sold under the brand name Tepezza. Binding of teprotumumab inhibits signaling through the IGF-1R / TSH-R complex and downstream pathways. Teprotumumab was first approved in the United States in 2020 for the treatment of acute and chronic TED. Teprotumumab is a fully human IgG1-type monoclonal antibody that is administered by intravenous infusion. For most indications, maintenance therapy requires repeated infusions, such as a total of 8 infusions, with the first recommended dose of 10 mg / kg, followed by doubling the dose to 20 mg / kg for 7 more infusions, each separated by three weeks. In the clinical setting, infusions typically take 60 to 90 minutes, which imposes a significant treatment burden on patients.

[0009] Gene therapy involves delivering nucleic acids into the cells of a patient to treat a disease. Advances have been made in the field of gene therapy using viruses to deliver therapeutic genetic material. Although a variety of physical and chemical methods have been developed to introduce foreign DNA into eukaryotic cells, viruses have generally been shown to be more effective for this purpose. Several DNA-containing viruses (e.g., parvoviruses, adenoviruses, herpes viruses, and poxviruses) and RNA-containing viruses (e.g., retroviruses) have been used to develop eukaryotic cloning and expression vectors. Some challenges of viral vectors include low efficiency, DNA packaging capacity, and lack of target cell specificity.

[0010] Brief description of the invention

[0011] Certain aspects of the present disclosure relate to the development of polynucleotides (e.g., antibody expression cassettes) encoding anti-insulin-like growth factor 1 receptor (anti-IGF-1R) antibodies or antigen-binding fragments thereof for gene therapy; vectors (e.g., viral vectors) comprising the polynucleotides; recombinant adeno-associated virus (rAAV) particles comprising the polynucleotides; compositions comprising the polynucleotides, which are suitable for delivering the polynucleotides encoding the anti-IGF-1R antibodies or antigen-binding fragments thereof to target sites of interest; and methods of using the polynucleotides. In some aspects, the present disclosure relates to the delivery of rAAV encoding an antibody expression cassette of an anti-IGF-1R antibody or antigen-binding fragment thereof to a subject in need thereof (e.g., a subject with Graves' orbitopathy).

[0012] Certain aspects of the present disclosure relate to recombinant adeno-associated virus (rAAV) particles comprising a capsid and a vector genome, the vector genome comprising an inverted terminal repeat sequence (ITR) and an antibody expression cassette, wherein the antibody expression cassette comprises (a) a promoter, (b) a nucleic acid sequence encoding a heavy chain variable region (VH) of an anti-insulin-like growth factor 1 receptor (anti-IGF-1R) antibody or an antigen-binding fragment thereof, and (c) a nucleic acid sequence encoding a light chain variable region (VL) of an anti-IGF-1R antibody or an antigen-binding fragment thereof.

[0013] In some aspects, the nucleic acid sequence encoding the VH of the anti-IGF-1R antibody or antigen-binding fragment thereof comprises (i) a nucleic acid encoding a VH complementarity determining region (CDR) 1 comprising a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 7 or 10 (or a VH CDR1 encoding sequence disclosed in Table 3 or 5), (ii) a nucleic acid encoding a VH CDR2 comprising a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 8, 11 or 14 (or a VH CDR2 encoding sequence disclosed in Table 3 or 5). 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 9, 12, or 15 (or a VH CDR3 encoding sequence disclosed in Table 3 or 5); and the nucleic acid sequence encoding the VL of the anti-IGF-1R antibody or antigen-binding fragment thereof comprises (i) a nucleic acid sequence comprising a VL CDR1 comprising a nucleotide sequence identical to SEQ ID NO: 16 (or a VL CDR2 encoding sequence disclosed in Table 4 or 7); 4, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 17, 20 or 23 (or the VL CDR2 encoding sequences disclosed in Table 4 or Table 7), and (iii) a nucleic acid sequence comprising a VL CDR3 comprising a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 18, 21 or 24 (or the VL CDR2 encoding sequences disclosed in Table 4 or Table 7). CDR3 encoding sequence) has a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical.

[0014] Certain aspects of the present disclosure relate to a vector (e.g., a vector genome) comprising an antibody expression cassette comprising:

[0015] (a) Promoter;

[0016] (b) a nucleic acid sequence encoding a heavy chain variable region (VH) of an anti-insulin-like growth factor 1 receptor (anti-IGF-1R) antibody or an antigen-binding fragment thereof, comprising (i) a nucleic acid encoding a VH complementarity determining region (CDR) 1 comprising a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 7 or 10 (or a VH CDR1 encoding sequence disclosed in Table 3 or 5), (ii) a nucleic acid encoding a VH CDR2 comprising a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 8, 11 or 14 (or a VH CDR2 encoding sequence disclosed in Table 3 or 5), (iii) a nucleic acid encoding a VH CDR3 comprising a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 95%, 96%, 97%, 98%, 99% or 100% identical to a VH CDR2 encoding sequence, and (iii) a nucleic acid encoding a VH CDR3 comprising a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 9, 12 or 15 (or a VH CDR3 encoding sequence disclosed in Table 3 or 5);

[0017] (c) a nucleic acid sequence encoding a light chain variable region (VL) of an anti-IGF-1R antibody or antigen-binding fragment thereof, comprising (i) a nucleic acid sequence comprising a VL CDR1 comprising a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 16 (or a VL CDR1 encoding sequence disclosed in Table 4 or Table 7), (ii) a nucleic acid sequence comprising a VL CDR2 comprising a nucleotide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 17, 20 or 23 (or a VL CDR2 encoding sequence disclosed in Table 4 or Table 7), %, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to a VL CDR2 encoding sequence, and (iii) a nucleic acid sequence comprising a VL CDR3 comprising a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 18, 21 or 24 (or a VL CDR3 encoding sequence disclosed in Table 4 or 7).

[0018] In some aspects, the antibody expression cassette comprises a nucleic acid sequence encoding a signal peptide. In some aspects, the antibody expression cassette comprises a nucleic acid sequence encoding a first signal peptide and a nucleic acid sequence encoding a second signal peptide. In some aspects, the first signal peptide and the second signal peptide are identical. In some aspects, the first signal peptide and the second signal peptide are different. In some aspects, the first signal peptide (e.g., HC signal peptide) comprises a human IL-10 signal sequence. In some aspects, the second signal peptide (e.g., LC signal peptide) comprises a human IL-2 signal sequence.

[0019] In some aspects, the signal peptide (e.g., the first signal peptide or the second signal peptide) comprises an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NO: 119 or 120.

[0020] In some aspects, the antibody expression cassette comprises a linker sequence selected from an internal ribosome entry site (IRES) sequence, a proteolytic cleavage site, or a combination thereof.

[0021] In some aspects, the proteolytic cleavage site comprises a furin cleavage site, a 2A cleavage site, or a combination thereof.

[0022] In some aspects, the antibody expression cassette comprises, in the 5'-3' direction, a promoter, a nucleic acid sequence encoding VH, an IRES, and a nucleic acid sequence encoding VL.

[0023] In some aspects, the antibody expression cassette comprises, in the 5'-3' direction, a promoter, a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding VH, an IRES, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding VL.

[0024] In some aspects, the antibody expression cassette comprises, in the 5'-3' direction, a promoter, a nucleic acid sequence encoding VL, an IRES, and a nucleic acid sequence encoding VH.

[0025] In some aspects, the antibody expression cassette comprises, in the 5'-3' direction, a promoter, a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding VL, an IRES, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding VH.

[0026] In some aspects, the antibody expression cassette comprises, in the 5'-3' direction, a promoter, a nucleic acid sequence encoding VH, a proteolytic cleavage site, and a nucleic acid sequence encoding VL.

[0027] In some aspects, the antibody expression cassette comprises, in the 5'-3' direction, a promoter, a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding VH, a proteolytic cleavage site, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding VL.

[0028] In some aspects, the antibody expression cassette comprises a promoter, a nucleic acid sequence encoding VL, a proteolytic cleavage site, and a nucleic acid sequence encoding VH in the 5'-3' direction.

[0029] In some aspects, the antibody expression cassette comprises, in the 5'-3' direction, a promoter, a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding VL, a proteolytic cleavage site, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding VH.

[0030] In some aspects, the IRES comprises a nucleic acid having a sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the IRES sequence disclosed in SEQ ID NO:43 or Table 15.

[0031] In some aspects, the furin cleavage site comprises a nucleic acid having a sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a furin cleavage site sequence disclosed in SEQ ID NO:44 or Table 15.

[0032] In some aspects, the 2A cleavage site comprises a nucleic acid having a sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a 2A cleavage site (e.g., F2A) sequence disclosed in SEQ ID NO:45 or Table 15.

[0033] In some aspects, the signal peptide is an IL-2 signal peptide or an IL-10 signal peptide. In some aspects, the encoded signal peptide comprises an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NO: 119 or 120. In some aspects, the nucleic acid sequence encoding the signal peptide comprises a nucleic acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NO: 121 or 122.

[0034] In some aspects, the antibody expression cassette comprises a second promoter.

[0035] In some aspects, the antibody expression cassette comprises, in the 5'-3' direction, a promoter (first promoter), a nucleic acid sequence encoding VL, a second promoter, and a nucleic acid sequence encoding VH.

[0036] In some aspects, the antibody expression cassette comprises in the 5'-3' direction a promoter (first promoter), a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding VL, a second promoter, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding VH.

[0037] In some aspects, the antibody expression cassette comprises, in the 5'-3' direction, a promoter (first promoter), a nucleic acid sequence encoding VH, a second promoter, and a nucleic acid sequence encoding VL.

[0038] In some aspects, the antibody expression cassette comprises in the 5'-3' direction a promoter (first promoter), a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding VH, a second promoter, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding VL.

[0039] In some aspects, the antibody expression cassette comprises, in the 5'-3' direction, a nucleic acid sequence encoding VH, a promoter (first promoter), a second promoter, and a nucleic acid sequence encoding VL.

[0040] In some aspects, the antibody expression cassette comprises, in the 5'-3' direction, a nucleic acid sequence encoding a first signal peptide, VH, a promoter (first promoter), a second promoter, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding VL.

[0041] In some aspects, the antibody expression cassette comprises, in the 5'-3' direction, a nucleic acid sequence encoding VL, a promoter (first promoter), a second promoter, and a nucleic acid sequence encoding VH.

[0042] In some aspects, the antibody expression cassette comprises in the 5'-3' direction a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding VL, a promoter (first promoter), a second promoter, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding VH.

[0043] In some aspects, the promoter and / or the second promoter is a constitutively active promoter, a cell type specific promoter, a synthetic promoter, or an inducible promoter.

[0044] In some aspects, the promoter and / or the second promoter is a CBA promoter, a CMV promoter (optionally, a human CMV promoter or a mouse CMV promoter), an EF1α promoter, a CAG promoter, or a tissue-specific promoter.

[0045] In some aspects, the promoter comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs:47-51, 83 or 93, or the promoter and / or enhancer sequences disclosed in Table 15.

[0046] In some aspects, the promoter is a muscle-specific promoter. In some aspects, the muscle-specific promoter is selected from the group consisting of desmin (DES) promoter, human skeletal muscle α-actin (HSA) promoter, myosin creatine kinase (MCK) promoter, α-myosin heavy chain myosin creatine kinase 7 (HMCK7) promoter, double MCK enhancer MCK (dMCK) promoter, triple MCK enhancer MCK (tMCK) promoter, double MCK enhancer muscle creatine kinase 8e (CK8e) promoter, SPc5-12 promoter, SP-301 promoter, α-myosin heavy chain (MHC) promoter, Sk-CRM promoter or Sk-CRM4 promoter.

[0047] In some aspects, the antibody expression cassette comprises an intron. In some aspects, the intron is a CAG intron, an SV40 intron, an MVM intron, or a human β-globin intron, or any combination thereof.

[0048] In some aspects, the intron comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to an intron sequence disclosed in SEQ ID NO:46 or 82, or Table 15.

[0049] In some aspects, the promoter comprises a first promoter and a second promoter that are different.

[0050] In some aspects, the first promoter and the second promoter initiate transcription in the same direction.

[0051] In some aspects, the first promoter and the second promoter initiate transcription in different directions.

[0052] In some aspects, the antibody expression cassette comprises a pause element between the first promoter and the second promoter.

[0053] In some aspects, the pause element comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a pause element sequence disclosed in SEQ ID NO:54 or Table 15.

[0054] In some aspects, the anti-IGF-1R antibody is a monoclonal antibody. In some aspects, VH CDR1-3 corresponds to the CDRs of teixumab and / or VL CDR1-3 corresponds to the CDRs of teixumab. In some aspects, the anti-IGF-1R antibody is teixumab.

[0055] In some aspects, the nucleic acid sequence encoding the VH comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 25-27 (or the VH encoding sequences disclosed in Table 5). In some aspects, the encoded VH comprises SEQ ID NO: 28 or SEQ ID NO: 91 (or any one of the VH amino acid sequences in Table 6).

[0056] In some aspects, the nucleic acid sequence encoding the VL comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 29-31 (or the VL encoding sequences disclosed in Table 7). In some aspects, the encoded VL comprises SEQ ID NO: 32 or SEQ ID NO: 92 (or any one of the VL amino acid sequences in Table 8).

[0057] In some aspects, the nucleic acid sequence encoding the heavy chain (HC) comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 35-37 (or the HC encoding sequences disclosed in Table 11). In some aspects, the encoded HC comprises SEQ ID NO: 38 (or the HC amino acid sequence in Table 12).

[0058] In some aspects, the nucleic acid sequence encoding the light chain (LC) comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 39-41 (or the LC encoding sequences disclosed in Table 13). In some aspects, the encoded LC comprises SEQ ID NO: 42 (or the LC amino acid sequence in Table 14).

[0059] In some aspects, the encoded anti-IGF-1R antibody is tefiximab.

[0060] In some aspects, the antibody expression cassette comprises a poly(A) sequence. In some aspects, the poly(A) sequence is selected from bGHpA, hGHpA, SV40pA or synthetic pA.

[0061] In some aspects, the poly(A) comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to a poly(A) sequence disclosed in SEQ ID NO: 52 or 53 or Table 15.

[0062] In some aspects, the antibody expression cassette comprises an open reading frame (ORF) comprising a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 57-67 and 94-97, or an ORF sequence disclosed in Table 16.

[0063] In some aspects, the antibody expression cassette comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 68-76 or an antibody expression cassette sequence disclosed in Table 17.

[0064] In some aspects, inverted terminal repeats (ITRs). In some aspects, the AAV ITRs include a pair of ITRs flanking the antibody expression cassette. In some aspects, the ITRs are of the same serotype as each other. In some aspects, the ITRs are of the AAV2 serotype.

[0065] In some aspects, the vector is packaged in an AAV capsid.

[0066] In some aspects, the AAV capsid serotype is selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVRh8, AAVrh9, AAV9, AAVrh10, AAV10, AAV11, AAV12, and modified forms thereof.

[0067] In some aspects, the AAV capsid serotype is selected from AAV1, AAV2, AAV6, AAV8, AAV9, and modified forms thereof.

[0068] Certain aspects of the present disclosure relate to host cells comprising a rAAV particle or vector disclosed herein.

[0069] Certain aspects of the present disclosure relate to compositions comprising a rAAV particle or vector disclosed herein and a carrier. In some aspects, the carrier is water or saline.

[0070] Certain aspects of the present disclosure relate to methods of expressing an anti-IGF-1R antibody or antigen-binding fragment thereof in a cell, comprising administering to the cell a rAAV particle, vector or composition disclosed herein, thereby expressing the anti-IGF-1R antibody or antigen-binding fragment thereof in the cell.

[0071] In some aspects, the cell is a fibroblast, an adipocyte, a myofibroblast, a myocyte cell, a muscle cell, or any combination thereof.

[0072] In some aspects, the administering is performed in vitro.

[0073] In some aspects, the administering is performed in vivo.

[0074] Certain aspects of the present disclosure relate to methods of expressing an anti-IGF-1R antibody or antigen-binding fragment thereof in a subject in need thereof, comprising administering to the subject a rAAV particle, vector or composition disclosed herein, thereby expressing the anti-IGF-1R antibody or antigen-binding fragment thereof in the subject.

[0075] In some aspects, the subject has a thyroid eye disease selected from active Graves' orbitopathy and chronic Graves' orbitopathy.

[0076] Certain aspects of the present disclosure relate to a method of treating thyroid eye disease in a subject in need thereof, comprising administering to the subject a rAAV particle, vector, or composition disclosed herein, thereby expressing an anti-IGF-1R antibody or antigen-binding fragment thereof in the subject and treating the thyroid eye disease.

[0077] In some aspects, the thyroid eye disease is selected from active Graves' orbitopathy and chronic Graves' orbitopathy.

[0078] In some aspects, administration is suitable for delivering the rAAV particle or vector to an ocular delivery site, a retro-orbital or peri-orbital delivery site, a retrobulbar delivery site, an extraocular muscle delivery site, a connective tissue delivery site, or any combination of their delivery sites.

[0079] In some aspects, administration is by injection or infusion.

[0080] In some aspects, administration is intramuscular (IM), intravenous (IV), intralymphatic, intraocular, retro-orbital, peri-orbital, retrobulbar, or any combination thereof.

[0081] In some aspects, administration is suitable for delivery to retro-orbital or peri-orbital fibroblasts, adipocytes, myofibroblasts, myocytes, or any combination thereof.

[0082] In some aspects, the administering is to an extraocular muscle.

[0083] In some aspects, the extraocular muscle is a levantor muscle or a glabellar muscle.

[0084] In some aspects, the administering is to connective tissue.

[0085] In some aspects, administration is transconjunctival into the periorbital space.

[0086] In some aspects, administration is intralymphatic administration to the preauricular or submandibular lymph nodes.

[0087] In some aspects, administration is a single dose. In some aspects, a single dose is multiple injections and / or infusions.

[0088] In some aspects, administration is a single dose. In some aspects, a single dose is multiple injections and / or infusions.

[0089] BRIEF DESCRIPTION OF THE DRAWINGS

[0090] Figure 1 A plasmid map of a vector containing the following ITR to ITR elements is shown: AAV2 ITRs flanking the CMV enhancer in 5' to 3' order, CBA promoter, CAG intron, nucleic acid encoding a signal peptide, nucleic acid encoding Teprotumumab heavy chain (TeproHC), F2A sequence, nucleic acid encoding a signal peptide, nucleic acid encoding Teprotumumab light chain (Tepro LC), and bovine polyadenylation (bGH pA).

[0091] Figure 2A plasmid map of a vector containing the following ITR to ITR elements is shown: AAV2 ITRs flanking the CMV enhancer in 5' to 3' order, a CBA promoter, a CAG intron, a nucleic acid encoding a signal peptide, a nucleic acid encoding a teprotumumab light chain (TeproLC), an IRES sequence (IRES2), a nucleic acid encoding a signal peptide, a nucleic acid encoding a teprotumumab heavy chain (Tepro HC), and a synthetic polyadenylation site (syn pA).

[0092] Figure 3 A plasmid map of a vector containing the following ITR to ITR elements is shown: AAV2 ITRs flanked by a CMV enhancer in 5' to 3' order, a CMV promoter, an SV40 intron, a nucleic acid encoding a signal peptide, a nucleic acid encoding a teixumab light chain (TeproLC), a bovine polyadenylation site (bGH pA), a pause site, an EF-1a core promoter, a truncated 5' LTR, a chimeric human β-globin / immunoglobulin heavy chain intron, a nucleic acid encoding a signal peptide, a nucleic acid encoding a teixumab heavy chain (TeproHC), and a synthetic polyadenylation site (syn pA).

[0093] Figures 4A-4D Protein and mRNA quantification of tefixime secreted from transfected HEK-293 cells is shown. Figure 4A is a graph showing the amount of Tefiximab secreted from HEK-293 cells transfected with H-F2A-L (ORF#1), H-F2A-L (ORF#2), L-IRES-H (ORF#12), L-IRES-H (ORF#13), dual promoter (ORF#4 and 5), or dual promoter (ORF#6 and 7) Tefiximab AAV plasmid constructs. Figure 4B is a graph showing the amount of tiuximab secreted from HEK-293 cells transfected with H-F2A-L (ORF#1), H-F2A-L (ORF#2), L-IRES-H (ORF#12), or L-IRES-H (ORF#13) tiuximab AAV plasmid constructs or H-F2A-L (ORF#1) (plasmid) or L-IRES-H (ORF#4 and 5) (plasmid) tiuximab non-AAV plasmid constructs. Figure 4C Western blot analysis of secreted light and heavy chains of Tefiximab performed under reducing and non-reducing conditions as indicated is shown. Figure 4D is a graph showing telotinumab mRNA levels in HEK-293 cells transfected with H-F2A-L (ORF#1), L-IRES-H (ORF#12), or dual promoter (ORF#4 and 5) telotinumab AAV plasmid constructs.

[0094] Figure 5A-B shows the binding of vectored tetumumab secreted from transfected HEK-293 cells to IGF-1R. Figure 5A is a graph showing the IGF-1R binding ability of Titumumab secreted from HEK-293 cells transfected with H-F2A-L (ORF#1), H-F2A-L (ORF#2), L-IRES-H (ORF#12), or L-IRES-H (ORF#13) Titumumab AAV plasmid constructs. Figure 5B is a graph showing the linearity of binding of vectored Tetumumab secreted from transfected HEK-293 cells to IGF-1R in two replicates of the same binding experiment.

[0095] Figure 6 is a graph showing the reduction in IGF-1R phosphorylation levels after treatment with recombinant tefixime or tefixime secreted from HEK-293 cells transfected with H-F2A-L (ORF#1) or H-F2A-L (ORF#2).

[0096] Fig. 7A -B Displayed on HT-1080( Fig. 7A ) and Colo205( Figure 7B ) cells, total IGF-1R and phosphorylated IGF-1R expression was reduced after 48 hours of treatment with the indicated recombinant or vectored tiuximab. All wells in the MSD plate were loaded with the same total amount of μg of HT-1080 or Colo205 whole cell lysate. All values ​​shown are percentages of the treated value / mean of the mock-treated value. N=3 technical replicates per sample, bar graphs are mean + / -SD. All statistics were one-way ANOVAs with post hoc comparisons of each tiuximab treatment to the mock-treated control, performed for total or phosphorylation values, respectively. All "vectored tiuximab" were HEK293T supernatants containing the corresponding ng of tiuximab after transduction with AAV expressing H-F2A-L (ORF#2).

[0097] Fig. 8A -C shows the expression of insulin growth factor 1 receptor (IGF-1R) protein in cultured primary fibroblasts isolated from peripheral blood of normal donors (denoted as Normal) or Graves' disease donors (denoted as Graves) after treatment with vectored Tepro (vTepro) or recombinant Tepro (rTepro) at a concentration of 500 ng / mL ( Fig. 8A )、Insulin receptor (IR) protein ( Figure 8B ) and insulin receptor substrate 1 (IRS-1) protein ( Figure 8C) was expressed as a percentage reduction in the expression of . All values ​​presented are percentages of (mean value of mock treatment / mean value of mock treatment*100)-(value of treatment / mean value of mock treatment*100), where each mean is n=2 technical replicates. Normal sample values ​​are plotted as the mean of n=2 biological replicates per sample, and the bar graph is the mean + / - SEM. Graves sample values ​​are plotted as N=1 biological replicate. All "vectored titumumab" are HEK293T supernatants containing the corresponding ng of titumumab after transduction with AAV expressing H-F2A-L (ORF#2). Treatment with vectored titumumab resulted in a significant decrease in the expression levels of IGF-1R, IR and IRS-1 proteins in Graves' disease fibroblasts.

[0098] Fig. 9 Immunocytochemistry for IGF-1R of Colo205 cells with or without 500 ng / mL recombinant tebuconazole for 24-48 hours is shown, showing a reduction in IGF-1R expression. Panels A and E show untreated cell controls for 24 hours; panels B and F show cells treated with tebuconazole for 24 hours. Panels C and G show untreated cell controls for 48 hours; panels D and H show cells treated with tebuconazole for 48 hours. Panels A, B, C, and D show non-permeabilized cells; panels E, F, G, and H show cells permeabilized with 0.1% Triton X-100.

[0099] Fig. 10A -C shows the expression of the antibody encoding Tefixumab delivered by AAV1 compared to untreated control mice and mice treated with recombinant Tefixumab (6 mg / kg every 7 days) as shown in the legend. Fig. 10A ), AAV2-delivered antibody expression cassette encoding Tetumumab ( Fig. 10B ) or an antibody expression cassette encoding telotinumab delivered by AAV9 ( Fig. 10C )-treated Colo205 xenograft mice.

[0100] Fig.11 Shown are the levels of telotumumab in tumors obtained from animals treated with an antibody expression cassette encoding telotumumab delivered by AAV1, an antibody expression cassette encoding telotumumab delivered by AAV2, an antibody expression cassette encoding telotumumab delivered by AAV9 from day 7 to day 31, and the levels of telotumumab in tumors obtained from animals treated with recombinant telotumumab (6 mg / kg every 7 days) at day 31. The bar graphs represent mean ± SEM. Days 7, 14, and 28 were sampling arms, and day 31 was the efficacy arm.

[0101] Fig.12Shown are the serum levels of Tefixumab in animals treated with an antibody expression cassette encoding Tefixumab delivered by AAV1, an antibody expression cassette encoding Tefixumab delivered by AAV2, an antibody expression cassette encoding Tefixumab delivered by AAV9 from day 7 to day 31, and the levels of Tefixumab in the serum of animals treated with recombinant Tefixumab (6 mg / kg every 7 days) on day 31. The bar graphs represent mean ± SEM. Days 7, 14, and 28 were sampling arms, and day 31 was the efficacy arm.

[0102] Fig.13 Shown are the levels of IGF-1R in tumors obtained from animals treated with an antibody expression cassette encoding tiuximab delivered by AAV1, an antibody expression cassette encoding tiuximab delivered by AAV2, and an antibody expression cassette encoding tiuximab delivered by AAV9 from day 7 to day 31, as well as the levels of IGF-1R in tumors obtained from animals treated with recombinant tiuximab (6 mg / kg every 7 days) on day 31. Error bars represent mean ± SEM. Days 7, 14, and 28 are sampling arms, and day 31 is the efficacy arm. The decrease in IFG-1R levels compared to untreated controls was statistically significant at all time points. On day 31, the decrease in IGF-1R levels caused by tiuximab delivered by AAV1 and tiuximab delivered by AAV9 was not statistically different from the decrease in IGF-1R levels caused by recombinant tiuximab (6 mg / kg every 7 days).

[0103] Fig.14 The vector genome copy number (expressed as copies / μg host genomic DNA) in tumors obtained from animals treated with AAV1-delivered antibody expression cassette encoding tefixumab, AAV2-delivered antibody expression cassette encoding tefixumab, AAV9-delivered antibody expression cassette encoding tefixumab, and untreated control animals on days 7, 14, and 28 are shown as indicated in the figure legends.

[0104] Fig.15 Shown are mRNA expression (expressed as single-stranded copies / μg host RNA) in tumors obtained from animals treated with AAV1-delivered antibody expression cassettes encoding tefixumab, AAV2-delivered antibody expression cassettes encoding tefixumab, AAV9-delivered antibody expression cassettes encoding tefixumab, and untreated control animals on days 7, 14, and 28, as indicated in the figure legends.

[0105] Fig.16Vector genome copy number (expressed as copies / μg host genomic DNA) and mRNA expression (expressed as single-stranded copies / μg host RNA) in tumors obtained from animals treated with AAV1-delivered antibody expression cassettes encoding tefixumab, AAV2-delivered antibody expression cassettes encoding tefixumab, AAV9-delivered antibody expression cassettes encoding tefixumab, and untreated control animals on days 7, 14, and 28 are shown as indicated in the figure legends.

[0106] Detailed Description of the Disclosure

[0107] Certain aspects of the present disclosure relate to gene therapy vectors and expression constructs encoding anti-insulin-like growth factor 1 receptor (anti-IGF-1R) antibodies or antigen-binding fragments thereof; viral vectors (e.g., rAAV vectors) comprising the same; compositions comprising the same suitable for delivery (e.g., retrobulbar, periorbital and / or intramuscular administration), and methods of using the same. In some aspects, the present disclosure relates to delivering an antibody expression cassette encoding an anti-IGF-1R antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof to a subject in need thereof using an adeno-associated viral vector (AAV).

[0108] Certain aspects of the present disclosure relate to polynucleotides (e.g., antibody expression cassettes) comprising nucleic acids encoding antibodies or antigen-binding fragments thereof that bind to insulin-like growth factor 1 receptor (also referred to herein as IGF-1R or IGF-1R). In some aspects, the polynucleotides (e.g., antibody expression cassettes) comprise an open reading frame (ORF) comprising a nucleic acid sequence encoding an anti-IGF-1R heavy chain and a nucleic acid sequence encoding an anti-IGF-1R light chain. In some aspects, the ORF is operably connected to a promoter (e.g., a CBA promoter or a CMV promoter). In some aspects, the ORF is operably connected to an enhancer (e.g., a CMV enhancer) and / or an intron sequence (e.g., a CAG intron or an SV40 intron sequence). In some aspects, the ORF is operably connected to a polyadenylation (poly A) element (e.g., bGHpA, hGHpA, SV40pA, or a synthetic pA).

[0109] In some aspects, ORF comprises a nucleic acid sequence encoding a signal peptide. In some aspects, the signal peptide is an IL-2 signal peptide or an IL-10 signal peptide. In some aspects, ORF comprises a nucleic acid sequence encoding a first signal peptide and a nucleic acid sequence encoding a second signal peptide. In some aspects, the first signal peptide and the second signal peptide are identical. In some aspects, the first signal peptide and the second signal peptide are different.

[0110] In some aspects, the ORF comprises a linker between a nucleic acid sequence encoding an anti-IGF-1R heavy chain and a nucleic acid sequence encoding an anti-IGF-1R light chain. In some aspects, the linker is an internal ribosome entry sequence (IRES), a proteolytic enzyme cleavage site (e.g., furin and / or 2A cleavage site (e.g., F2A)) or a combination thereof. In some aspects, the OFR also comprises a nucleic acid encoding a signal sequence. In some aspects, the OFR is located between two inverted terminal repeats (ITRs).

[0111] In some aspects, the polynucleotide (eg, antibody expression cassette) comprises in the 5'-3' direction a promoter, a nucleic acid sequence encoding an anti-IGF-1R heavy chain region, an IRES, and a nucleic acid sequence encoding an anti-IGF-1R light chain region.

[0112] In some aspects, the polynucleotide (e.g., an antibody expression cassette) comprises, in the 5'-3' direction, a promoter, a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding an anti-IGF-1R heavy chain region, an IRES, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding an anti-IGF-1R light chain region.

[0113] In some aspects, the polynucleotide (eg, antibody expression cassette) comprises in the 5'-3' direction a promoter, a nucleic acid sequence encoding an anti-IGF-1R light chain region, an IRES, and a nucleic acid sequence encoding an anti-IGF-1R heavy chain region.

[0114] In some aspects, the polynucleotide (e.g., an antibody expression cassette) comprises, in the 5'-3' direction, a promoter, a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding an anti-IGF-1R light chain region, an IRES, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding an anti-IGF-1R heavy chain region.

[0115] In some aspects, the polynucleotide (eg, antibody expression cassette) comprises in the 5'-3' direction a promoter, a nucleic acid sequence encoding an anti-IGF-1R heavy chain region, a F2A cleavage site, and a nucleic acid sequence encoding an anti-IGF-1R light chain region.

[0116] In some aspects, the polynucleotide (e.g., an antibody expression cassette) comprises, in the 5'-3' direction, a promoter, a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding an anti-IGF-1R heavy chain region, a F2A cleavage site, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding an anti-IGF-1R light chain region.

[0117] In some aspects, the polynucleotide (eg, antibody expression cassette) comprises in the 5'-3' direction a promoter, a nucleic acid sequence encoding an anti-IGF-1R light chain region, a F2A cleavage site, and a nucleic acid sequence encoding an anti-IGF-1R heavy chain region sequence.

[0118] In some aspects, the polynucleotide (e.g., an antibody expression cassette) comprises, in the 5'-3' direction, a promoter, a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding an anti-IGF-1R light chain region, a F2A cleavage site, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding an anti-IGF-1R heavy chain region sequence.

[0119] In some aspects, the polynucleotide (eg, an antibody expression cassette) further comprises a second promoter.

[0120] In some aspects, the polynucleotide (eg, an antibody expression cassette) comprises in the 5'-3' direction a first promoter, a nucleic acid sequence encoding an anti-IGF-1R light chain, a second promoter, and a nucleic acid sequence encoding an anti-IGF-1R heavy chain.

[0121] In some aspects, the polynucleotide (e.g., an antibody expression cassette) comprises, in the 5'-3' direction, a first promoter, a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding an anti-IGF-1R light chain, a second promoter, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding an anti-IGF-1R heavy chain.

[0122] In some aspects, a polynucleotide (eg, an antibody expression cassette) comprises, in the 5'-3' direction, a first promoter, a nucleic acid sequence encoding an anti-IGF-1R heavy chain, a second promoter, and a nucleic acid sequence encoding an anti-IGF-1R light chain.

[0123] In some aspects, the polynucleotide (e.g., an antibody expression cassette) comprises, in the 5'-3' direction, a first promoter, a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding an anti-IGF-1R heavy chain, a second promoter, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding an anti-IGF-1R light chain.

[0124] In some aspects, a polynucleotide (eg, an antibody expression cassette) comprises, in the 5'-3' direction, a nucleic acid sequence encoding an anti-IGF-1R heavy chain, a first promoter, a second promoter, and a nucleic acid sequence encoding an anti-IGF-1R light chain.

[0125] In some aspects, the polynucleotide (e.g., an antibody expression cassette) comprises, in the 5'-3' direction, a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding an anti-IGF-1R heavy chain, a first promoter, a second promoter, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding an anti-IGF-1R light chain.

[0126] In some aspects, a polynucleotide (eg, an antibody expression cassette) comprises, in the 5'-3' direction, a nucleic acid sequence encoding an anti-IGF-1R light chain, a first promoter, a second promoter, and a nucleic acid sequence encoding an anti-IGF-1R heavy chain.

[0127] In some aspects, the polynucleotide (e.g., an antibody expression cassette) comprises, in the 5'-3' direction, a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding an anti-IGF-1R light chain, a first promoter, a second promoter, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding an anti-IGF-1R heavy chain.

[0128] In some aspects, promoter is constitutively active promoter, cell type specific promoter, synthetic promoter or inducible promoter.In some aspects, promoter is selected from CAG promoter, CBA promoter, mankind CMV promoter, mouse CMV promoter, EF1α promoter, EF1α promoter with CMV enhancer, CMV promoter (CMVe / p) with CMV enhancer, CMV promoter or tissue-specific promoter with SV40 intron.In some aspects, cell type specific promoter is muscle specific promoter, including DES promoter, HSA promoter, MCK promoter, HMCK7 promoter, dMCK promoter, tMCK promoter, CK8e promoter, SPc5-12 promoter, SP-301 promoter, MH promoter, Sk-CRM promoter or Sk-CRM4 promoter (see, for example, Skopenkova et al., Acta Naturae 13:47-58,2012).

[0129] In some aspects, the promoter comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 47-51, 83 or 93, or a promoter and / or enhancer sequence disclosed in Table 15. In some aspects, the nucleic acid sequence comprising the promoter may comprise an intron. In some aspects, the intron is selected from a CAG intron, an SV40 intron, an MVM intron, a human beta globin intron, or a chimeric human beta globin-human immunoglobulin chain intron. In some aspects, the CAG intron comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 82. In some aspects, the SV40 intron comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 46. In some aspects, the promoter comprises an intron sequence disclosed in Table 15.

[0130] In some aspects, the promoter comprises a first promoter and a second promoter. In some aspects, the first promoter and the second promoter are different. In some aspects, the first promoter and the second promoter are identical. In some aspects, the first promoter and the second promoter initiate transcription in the same direction. In some aspects, the first promoter and the second promoter initiate transcription in different directions. In some aspects, the first and / or the second promoter is a CMV promoter. In some aspects, the first and / or the second promoter is an EF-1α promoter. In some aspects, the first and / or the second promoter is a CBA promoter.

[0131] In some aspects, the nucleic acid sequence encoding the first promoter and the nucleic acid sequence encoding the second promoter are operably connected. In some aspects, the nucleic acid sequence encoding the first promoter and the nucleic acid sequence encoding the second promoter are operably connected through a pause element. In some aspects, the pause element comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the pause element sequence disclosed in SEQ ID NO:54 or Table 15.

[0132] In some aspects, the signal peptide is an endogenous signal peptide of HGH and variants thereof; an endogenous signal peptide of interferon and variants thereof, including signal peptides and variants thereof of type I, type II and type III interferon; endogenous signal peptides and variants thereof of known cytokines, such as signal peptides and variants thereof of erythropoietin (EPO), insulin, TGF-β1, TNF, IL1-α and IL1-β. In some embodiments, the signal peptide is a modified signal peptide. In some aspects, the signal peptide is an IL-2 signal peptide. In some aspects, the signal peptide is an IL-10 signal peptide. In some aspects, the signal peptide comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: 119 or 120.

[0133] In some aspects, the anti-IGF-1R antibody is a monoclonal antibody. In some aspects, the anti-IGF-1R antibody is tetumumab.

[0134] In some aspects, the anti-IGF-1R antibody heavy chain comprises a heavy chain variable region (VH) comprising complementarity determining region (CDR) 1, VH CDR2, and VH CDR3. In some aspects, VH CDR1-3 correspond to the CDRs of tefixime. In some aspects, the nucleic acid sequence encoding VH CDR1 comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 7 or 10 (or a VH CDR1 encoding sequence disclosed in Table 3 or Table 5); the nucleic acid sequence encoding VH CDR2 comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 8, 11 or 14 (or a VH CDR2 encoding sequence disclosed in Table 3 or Table 5); and the nucleic acid sequence encoding VH CDR3 comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: NO: 9, 12 or 15 (or the VH CDR3 encoding sequences disclosed in Table 3 or Table 5) has a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical.

[0135] In some aspects, the anti-IGF-1R antibody light chain comprises a light chain variable region (VL) comprising complementarity determining region (CDR) 1, VL CDR2, and VL CDR3. In some aspects, VL CDR1-3 correspond to the CDRs of tefixime. In some aspects, the nucleic acid sequence encoding VL CDR1 comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 16 (or a VL CDR1 encoding sequence disclosed in Table 4 or Table 7); the nucleic acid sequence encoding VL CDR2 comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 17, 20 or 23 (or a VL CDR2 encoding sequence disclosed in Table 4 or Table 7); and the nucleic acid sequence encoding VL CDR3 comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: NO:18, 21 or 24 (or the VL CDR3 encoding sequences disclosed in Table 4 or Table 7) have a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical.

[0136] In some aspects, the nucleic acid sequence encoding the heavy chain variable region (VH) comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 25-27 (or the VH encoding sequences disclosed in Table 5). In some aspects, the encoded VH comprises SEQ ID NO: 28 or SEQ ID NO: 91 (or any one of the VH amino acid sequences in Table 6). In some aspects, the nucleic acid sequence encoding the light chain variable region (VL) comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 29-31 (or the VL encoding sequences disclosed in Table 7). In some aspects, the encoded VL comprises SEQ ID NO: 32 or SEQ ID NO: 92 (or any one of the VL amino acid sequences in Table 8).

[0137] In some aspects, the nucleic acid sequence encoding the heavy chain (HC) comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 35-37 (or the HC coding sequences disclosed in Table 11). In some aspects, the encoded HC comprises SEQ ID NO: 38 (or the HC amino acid sequence in Table 12). In some aspects, the nucleic acid sequence encoding the light chain (LC) comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 39-41 (or the LC coding sequences disclosed in Table 13). In some aspects, the encoded LC comprises SEQ ID NO: 42 (or a LC amino acid sequence in Table 14).

[0138] In some aspects, the nucleic acid sequence encoding the heavy chain is operably connected to the nucleic acid sequence encoding the light chain. In some aspects, the nucleic acid sequence encoding the heavy chain is operably connected to the nucleic acid sequence encoding the light chain by a joint sequence. In some aspects, the joint sequence is selected from an IRES sequence, a proteolytic cleavage site (e.g., furin and / or 2A cleavage site, e.g., F2A) or a combination thereof. In some aspects, IRES comprises a nucleic acid having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical sequence to the IRES sequence disclosed in SEQ ID NO:43 or Table 15. In some aspects, the furin cleavage site comprises a nucleic acid having a sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a furin cleavage site sequence disclosed in SEQ ID NO: 44, or Table 15. In some aspects, the 2A cleavage site comprises a nucleic acid having a sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a 2A cleavage site (e.g., F2A) sequence disclosed in SEQ ID NO: 45, or Table 15.

[0139] In some aspects, the polynucleotide comprises an open reading frame (ORF) comprising a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 57-67 and 94-97, or an ORF sequence disclosed in Table 16.

[0140] In some aspects, the polynucleotide (e.g., antibody expression cassette) comprises poly (A). In some aspects, the poly A sequence comprises a human growth hormone poly A signal sequence. In some aspects, the poly A sequence comprises a bovine growth hormone poly A signal sequence. In some aspects, the poly A sequence comprises a synthetic poly A sequence. In some aspects, the poly A sequence comprises an SV40 poly A signal sequence (SV40pA). In some aspects, the polynucleotide (e.g., antibody expression cassette) comprises a poly (A) sequence comprising a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NO:52 or 53 or a poly (A) sequence disclosed in Table 15.

[0141] In some aspects, the antibody expression cassette comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 68-76 or an antibody expression cassette sequence disclosed in Table 17.

[0142] Certain aspects of the present disclosure relate to methods of expressing and / or producing an anti-IGF-1R antibody or an antigen-binding fragment thereof, comprising administering a polynucleotide (e.g., an antibody expression cassette), a vector or an rAAV particle of the present disclosure to a cell, thereby expressing and / or producing the anti-IGF-1R antibody or an antigen-binding fragment thereof in the cell. In some aspects, the cell is a fibroblast, an adipocyte, a myofibroblast, a myocyte, a muscle cell, or any combination thereof.

[0143] Certain aspects of the present disclosure relate to compositions (eg, gene therapy compositions) comprising a polynucleotide (eg, an antibody expression cassette), vector, or rAAV particle of the present disclosure.

[0144] In some aspects, the polynucleotides (e.g., antibody expression cassettes), vectors, rAAV particles or compositions of the present disclosure are suitable for delivery to subjects in need (e.g., subjects suffering from Graves' ophthalmopathy). In some aspects, the polynucleotides (e.g., antibody expression cassettes), vectors, rAAV particles or compositions of the present disclosure are suitable for delivery to eye delivery sites, post-orbital or peri-orbital delivery sites, post-ocular delivery sites, extraocular muscle delivery sites, connective tissue delivery sites or any combination of delivery sites thereof. In some aspects, delivery is carried out by injection or infusion. In some aspects, delivery is carried out by a route of administration selected from intramuscular (IM), intravenous (IV), intralymphatic, intraocular, post-orbital, peri-orbital, post-ocular or any combination thereof. In some aspects, administration is suitable for delivery to post-orbital or peri-orbital fibroblasts, adipocytes, myofibroblasts, myocytes or any combination thereof. In some aspects, administration is administration to extraocular muscles. In some aspects, extraocular muscles are levator muscles or glabellar muscles. In some aspects, administration is administration to connective tissue. In some aspects, administration enters the periorbital space through the conjunctiva. In some aspects, administration is intralymphatic administration to the preauricular or submandibular lymph nodes. In some aspects, the polynucleotides (e.g., antibody expression cassettes), vectors, rAAV particles or compositions of the present disclosure are suitable for single dose administration. In some aspects, single dose multiple injections and / or infusions.

[0145] Certain aspects of the present disclosure relate to methods of expressing a therapeutic antibody or antigen-binding fragment thereof that binds IGF-1R in a subject in need thereof, comprising administering to the subject an effective amount of a polynucleotide of the present disclosure (e.g., an antibody expression cassette), a vector, a rAAV particle, or a composition. In some aspects, administration is a single dose. In some aspects, a single dose comprises multiple injections into the eye, retro-orbital or peri-orbital, retrobulbar, ocular muscle, or any other delivery site disclosed herein.

[0146] In some aspects, delivery or application can be intramuscular (IM), intravenous (IV), intraocular (IC), intralymphatic, periorbital, behind the eyeball or any combination thereof. In some aspects, delivery or application is delivery or application to eyes (e.g., one or both eyes) or near eyes (e.g., one or both eyes), such as intraocular, post-orbital or periorbital, behind the eyeball, near the eye muscle (e.g., delivery or application to levator and / or procerus), delivery or application to connective tissue near the eye, or any combination thereof. In some aspects, delivery or application is delivery or application to post-orbital or periorbital fibroblasts, adipocytes, myofibroblasts, myocytes or any combination thereof. In some aspects, delivery or application is carried out by injection. In some aspects, delivery or application is carried out by infusion. In some aspects, delivery or application is carried out by injection and / or infusion with a single dose. In some aspects, single dose administration includes multiple injections or infusions.

[0147] Also provided herein is a method of expressing an anti-IGF-1R antibody or an antigen-binding fragment thereof in a subject in need thereof, comprising administering to the subject an effective amount of a polynucleotide of the present disclosure (e.g., an antibody expression cassette), a vector, a rAAV particle, or a composition, wherein the administration is intramuscular (IM), intravenous (IV), intraocular (IC), intralymphatic, periorbital, retrobulbar, or any combination thereof. In some aspects, the gene therapy composition or AAV capsid is administered by periorbital, retrobulbar, and / or intramuscular injection (e.g., injection into the levator and / or proglottid muscle). In some aspects, administration is administration to an extraocular muscle. In some aspects, the extraocular muscle is the levator or proglottid muscle. In some aspects, administration is administration to connective tissue. In some aspects, administration is transconjunctival into the periorbital space. In some aspects, administration is intralymphatic administration to the preauricular or submandibular lymph nodes. In some aspects, administration results in expression of an anti-IGF-1R antibody or an antigen-binding fragment thereof in a cell type selected from fibroblasts, adipocytes, myofibroblasts, myocytes, and any combination thereof.

[0148] In some aspects, the subject has thyroid eye disease (TED), such as active or chronic Graves' ophthalmopathy.

[0149] Non-limiting examples of various aspects are presented in this disclosure.

[0150] I. Definitions

[0151] In order to make the present disclosure more easily understood, certain terms are first defined. Additional definitions are set forth in the detailed disclosure.

[0152] It should be noted that the term "a" or "an" entity refers to one or more / one or more of the entity; for example, "a / a nucleic acid sequence" should be understood to mean one or more / one or more nucleic acid sequences, unless otherwise specified. Therefore, the terms "a" (or "a kind"), "one or more / one or more" and "at least one / a kind" can be used interchangeably herein.

[0153] Furthermore, "and / or" as used herein should be considered as specific disclosure of each of the two specified features or components, with or without the other. Thus, the term "and / or" as used in phrases such as "A and / or B" herein is intended to include "A and B," "A or B," "A" (alone), and "B" (alone). Similarly, the term "and / or" as used in phrases such as "A, B, and / or C" is intended to cover each of the following: A, B, and C; A, B or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0154] The values ​​presented in this article can be written, or expressed in scientific notation, as x×10 y, or in scientific E notation xEy.

[0155] It should be understood that wherever herein aspects are described with the language "comprising," similar aspects described with "consisting of" and / or "consisting essentially of" are also provided.

[0156] The term "about" is used herein to mean approximately, roughly, around, or in the region of. When the term "about" is used with a numerical range, it modifies the range by extending the upper and lower boundaries of the listed numerical values. In general, the term "about" can modify a numerical value to be above or below the stated value, for example, up or down (higher or lower) by a 10% difference.

[0157] The term "at least" before a number or a series of numbers should be understood to include the number next to the term "at least", as well as all subsequent numbers or integers that can be logically included, as is apparent from the context. For example, the number of nucleotides in a nucleic acid molecule must be an integer. For example, "at least 18 nucleotides in a nucleic acid molecule of 21 nucleotides" means 18, 19, 20, or 21 nucleotides having the indicated properties. When "at least" appears before a series of numbers or a range, it should be understood that "at least" can modify each number in the series or range. "At least" is also not limited to integers (for example, "at least 5%" includes 5.0%, 5.1%, 5.18%, regardless of the number of significant figures).

[0158] As used herein, "not more than" or "less than" should be understood to mean the value next to the phrase and logically smaller values ​​or integers (such as are logical from the context) up to zero. When "not more than" appears before a series of numbers or a range, it should be understood that "not more than" can modify each number in the series or range.

[0159] As used herein, the term "intraocular" refers to a location within or present throughout the eye.

[0160] The term "intraorbital" as used herein refers to a location within the eye socket. The eye socket refers to a cavity within the skull that contains the eye, muscles, glands, blood vessels, nerves, etc. associated with the eye.

[0161] As used herein, the term "periorbital" refers to the area surrounding or surrounding the orbit (eg, the tissue surrounding or lining the orbit of the eye).

[0162] As used herein, the term "retroorbital" or "retrobulbar" refers to a location located or present behind the eyeball.

[0163] As used herein, the term "retrobulbar" refers to a location located or present behind the eyeball.

[0164] As used herein, "intralymphatic" refers to a location associated with a lymph node or lymphatic vessel.

[0165] As used herein, the term "delivery vector" or "vector" refers to any vector used to clone and / or transfer nucleic acids into a host cell, such as a plasmid, phage, transposon, cosmid, chromosome, artificial chromosome, virus, virion, etc. A vector can be a replicon to which another nucleic acid fragment can be attached to cause the replication of the attached fragment. "Replicon" refers to any genetic element (e.g., plasmid, phage, cosmid, chromosome, virus) that serves as an autonomous replication unit in vivo, i.e., can replicate under its own control. The term "delivery vector" or "vector" includes viral and non-viral vectors for introducing nucleic acids into cells in vitro, in vitro or in vivo. A large number of vectors are known and used in the art, including, for example, plasmids, modified eukaryotic viruses, or modified bacterial viruses. In some aspects, the insertion of a polynucleotide into a suitable vector can be achieved by connecting an appropriate polynucleotide fragment to a selected vector with complementary sticky ends. A vector can be engineered to encode a selective marker or reporter factor for the selection or identification of cells into which the vector has been incorporated. The expression of a selective marker or reporter allows identification and / or selection of host cells that incorporate and express other coding regions contained on the vector. Examples of selectable marker genes known and used in the art include: genes that provide resistance to ampicillin, streptomycin, gentamicin, kanamycin, hygromycin, bialaphos herbicides, sulfonamides, etc.; and genes used as phenotypic markers, i.e., anthocyanidin regulatory genes, isopentyl transferase genes, etc. Examples of reporter factors known and used in the art include: luciferase (Luc), green fluorescent protein (GFP), chloramphenicol acetyltransferase (CAT), β-galactosidase (LacZ), β-glucuronidase (Gus), etc. Selectable markers can also be considered as reporter factors. In some aspects, the delivery vector is selected from a viral vector (e.g., an AAV vector), a plasmid, a lipid, a protein particle, a bacterial vector, and a lysosome.

[0166] Some aspects of the present disclosure relate to biological vectors, which can include viruses, particularly attenuated and / or replication-defective viruses.

[0167] As used herein, the term "promoter" refers to a DNA sequence recognized by a cellular mechanism or an introduced synthetic mechanism required to initiate specific transcription of a gene. The term "promoter" is also intended to encompass those nucleic acid elements sufficient for promoter-dependent gene expression that can be controlled to be cell type-specific, tissue-specific, or induced by an external signal or agent; such elements may be located in the 5' or 3' region of a natural gene. In some aspects, the promoter is a constitutively active promoter, a cell type-specific promoter, or an inducible promoter.

[0168] As used herein, the term "enhancer" is a cis-acting element that stimulates or inhibits transcription of an adjacent gene. Enhancers that inhibit transcription are also referred to as "silencers." Enhancers can act in either direction (e.g., can be associated with a coding sequence) up to several thousand base pairs (kb) downstream of the coding sequence and the transcribed region.

[0169] As used herein, the term "regulatable promoter" is any promoter whose activity is influenced by cis- or trans-acting factors (eg, an inducible promoter, such as an external signal or agent).

[0170] As used herein, the term "constitutive promoter" is any promoter that directs RNA production in many or all tissues / cell types most of the time, for example, the human CMV immediate early enhancer / promoter region that promotes constitutive expression of a cloned DNA insert in mammalian cells.

[0171] The terms "transcriptional regulatory protein", "transcriptional regulatory factor" and "transcription factor" are used interchangeably herein and refer to nuclear proteins that bind to DNA response elements and thereby transcriptionally regulate the expression of related genes. Transcriptional regulatory proteins usually bind directly to DNA response elements, but in some cases, binding to DNA can be indirect through binding to another protein, which in turn binds to or has bound to the DNA response element.

[0172] As used herein, the term "termination signal sequence" can be any genetic element that causes RNA polymerase to terminate transcription, such as a polyadenylation signal sequence. The polyadenylation signal sequence is a recognition region necessary for endonuclease cleavage of an RNA transcript followed by the polyadenylation consensus sequence AATAAA. The polyadenylation signal sequence provides a "poly A site", i.e., a site on the RNA transcript to which adenine residues will be added by post-transcriptional polyadenylation.

[0173] As used herein, the term "signal peptide" refers to a polypeptide sequence or sequence combination sufficient to mediate the transport of a polypeptide to the cell surface. Without being bound by any particular theory, the transport of a polypeptide to the cell surface can be mediated by a secretory pathway, including the transport of a polypeptide from the cytosol to the endoplasmic reticulum, followed by the transport of the polypeptide to the cell membrane through the Golgi apparatus, where the protein can remain embedded in the cell membrane, or secreted from the cell. "Signal peptides" used herein include naturally occurring and synthetic signal sequences, signal "patches", and the like. Examples of signal peptides include, but are not limited to, endogenous signal peptides of HGH and variants thereof; endogenous signal peptides of interferons and variants thereof, including signal peptides of type I, type II, and type III interferons and variants thereof; and endogenous signal peptides of known cytokines and variants thereof, such as signal peptides and variants thereof of erythropoietin (EPO), insulin, TGF-β1, TNF, IL1-α, and IL1-β. In some aspects, the signal peptide is an IL-2 signal peptide. In some aspects, the signal peptide is an IL-10 signal peptide. In some embodiments, the signal peptide is a modified signal peptide.

[0174] As used herein, the term "internal ribosome entry site" or "IRES" refers to an element that facilitates direct internal ribosome entry into the start codon (e.g., ATG) of a cistron (protein coding region), resulting in cap-independent translation of the gene. See, e.g., Jackson RJ et al., Trends Biochem Sci 15(12):477-83 (199); Jackson RJ and Kaminski, A. RNA 1(10):985-1000 (1995). As used herein, "under the translational control of an IRES" means that translation is associated with the IRES and occurs in a cap-independent manner.

[0175] The term "self-processing cleavage site" or "self-processing cleavage sequence" as used herein refers to a post-translational or co-translational processing cleavage site or sequence. Such a "self-processing cleavage" site or sequence refers to a DNA or amino acid sequence, and 2A sites, sequences or domains or 2A-like sites, sequences or domains are used as examples herein. The term "self-processing peptide" is defined herein as a peptide expression product of a DNA sequence encoding a self-processing cleavage site or sequence, which mediates rapid intramolecular (cis) cleavage of a protein or polypeptide containing the self-processing cleavage site during translation to produce a discrete mature protein or polypeptide product.

[0176] As used herein, the term "additional proteolytic cleavage site" refers to a sequence adjacent to a self-processing cleavage site (e.g., a 2A or 2A-like sequence) incorporated into an expression construct of the present disclosure, and provides a method for removing additional amino acids remaining after cleavage of the self-processing cleavage sequence. Exemplary 2A peptides include, but are not limited to, P2A, E2A, F2A, and T2A. Exemplary "additional proteolytic cleavage sites" are described herein, including, but not limited to, furin cleavage sites having a consensus sequence RXK(R)R. Such furin cleavage sites can be cleaved by endogenous subtilisin-like proteases (e.g., furin and other serine proteases within the protein secretion pathway). In some aspects, other exemplary "additional proteolytic cleavage sites" may be used, as described in Lie et al., Sci Rep 7, 2193 (2017).

[0177] The terms "operably linked", "operably inserted", "operably positioned", "under the control of", or "under the transcriptional control of" refer to a promoter that is in the correct position and orientation relative to the nucleic acid to control initiation of RNA polymerase and expression of the gene. The term "operably linked" refers to a DNA sequence and a regulatory sequence that are linked in such a way as to allow gene expression when an appropriate molecule (e.g., a transcriptional activator) binds to the regulatory sequence. The term "operably inserted" refers to a DNA of interest introduced into a cell that is located near DNA sequences that direct transcription and translation of the introduced DNA (i.e., promote production of, for example, a polypeptide encoded by the DNA of interest).

[0178] The term "expression vector or construct" refers to any type of genetic construct comprising a nucleic acid, wherein part or all of the nucleic acid coding sequence can be transcribed.

[0179] As used herein, the term "polycistronic" or "polycistronic vector" refers to a nucleic acid sequence having two or more open reading frames (e.g., genes). An open reading frame in this context is a sequence of codons that can be translated into a polypeptide or protein (e.g., a heavy chain or a light chain). A "bicistronic" or "bicistronic vector" refers to a nucleic acid sequence having two open reading frames (e.g., genes). An open reading frame in this context is a sequence of codons that can be translated into a polypeptide or protein (e.g., a heavy chain or a light chain). In some aspects, the construct of the present disclosure is a polycistronic (e.g., bicistronic) construct (e.g., comprising a heavy chain and a light chain).

[0180] "Viral vector" refers to a vector created from at least a portion of a viral genome that can be used to carry or deliver one or more polynucleotide regions encoding or containing a molecule of interest (e.g., a protein, peptide, and oligonucleotide or a plurality thereof). Viral vectors can be used to deliver genetic material into cells. Viral vectors can be modified for specific applications. In some aspects, the delivery vector of the present disclosure is a viral vector selected from an adeno-associated virus (AAV) vector, an adenoviral vector, a lentiviral vector, or a retroviral vector.

[0181] The term "adeno-associated virus vector" or "AAV vector" as used herein refers to any vector that contains or is derived from a component of an adeno-associated vector and is suitable for infecting mammalian cells (preferably human cells). The term AAV vector generally refers to an AAV-type viral particle or virion containing a payload. AAV vectors can be derived from various serotypes, including combinations of serotypes (i.e., "pseudotyped" AAV) or from various genomes (e.g., single-stranded or self-complementary). In addition, AAV vectors can be replication-defective and / or targeted. As used herein, the term "adeno-associated virus" (AAV) includes, but is not limited to, AAV type 1, AAV type 2, AAV type 3 (including AAV type 3A and AAV type 3B), AAV type 4, AAV type 5, AAV type 6, AAV type 7, AAV type 8, AAV type 9, AAV type 10, AAV type 11, AAV type 12, AAV type 13, AAVrh8, AAVrh10, AAVrh.74, snake AAV, avian AAV, bovine AAV, canine AAV, equine AAV, ovine AAV, goat AAV, shrimp AAV, those AAV serotypes and evolutionary branches disclosed by Gao et al. (J. Virol. 78:6381 (2004)) and Moris et al. (Virol. 33:375 (2004)), and any other AAV now known or later discovered. See, e.g., FIELDS et al., VIROLOGY, Vol. 2, Chapter 69 (4th Edition, Lippincott-Raven Publishers). In some aspects, "AAV vectors" include derivatives of known AAV vectors. In some aspects, "AAV vectors" include modified or artificial AAV vectors (e.g., muscle-tropic AAVs, such as AAVMYO (see Weinmann et al. Nat. Comm. 11:5432, 2020)). The terms "AAV genome" and "AAV vector" can be used interchangeably. In some aspects, the AAV vector is modified relative to the wild-type AAV serotype sequence.

[0182] As used herein, an "AAV particle" is an AAV virus comprising an AAV vector genome having at least one payload region (e.g., a polynucleotide encoding a therapeutic protein or peptide (e.g., an antibody expression cassette)) and at least one inverted terminal repeat (ITR) region. In some aspects, the term "AAV vector of the present disclosure" or "AAV vector" refers to an AAV vector comprising a polynucleotide encoding an antibody (e.g., an antibody expression cassette) (e.g., encapsulated in an AAV particle).

[0183] A "coding sequence" or a sequence that "encodes" a particular molecule (e.g., a therapeutic protein or peptide) is a nucleic acid that is transcribed (in the case of DNA) or translated (in the case of mRNA) into a polypeptide in vitro or in vivo when operably linked to an appropriate regulatory sequence (e.g., a promoter). The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. The coding sequence may include, but is not limited to, cDNA from prokaryotic or eukaryotic mRNA, genomic DNA sequences from prokaryotic or eukaryotic DNA, and synthetic DNA sequences. The transcription termination sequence is usually located 3' to the coding sequence.

[0184] As used herein, the term "derived from / or derived from" refers to a component separated from or made using a specific molecule or organism or information (e.g., amino acid or nucleic acid sequence) from a specific molecule or organism. For example, a nucleic acid sequence (e.g., an AVV vector) derived from a second nucleic acid sequence (e.g., another AVV vector) may include a nucleotide sequence that is identical or substantially similar to the nucleotide sequence of the second nucleic acid sequence.

[0185] For the polynucleotides disclosed herein, the derived material can be obtained by, for example, naturally occurring mutagenesis, artificial directed mutagenesis, or artificial random mutagenesis. The mutagenesis used to derive the polynucleotides can be intentionally directed or intentionally random, or a mixture of the two. The mutagenesis of a polynucleotide to produce a different polynucleotide derived from the first polynucleotide can be a random event (e.g., caused by polymerase distortion), and the identification of the derived polynucleotides can be carried out by appropriate screening methods.

[0186] As used herein, the term "mutation" refers to any change in the structure of a gene, resulting in a variant (also called a "mutant") form that can be passed on to future generations. A mutation in a gene may be caused by a change in a single base in the DNA or by a deletion, insertion, or rearrangement of a larger portion of a gene or chromosome.

[0187] As used herein, the term "administering" refers to administering a composition of the disclosure (e.g., a polynucleotide disclosed herein (e.g., an antibody expression cassette), an AAV vector, a rAAV particle, or a composition) to a subject or system. Administration to an animal subject (e.g., administration to a human) can be by any appropriate route, such as, but not limited to, periorbital, retrobulbar, intralymphatic, and / or intramuscular injection.

[0188] As used herein, the term "modification" refers to a change in the state or structure of a molecule of the present disclosure. A molecule can be modified in a variety of ways, including chemical, structural, and functional modifications. In some aspects, the modification is relative to a reference wild-type molecule.

[0189] As used herein, the term "synthetic" refers to artificial production, preparation and / or manufacture. The synthesis of polynucleotides or polypeptides or other molecules of the present disclosure can be chemical synthesis or enzymatic synthesis.

[0190] "Nucleic acid", "polynucleotide" and "oligonucleotide" are used interchangeably in this application. These terms refer only to the primary structure of the molecule. Therefore, these terms include double-stranded and single-stranded DNA, and double-stranded and single-stranded RNA. The terms "nucleic acid", "polynucleotide" and "oligonucleotide" used herein are defined as molecules comprising two or more covalently linked nucleosides as generally understood by those skilled in the art. Such covalently linked nucleosides may also be referred to as nucleic acid molecules or oligomers. Polynucleotides may be recombinant, enzymatic or synthetically prepared, for example, by solid phase chemical synthesis and then purified. When referring to the sequence of a polynucleotide or nucleic acid, it refers to the sequence or order of the covalently linked nucleotides or nucleosides' core base moieties or their modifications.

[0191] As used herein, the term "mRNA" refers to a single-stranded RNA that encodes the amino acid sequence of one or more polypeptide chains.

[0192] The term "antisense" as used herein refers to a nucleic acid that is fully complementary to all or part of a gene, primary transcript, or processed mRNA, thereby interfering with the expression of an endogenous gene. A "complementary" polynucleotide is a polynucleotide that can base pair according to the standard Watson-Crick complementarity rules. Specifically, purines will pair with pyrimidine bases to form a combination of guanine and cytosine pairing (G:C) and adenine and thymine pairing (A:T) (in the case of DNA) or adenine and uracil pairing (A:U) (in the case of RNA). It should be understood that even if two polynucleotides are not completely complementary to each other, as long as each polynucleotide has at least one region that is substantially complementary to another polynucleotide, they can also hybridize to each other.

[0193] The terms "antisense strand" and "guide strand" refer to a strand of a dsRNA, such as an shRNA, that includes a region that is substantially complementary to a target sequence (e.g., mRNA). The antisense strand has a sequence that is sufficiently complementary to the desired target mRNA sequence to guide target-specific silencing, e.g., complementarity is sufficient to trigger destruction of the desired target mRNA by an RNAi mechanism or process.

[0194] The terms "sense strand" and "passenger strand" as used herein refer to a strand of a dsRNA, such as an shRNA, that includes a region that is substantially complementary to the antisense strand region as defined herein. The antisense strand and the sense strand of a dsRNA, such as an shRNA, hybridize to form a double-stranded structure.

[0195] As used herein, the term "polypeptide" is intended to encompass the singular "polypeptide" as well as the plural "polypeptides", and includes any one or more chains of two or more amino acids. Thus, as used herein, "peptide", "peptide subunit", "protein", "amino acid chain", "amino acid sequence" or any other term used to refer to one or more chains of two or more amino acids are included in the definition of "polypeptide", even though each of these terms may have a more specific meaning. The term "polypeptide" may replace any of these terms or be used interchangeably with any of these terms. The term also includes polypeptides that have been modified post-translationally or post-synthetically, such as conjugation of palmitoyl groups, glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting / blocking groups, proteolytic cleavage, or modification by non-naturally occurring amino acids. The term "peptide" as used herein encompasses full-length peptides and fragments, variants, or derivatives thereof. The "peptide" disclosed herein may be part of a fusion polypeptide comprising additional components, such as an Fc domain or an albumin domain, to increase half-life. The peptides described herein may also be derivatized in a variety of different ways. The peptides described herein may comprise modifications including, for example, conjugation of a palmitoyl group.

[0196] The terms "antibody" and "antibodies" refer to immunoglobulin molecules that recognize and specifically bind to a target (e.g., a protein, a polypeptide, a peptide, a carbohydrate, a polynucleotide, a lipid, or a combination thereof) through at least one antigen recognition site within the variable region of the immunoglobulin molecule. As used herein, the term "antibody" encompasses complete polyclonal antibodies, complete monoclonal antibodies, chimeric antibodies, humanized antibodies, human antibodies, fusion proteins comprising antibodies, and any other modified immunoglobulin molecules, as long as the antibody exhibits the desired biological activity.

[0197] Antibodies can belong to any of the five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, or subclasses (isotypes) thereof (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), which are based on the identity of their heavy chain constant domains, referred to as alpha, delta, epsilon, gamma, and mu, respectively. The different types of immunoglobulins have distinct and well-known subunit structures and three-dimensional configurations. Antibodies can be naked or conjugated to other molecules (e.g., toxins, radioisotopes, etc.).

[0198] The term "antibody fragment" refers to a portion of a complete antibody. "Antigen binding fragment", "antigen binding domain" or "antigen binding region" refers to a portion of a complete antibody that binds to an antigen. The antigen binding fragment may contain the antigen recognition site of the complete antibody (e.g., a complementary determining region (CDR) sufficient to bind to the antigen). Examples of antigen binding fragments of antibodies include, but are not limited to, Fab, Fab', F(ab')2 and Fv fragments, linear antibodies and single-chain antibodies (e.g., nanobodies). Antigen binding fragments of antibodies may be derived from any animal species, such as rodents (e.g., mice, rats or hamsters) and humans, or may be artificially produced.

[0199] The term "nanobody" or "nanobodies" or "single domain antibody" or "sdAb" refers to a class of antigen-binding fragments, which are single-chain immunoglobulin molecules composed of monomeric variable antibody domains, that recognize and specifically bind an antigen.

[0200] The term "monoclonal" antibody or its antigen binding fragment refers to a homogeneous antibody or antigen binding fragment group that participates in highly specific recognition and binding to a single antigenic determinant or epitope. This is in contrast to polyclonal antibodies that typically include different antibodies for different antigenic determinants. The term "monoclonal" antibody or its antigen binding fragment encompasses complete and full-length monoclonal antibodies as well as antibody fragments (e.g., Fab, Fab', F(ab')2, Fv), single-chain (scFv) mutants, fusion proteins comprising antibody portions, and any other modified immunoglobulin molecules comprising antigen recognition sites. In addition, "monoclonal" antibody or its antigen binding fragment refers to such antibodies and their antigen binding fragments made in any variety of ways, including but not limited to by hybridoma, phage selection, recombinant expression, and transgenic animals.

[0201] The term "bispecific" or "bifunctional antibody" or its antigen-binding fragment refers to an artificial hybrid antibody with two different heavy / light chain pairs and two different binding sites. Bispecific antibodies can be produced by a variety of methods, including hybridoma fusion or Fab' fragment connection. See, for example, Songsivilai & Lachmann, Clin. Exp. Immunol. 79: 315-321 (1990); Kostelny et al., J. Immunol. 148, 1547-1553 (1992).

[0202] The term "multispecific antibody" refers to an antibody that has specificity for more than two different epitopes (generally non-overlapping epitopes) or an antibody that contains more than two different antigen-binding sites.

[0203] The term "immunoglobulin" is used herein to include antibodies, their functional fragments, Fab, scFv, single domain antibodies (e.g., nanobodies), DART, F(ab')2, BITE and immunoadhesin. These antibody fragments or artificial constructs can include single-chain antibodies, Fab fragments, monovalent antibodies, divalent or multivalent antibodies or immunoadhesins. The binding or neutralization antibody construct can be a monoclonal antibody, a "humanized" antibody, a multivalent antibody or another suitable construct. An "immunoglobulin molecule" is a protein containing an immunologically active portion of an immunoglobulin heavy chain and an immunoglobulin light chain that are covalently coupled together and can be specifically bound to an antigen. An immunoglobulin molecule can be any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), a category (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or a subclass. The terms "antibody" and "immunoglobulin" can be used interchangeably herein. An "immunoglobulin heavy chain" is a polypeptide comprising at least a portion of an antigen binding domain of an immunoglobulin and at least a portion of a heavy chain variable region of an immunoglobulin. Thus, an immunoglobulin-derived heavy chain has a significant region of amino acid sequence homology with a member of the immunoglobulin gene superfamily. For example, the heavy chain in a Fab fragment is an immunoglobulin-derived heavy chain. An "immunoglobulin light chain" is a polypeptide comprising at least a portion of an antigen binding domain of an immunoglobulin and at least a portion of a variable region. Thus, an immunoglobulin-derived light chain has a significant region of amino acid homology with a member of the immunoglobulin gene superfamily. An "immunoadhesin" is a chimeric antibody-like molecule that combines a functional domain of a binding protein (usually a receptor, a ligand, a cell adhesion molecule, or 1-2 immunoglobulin variable domains) with an immunoglobulin constant domain (usually including a hinge or GS linker and an Fc region). A "fragment antigen binding" (Fab) fragment" is a region of an antibody that binds to an antigen. It consists of one constant domain and one variable domain of each of the heavy and light chains. With respect to the immunoglobulins or antibodies described herein, each fragment of an immunoglobulin coding sequence may be derived from one or more sources, or may be synthetic. Suitable fragments may include, for example, coding regions for one or more of a heavy chain, a light chain, and / or a fragment thereof, such as a constant region or variable region (CH1, CH2, and / or CH3) of a heavy chain and / or a constant region or variable region of a light chain. Alternatively, the variable region of a heavy or light chain may be used. Where appropriate, these sequences may be modified from the "natural" sequences from which they are derived, as described herein. The term "immunoglobulin construct" as used herein refers to any of the above-mentioned immunoglobulins or fragments thereof encoded by and contained in the expression cassettes and viral vectors described herein.

[0204] As used herein, the term "variable region" or "variable domain" is used interchangeably and is common in the art. Variable region generally refers to a part of an antibody, generally refers to a part of a light chain or a heavy chain, generally about 110 to 120 amino acids or 110 to 125 amino acids at the amino terminal in a mature heavy chain, and about 90 to 115 amino acids in a mature light chain, which are very different in sequence between antibodies, and are used for the combination and specificity of a particular antibody to its specific antigen. The variability of the sequence is concentrated in those regions referred to as complementary determining regions (CDRs), and the more highly conserved regions in the variable domains are referred to as framework regions (FRs). It is not desirable to be constrained by any particular mechanism or theory, and it is believed that the CDRs of light and heavy chains are primarily responsible for the interaction and specificity of antibodies with antigens. In some respects, variable region is a human variable region. In some respects, variable region includes rodent or murine CDRs and human framework regions (FRs). In some respects, variable region is a primate (e.g., non-human primate) variable region. In some aspects, the variable regions include rodent or murine CDRs and primate (eg, non-human primate) framework regions (FRs).

[0205] The terms "VL" and "VL domain" are used interchangeably to refer to the light chain variable region of an antibody.

[0206] The terms "VH" and "VH domain" are used interchangeably to refer to the heavy chain variable region of an antibody.

[0207] The VH and VL regions can be further subdivided into regions of high variability, called complementarity determining regions (CDRs), interspersed with more conserved regions, called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs, arranged in the following order from amino-terminus to carboxyl-terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of an antibody can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.

[0208] The term "Kabat numbering" and similar terms are recognized in the art, and refer to the numbering system of amino acid residues in the heavy chain and light chain variable region of an antibody or its antigen-binding fragment. In some aspects, CDR can be determined according to the Kabat numbering system (see, e.g., Kabat EA & Wu TT (1971) Ann NY Acad Sci 190: 382-391 and Kabat EA et al., (1991) Sequences of Proteins of Immunological Interest, 5th edition, US Department of Health and Human Services, NIH Publication No. 91-3242). Using the Kabat numbering system, the CDR in the antibody heavy chain molecule is usually present at amino acid positions 31 to 35, which may optionally include one or two additional amino acids, after 35 (referred to as 35A and 35B in the Kabat numbering scheme) (CDR1), amino acid positions 50 to 65 (CDR2) and amino acid positions 95 to 102 (CDR3). Using the Kabat numbering system, the CDRs within an antibody light chain molecule are typically present at amino acid positions 24 to 34 (CDR1), amino acid positions 50 to 56 (CDR2), and amino acid positions 89 to 97 (CDR3). In some aspects, the CDRs of the antibodies described herein have been determined according to the Kabat numbering scheme.

[0209] As used herein, the terms "constant region" or "constant domain" are interchangeable and have common meanings in the art. The constant region is a portion of an antibody, such as the carboxyl terminal portion of a light chain and / or a heavy chain, which is not directly involved in the binding of the antibody to an antigen, but can exhibit various effector functions, such as interactions with Fc receptors. The constant region of an immunoglobulin molecule typically has an amino acid sequence that is more conservative relative to an immunoglobulin variable domain. In some aspects, an antibody or antigen-binding fragment comprises a constant region or portion thereof sufficient to achieve antibody-dependent cell-mediated cytotoxicity (ADCC).

[0210] As used herein, the term "heavy chain" or "HC" when used to refer to an antibody can refer to any of the different types of amino acid sequences based on the constant domain, such as alpha (α), delta (δ), epsilon (ε), gamma (γ), and mu (μ), which produce IgA, IgD, IgE, IgG, and IgM class antibodies, respectively, including subclasses of IgG, such as IgG1, IgG2, IgG3, and IgG4. Heavy chain amino acid sequences are well known in the art. In some aspects, the heavy chain is a human heavy chain.

[0211] As used herein, the term "light chain" or "LC" when used to refer to an antibody can refer to any of the different types based on the amino acid sequence of the constant domain, for example, kappa (κ) or lambda (λ). Light chain amino acid sequences are well known in the art. In some aspects, the light chain is a human light chain.

[0212] "Fc region" (fragment crystallizable region) or "Fc domain" or "Fc" refers to the C-terminal region of an antibody heavy chain that mediates the binding of the immunoglobulin to host tissues or factors, including binding to Fc receptors located on various cells of the immune system (e.g., effector cells) or to the first component (C1q) of the classical complement system.

[0213] A "native sequence Fc region" or "native sequence Fc" comprises an amino acid sequence identical to the amino acid sequence of an Fc region found in nature. Native sequence human Fc regions include native sequence human IgG1 Fc regions; native sequence human IgG2 Fc regions; native sequence human IgG3 Fc regions; and native sequence human IgG4 Fc regions and naturally occurring variants thereof. Native sequence Fc includes various isotypes of Fc (see, e.g., Jefferis et al., (2009) mAbs 1:1; Vidarsson G. et al. Front Immunol. 5:520 (published online Oct. 20, 2014)).

[0214] "Fc receptor" or "FcR" is a receptor that binds to the Fc region of an immunoglobulin. FcRs that bind to IgG antibodies include receptors of the FcγR family, including allelic variants and alternatively spliced ​​forms of these receptors. The FcγR family consists of three activating receptors (FcγRI, FcγRIII, and FcγRIV in mice; FcγRIA, FcγRIIA, and FcγRIIIA in humans) and one inhibitory receptor (FcγRIIB). Human IgG1 binds to most human Fc receptors and triggers the strongest Fc effector function. In terms of the type of activating Fc receptor it binds, it is considered to be comparable to mouse IgG2a. In contrast, human IgG4 triggers the smallest Fc effector function. Vidarsson G. et al., Front Immunol. 5:520 (published online on October 20, 2014).

[0215] The constant region can be operated, for example, by recombinant technology, to eliminate one or more effector functions. "Effector function" refers to the interaction of an antibody Fc region with an Fc receptor or ligand, or the biochemical events resulting therefrom. Exemplary "effect functions" include C1q binding, complement dependent cytotoxicity (CDC), Fc receptor binding, FcγR-mediated effector functions (e.g., ADCC and antibody-dependent cell-mediated phagocytosis (ADCP)) and down-regulation of cell surface receptors (e.g., B cell receptor; BCR). Such effector functions generally require the Fc region to be combined with a binding domain (e.g., an antibody variable domain). Therefore, the term "constant region without Fc function" includes constant regions with reduced or no one or more effector functions mediated by the Fc region.

[0216] The effector function of antibodies can be reduced or avoided by different methods. The effector function of antibodies can be reduced or avoided by using antibody fragments lacking Fc regions (e.g., Fab, F(ab')2, single-chain Fv (scFv) or sdAbs consisting of monomeric VH or VL domains). Alternatively, so-called aglycosylated antibodies can be produced by removing the sugars connected to specific residues in the Fc region to reduce the effector function of antibodies while retaining other valuable properties of the Fc region (e.g., extended half-life and heterodimerization). Aglycosylated antibodies can be produced by, for example, deleting or changing the residues to which sugars are attached, enzymatically removing sugars, producing antibodies in cells cultured in the presence of glycosylation inhibitors, or by expressing antibodies in cells (e.g., bacterial host cells) that cannot glycosylate proteins. See, for example, U.S. Publication No. 20120100140. Another method is to use Fc regions from IgG subclasses with reduced effector functions. For example, IgG2 and IgG4 antibodies are characterized by having Fc effector function levels lower than IgG1 and IgG3. The residues closest to the hinge region in the CH2 domain of the Fc portion are responsible for the effector function of the antibody because it contains a binding site that highly overlaps with C1q (complement) and IgG-Fc receptors (FcγR) on effector cells of the innate immune system. Vidarsson G. et al., Front Immunol. 5: 520 (published online on October 20, 2014). Therefore, antibodies with reduced or no Fc effector function can be prepared by generating, for example, a chimeric Fc region comprising a CH2 domain of an IgG antibody of the IgG4 isotype and a CH3 domain of an IgG antibody of the IgG1 isotype, or a chimeric Fc region comprising a hinge region from IgG2 and a CH2 region from IgG4 (see, for example, Lau C. et al., J. Immunol. 191: 4769-4777 (2013)), or an Fc region with a mutation that results in an altered Fc effector function (e.g., reduced Fc function or no Fc function). See, eg, US Publication No. 20120100140 and the US and PCT applications cited therein, and An et al., mAbs 1:6, 572-579 (2009); the disclosures of which are herein incorporated by reference in their entireties.

[0217] In some aspects, an antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof can be modified so that it does not bind to the Fc region. See, for example, Saunders K., Front. Immunol., 10: 1296 (2019).

[0218] "Hinge", "hinge domain", "hinge region" or "antibody hinge region" are used interchangeably and refer to the domain of the heavy chain constant region that connects the CH1 domain to the CH2 domain and includes the upper, middle and lower segments of the hinge (Roux et al., J. Immunol. 1998 161: 4083). The hinge provides varying degrees of flexibility between the binding and effector regions of the antibody and also provides a site for intermolecular disulfide bonds between the two heavy chain constant regions.

[0219] As used herein, "isotype" refers to the antibody class encoded by the heavy chain constant region genes (e.g., IgGl, IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgD, and IgE antibodies).

[0220] The phrases "an antibody that recognizes an antigen" and "an antibody specific for an antigen" are used interchangeably herein with the term "an antibody that specifically binds to an antigen."

[0221] As used herein, "isolated antibody" is intended to refer to an antibody that is substantially free of other antibodies with different antigenicity. However, an isolated antibody that specifically binds to a protein epitope may have cross-reactivity with other corresponding proteins from different species.

[0222] The term "chimeric" antibody or antigen-binding fragment thereof refers to an antibody or antigen-binding fragment thereof in which the amino acid sequence is derived from two or more species. Typically, the variable regions of the light and heavy chains correspond to the variable regions of an antibody or antigen-binding fragment thereof derived from one mammalian species (e.g., mouse, rat, rabbit, etc.) with the desired specificity, affinity, and capacity, while the constant regions are homologous to sequences in an antibody or antigen-binding fragment thereof derived from another (usually human) species to avoid eliciting an immune response in that species.

[0223] The term "humanized" antibody or its antigen-binding fragment refers to a form of a non-human (e.g., mouse) antibody or antigen-binding fragment that is a specific immunoglobulin chain, chimeric immunoglobulin, or fragment thereof containing minimal non-human (e.g., mouse) sequences. Typically, a humanized antibody or its antigen-binding fragment is a human immunoglobulin in which residues from a complementary determining region (CDR) are replaced ("CDR grafting") with residues from a CDR of a non-human species (e.g., mouse, rat, rabbit, hamster) having the desired specificity, affinity, and capacity (Jones et al., Nature 321: 522-525 (1986); Riechmann et al., Nature 332: 323-327 (1988); Verhoeyen et al., Science 239: 1534-1536 (1988)). In some aspects, a humanized antibody or its antigen-binding fragment may comprise at least a portion of an immunoglobulin constant region or domain (Fc), typically of a human immunoglobulin. Examples of methods for producing humanized antibodies are described in U.S. Pat. No. 5,225,539; Roguska et al., Proc. Natl. Acad. Sci., USA, 91(3):969-973 (1994) and Roguska et al., Protein Eng. 9(10):895-904 (1996). In some aspects, a "humanized antibody" is a resurfaced antibody.

[0224] The term "human" antibody (HuMAb) or its antigen-binding fragment refers to an antibody or its antigen-binding fragment having an amino acid sequence derived from a human immunoglobulin locus, wherein such an antibody or antigen-binding fragment is made using any technology known in the art. This definition of a human antibody or its antigen-binding fragment includes complete or full-length antibodies and fragments thereof. In some aspects, a human antibody is a fully human antibody, that is, the antibody has an amino acid sequence derived from a human immunoglobulin locus, and does not include an amino acid sequence from a non-human immunoglobulin locus. In some aspects, a human antibody is a partially human antibody, that is, the antibody has an amino acid sequence derived from a human immunoglobulin locus and an amino acid sequence derived from a non-human immunoglobulin locus. In some aspects, a human antibody is a fully human antibody, a partially human antibody, or a humanized antibody. In some aspects, a human antibody is a chimeric human antibody, that is, the antibody has an amino acid sequence derived from a human immunoglobulin locus and an amino acid sequence derived from a non-human immunoglobulin locus of approximately similar amounts.

[0225] "Blocking" or "blocks" or "inhibitory" or "inhibits" antibodies are antibodies that reduce or inhibit (partially or completely) the binding of their target protein to one or more ligands when the antibody binds to the target protein, and / or antibodies that reduce or inhibit (partially or completely) one or more activities or functions of the target protein when the antibody binds to the target protein.

[0226] As used herein, "epitope" is a term of art and refers to a local region of an antigen to which an antibody or antigen-binding fragment thereof can specifically bind. An epitope can be, for example, contiguous amino acids of a polypeptide (linear or continuous epitope), or an epitope can be, for example, clustered together from two or more discrete regions of one or more polypeptides (conformational, nonlinear, discontinuous or non-continuous epitopes). The term "epitope mapping" refers to the process of identifying molecular determinants of antibody-antigen recognition.

[0227] As used herein, the phrase "contacting a cell" (e.g., contacting a cell with a polynucleotide (e.g., an antibody expression cassette), vector, rAAV particle, or composition of the present disclosure) includes contacting the cell directly or indirectly. In some aspects, contacting a cell with a polynucleotide (antibody expression cassette), vector, rAAV particle, or composition includes contacting the cell with the polynucleotide (antibody expression cassette), vector, rAAV particle, or composition in vitro, or contacting the cell with the polynucleotide (antibody expression cassette), vector, rAAV particle, or composition in vivo. Thus, for example, an individual performing the method may physically contact the polynucleotide (antibody expression cassette), vector, rAAV particle, or composition with the cell, or may place the polynucleotide (antibody expression cassette), vector, rAAV particle, or composition in a condition that permits or results in its subsequent contact with the cell.

[0228] In some aspects, contacting cells in vitro can be accomplished, for example, by incubating cells with polynucleotides (antibody expression cassettes), vectors, rAAV particles or compositions. In some aspects, contacting cells in vivo can be accomplished, for example, by injecting polynucleotides (antibody expression cassettes), vectors, rAAV particles or compositions of the present disclosure into or near the tissues where the cells are located (e.g., behind the eyeball, around the orbit or eye muscles), or by injecting polynucleotides (antibody expression cassettes), vectors, rAAV particles or compositions into another area (e.g., bloodstream or subcutaneous space) so that the agent subsequently reaches the tissue where the cells to be contacted are located. For example, the AAV vector genome can be encapsulated and / or coupled to a ligand that guides the AAV vector genome to a site of interest. A combination of in vitro and in vivo contact methods is also possible. For example, cells can be contacted with polynucleotides (antibody expression cassettes), vectors, rAAV particles or compositions of the present disclosure in vitro and then transplanted into a subject.

[0229] In some aspects, contacting a cell with a polynucleotide (antibody expression cassette), vector, rAAV particle or composition of the present disclosure includes "introducing" or "delivering" (directly or indirectly) the polynucleotide (antibody expression cassette), vector, rAAV particle or composition into the cell by promoting or affecting the uptake or absorption of the cell. The introduction of a polynucleotide (antibody expression cassette), vector, rAAV particle or composition into a cell can be in vitro and / or in vivo. For example, for in vivo introduction, the polynucleotide (antibody expression cassette), vector, rAAV particle or composition can be injected into a specific tissue site (e.g., a site where a therapeutic effect is desired) or systemically administered (e.g., administering a polynucleotide (antibody expression cassette), vector or rAAV particle targeted to a site where a therapeutic effect is desired). In vitro introduction into cells includes methods known in the art, such as electroporation and lipofection.

[0230] As used herein, the terms "effective amount", "therapeutically effective amount" and "sufficient amount" of, for example, a polynucleotide, expression cassette, vector, rAAV particle or composition of the present disclosure refer to an amount sufficient to produce a beneficial or desired outcome (including a clinical outcome) when administered to a subject (including a human), and thus, "effective amount" or its synonyms depend on the context in which it is used. In some aspects, a therapeutically effective amount of an agent (e.g., a polynucleotide (antibody expression cassette), vector, rAAV particle or composition disclosed herein) is an amount that produces a beneficial or desired outcome in a subject compared to a control.

[0231] The amount of a given agent (e.g., a polynucleotide (antibody expression cassette), vector, rAAV particle or composition of the present disclosure) will correspond to an amount that will vary depending on various factors, such as the given agent, drug formulation, route of administration, type of disease or condition, identity of the subject (e.g., age, sex and / or weight) or host being treated, etc.

[0232] As used herein, the term "gene therapy" is the insertion of a nucleic acid sequence (e.g., an antibody expression cassette comprising a promoter operably linked to a nucleic acid encoding a therapeutic molecule disclosed herein) into an individual's cells and / or tissues to treat, alleviate the symptoms of a disease, or reduce the likelihood of a disease. Gene therapy also includes the insertion of a transgene with an inhibitory property, i.e., inhibiting, reducing, or decreasing the expression, activity, or function of an endogenous gene or protein (e.g., an undesirable or abnormal (e.g., pathogenic) gene or protein). Such transgenes may be exogenous. Exogenous molecules or sequences are understood to be molecules or sequences that do not normally occur in the cells, tissues, and / or individuals to be treated. Both acquired and congenital diseases are suitable for gene therapy.

[0233] As used herein, the term "prophylactically effective amount" includes an amount of an agent (e.g., a polynucleotide (antibody expression cassette), vector, rAAV particle or composition disclosed herein) when the agent is administered to a subject suffering from or susceptible to a disease or condition (e.g., Graves' orbitopathy). Ameliorating a disease or condition includes slowing the progression of the disease or condition or reducing the severity of a later-developing disease or condition. A "prophylactically effective amount" can vary depending on the characteristics of the agent, e.g., the polynucleotide (antibody expression cassette), vector, rAAV particle or composition of the present disclosure, the mode of administration of the agent, the degree of disease risk, and medical history, age, weight, family history, genetic makeup, type of previous or concurrent treatment (if any), and other individual characteristics of the patient to be treated.

[0234] As used herein, "off-target" refers to any unintended effect on any one or more targets, genes, or cellular transcripts.

[0235] As used herein, "in vitro" refers to events that occur in an artificial environment, such as in a test tube or reaction vessel, in cell culture, in a petri dish, etc., rather than within an organism (eg, an animal, plant, or microorganism).

[0236] As used herein, the term "in vivo" refers to events that occur within an organism (eg, an animal, plant, or microorganism, or a cell or tissue thereof).

[0237] As used herein, the term "transfection" refers to a method of introducing exogenous nucleic acid into a cell. Transfection methods include, but are not limited to, chemical methods, physical treatments, and cationic lipids or mixtures. The list of agents that can be transfected into cells is large, including, for example, siRNA, shRNA, sense and / or antisense sequences, DNA encoding one or more genes and organized into expression plasmids, such as vectors.

[0238] "Determining protein levels" refers to directly or indirectly detecting a protein or mRNA encoding the protein by methods known in the art. "Direct determination" refers to performing a process (e.g., determining or testing a sample or "analyzing a sample", as defined herein) to obtain a physical entity or value. "Indirect determination" refers to receiving a physical entity or value from another party or source (e.g., a third-party laboratory that directly obtains a physical entity or value). The method for measuring protein levels generally includes, but is not limited to, Western blotting, immunoblotting, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immunoprecipitation, immunofluorescence, surface plasmon resonance, chemiluminescence, fluorescence polarization, phosphorescence, immunohistochemistry, matrix-assisted laser desorption / ionization time of flight (MALDI-TOF) mass spectrometry, liquid chromatography (LC)-mass spectrometry, microcytometry, microscopy, fluorescence activated cell sorting (FACS) and flow cytometry, as well as assays based on protein properties (including but not limited to enzyme activity or interactions with other protein partners). The method for measuring mRNA levels is known in the art.

[0239] "Percentage (%) of sequence identity" relative to a reference polynucleotide or polypeptide sequence is defined as the percentage of nucleic acids or amino acids in a candidate sequence that are identical to those in a reference polynucleotide or polypeptide sequence, after the sequences are aligned and gaps are introduced (if necessary) to achieve maximum percentage of sequence identity. The comparison for determining nucleic acid or amino acid sequence identity percentage can be achieved in a variety of ways within the capabilities of those skilled in the art, for example, using publicly available computer software, such as BLAST, BLAST-2 or Megalign software. Those skilled in the art can determine appropriate parameters for comparing sequences, including any algorithm required for achieving maximum alignment of the full length of the compared sequences. For example, the sequence comparison computer program BLAST can be used to generate sequence identity percentage values.

[0240] "Level" refers to the level or activity of a protein or mRNA encoding a protein, optionally compared to a reference. A reference can be any useful reference, as defined herein. A "reduced level" or "elevated level" of a protein refers to a decrease or increase in the level of a protein compared to a reference value. The protein level can be expressed as a percentage of mass / volume (e.g., g / dL, mg / mL, μg / mL, ng / mL) or relative to the total protein or mRNA in the sample.

[0241] The term "pharmaceutical composition" as used herein refers to a composition comprising a compound or molecule described herein (e.g., a polynucleotide (antibody expression cassette), vector or rAAV particle disclosed herein), formulated with a pharmaceutically acceptable excipient, and which can be manufactured or sold as part of a therapeutic regimen for treating a mammalian disease with the approval of a governmental regulatory agency.

[0242] As used herein, "pharmaceutically acceptable excipient" refers to any ingredient other than a compound described herein (eg, a carrier capable of suspending or dissolving the active compound) and which is substantially non-toxic and non-inflammatory to the patient.

[0243] "Reference" refers to any useful reference for comparing protein or mRNA levels or activity. A reference can be any sample, standard, standard curve, or level for comparison purposes. A reference can be a normal reference sample or a reference standard or level. A "reference sample" can be, for example, a control, such as a predetermined negative control value, such as a "normal control" or a previous sample collected from the same subject; a sample from a normal healthy subject, such as a normal cell or normal tissue; a sample (e.g., a cell or tissue) from a subject who does not have a disease; a sample from a subject diagnosed with a disease but not yet treated with a compound described herein; a sample from a subject who has been treated with a compound described herein; or a sample of a purified protein (e.g., any of those described herein) of known normal concentration.

[0244] As used herein, the term "subject" refers to any organism to which a composition disclosed herein (e.g., a polynucleotide (antibody expression cassette), vector, rAAV particle, or composition of the disclosure) can be administered, e.g., for experimental, diagnostic, preventive, and / or therapeutic purposes. Typical subjects include any animal (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans). A subject can be a person or animal seeking or in need of treatment, in need of treatment, currently receiving treatment, in the future receiving treatment, or receiving care from a trained professional for a particular disease or condition.

[0245] As used herein, the terms "treat," "treated," and "treating" refer to both therapeutic treatment and prophylactic or preventive measures, wherein the purpose is to prevent or mitigate (alleviate) an unwanted physiological condition, disorder, or disease, or to obtain a beneficial or desired clinical outcome. In some aspects, treatment reduces or alleviates symptoms associated with a disease or disorder. In some aspects, treatment produces a beneficial or desired clinical outcome.

[0246] As used herein, "Graves' orbitopathy" (GO) refers to the active or chronic stage of an autoimmune orbital inflammatory thyroid-related condition. "Active" GO or "dynamic" GO can last for about 6 to 24 months and can be followed by "inactive" or "chronic" GO.

[0247] Beneficial or desired clinical results include, but are not limited to, symptom relief; reduced severity of condition, disorder, or disease; stable (i.e., not worsening) condition, disorder, or disease state; delayed onset or slowed progression of condition, disorder, or disease; improved or alleviated (whether partially or completely) condition, disorder, or disease state, whether detectable or undetectable; improvement of at least one measurable physical parameter, not necessarily discernible by the patient; or enhancement or improvement of condition, disorder, or disease. In some aspects, treatment includes inducing a clinically significant response without excessive side effects. In some aspects, treatment includes extending survival compared to the expected survival without treatment. As used herein, the term "improvement" or "mitigation" refers to reducing the severity of at least one indicator of a condition or disease. As used herein, the term "preventing" or "prevention" refers to delaying or preventing the onset, development, or progression of a condition or disease for a period of time, including weeks, months, or years.

[0248] II. Therapeutic Antibodies

[0249] The present disclosure provides polynucleotides (e.g., antibody expression cassettes), vectors, and rAAV particles for delivering and expressing therapeutic anti-IGF-1R antibodies to cells or subjects. In some aspects, the antibody expression cassette comprises a promoter operably linked to a nucleic acid encoding an antibody or antigen-binding fragment thereof that binds to insulin-like growth factor-1 receptor (also interchangeably referred to herein as "anti-IGF receptor antibodies," "anti-IGF-1 receptor antibodies," "anti-IGF-1R antibodies," and "anti-IGF-1R antibodies").

[0250] In some aspects, the anti-IGF-1R antibody is an antibody or antigen-binding fragment thereof selected from a monoclonal antibody, a bispecific antibody or a multispecific antibody, or an antigen-binding fragment thereof. In some aspects, the therapeutic protein is an antibody fragment selected from Fab, Fab', F(ab')2, Fv fragment, linear antibody or single-chain antibody (e.g., nanobody).

[0251] In some aspects, the antibody is selected from the group consisting of a monoclonal antibody, a bispecific antibody, a nanobody, and a multispecific antibody.

[0252] In some aspects, the antibody is a monoclonal antibody.

[0253] In some aspects, the antibody expression cassette disclosed herein comprises a nucleic acid sequence encoding a heavy chain (HC) and / or a light chain (LC). In some aspects, the antibody expression cassette disclosed herein comprises a nucleic acid sequence encoding a variable heavy chain (VH) and / or a variable light chain (VL).

[0254] In some aspects, the antibody (eg, a monoclonal antibody) or antigen-binding fragment thereof is a chimeric antibody.

[0255] In some aspects, the antibody (eg, monoclonal antibody) or antigen-binding fragment thereof is a humanized antibody.

[0256] In some aspects, antibody (for example, monoclonal antibody) or its antigen-binding fragment is human antibody.In some aspects, human antibody is fully human antibody, it comprises the amino acid sequence derived from human immunoglobulin locus, and does not comprise the amino acid sequence from non-human immunoglobulin locus.In some aspects, human antibody is partially human antibody, it comprises the amino acid sequence derived from human immunoglobulin locus and the amino acid sequence derived from non-human immunoglobulin locus.In some aspects, human antibody is fully human antibody, partially human antibody or humanized antibody.In some aspects, human antibody is chimeric human antibody, that is, the antibody has the amino acid sequence derived from human immunoglobulin locus and the amino acid sequence derived from non-human immunoglobulin locus of about similar amount.

[0257] In some aspects, the anti-IGF-1R antibody is teitutumumab, VRDN-01100 (SEQ ID NO: 113), VRDN-02700 (SEQ ID NO: 116), ganitumab (AMG 479), figitumumab, CP-751,871, cixutumumab (AMG 655), IMC-A12, dalotuzumab, MK0646, RG1507, robatumumab, SCH 717454, AVE-1642a, MEDI-573, BIIB022, rhuMab IGFR, L1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11, L12H12, L13H13, L14H14, L15H1 5. L16H16, L17H17, L18H18, L19H19, L20H20, L21H21, L22H22, L23H23, L24H24, L25H25, L26H26, L27H27, L28H2 8. L29H29, L30H30, L31H31, L32H32, L33H33, L34H34, L35H35, L36H36, L37H37, L38H38, L39H39, L40H40, L41H41, L42H42, L43H43, L44H44, L45H45, L46H46, L47H47, L48H48, L49H49, L50H50, L51H51 or L52H52, or a fragment, variant or derivative thereof.

[0258] In some aspects, the anti-IGF-1R antibody is VRDN-01100 or VRDN-02700, or a fragment, variant or derivative thereof. In some aspects, the anti-IGFR antibody comprises SEQ ID NO: 113 (corresponding to VRDN-01100). In some aspects, the anti-IGFR antibody comprises SEQ ID NO: 116 (corresponding to VRDN-002700).

[0259] In some aspects, the anti-IGF-1R antibody is tetumumab, or a fragment, variant, or derivative thereof.

[0260] In some aspects, the antibody expression cassette comprises a nucleic acid encoding a signal peptide, which is operably linked to a nucleic acid encoding an antibody or an antigen-binding fragment thereof, which binds to an insulin-like growth factor-1 receptor. In some aspects, the signal peptide is an endogenous signal peptide of HGH and its variants; an endogenous signal peptide of interferon and its variants, including signal peptides of type I, type II and type III interferon and their variants; endogenous signal peptides of known cytokines and their variants, such as erythropoietin (EPO), insulin, TGF-β1, TNF, IL1-α and IL1-β signal peptides and their variants. In some embodiments, the signal peptide is a modified signal peptide. In some aspects, the signal peptide is an IL-2 signal peptide. In some aspects, the signal peptide is an IL-10 signal peptide. In some aspects, the signal peptide comprises an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 119 or 120. In some aspects, the nucleic acid sequence encoding the signal peptide comprises a nucleic acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NO: 121 or 122.

[0261] In certain aspects, a composition comprising a delivery vector (eg, a viral vector) comprising a nucleic acid encoding an immunoglobulin (eg, an anti-IGF-1R antibody) disclosed herein is suitable for delivery to a subject in need thereof.

[0262] In some aspects, an antibody expression cassette comprising a nucleic acid sequence encoding an anti-IGF-1R antibody can be packaged in a viral vector disclosed herein (e.g., an AAV vector), wherein the nucleic acid sequence encoding the anti-IGF-1R antibody is operably linked to a promoter. In some aspects, the promoter can drive the expression of the anti-IGF-1R antibody in a host cell (e.g., a fibroblast, an adipocyte, a myofibroblast, a myocyte, a muscle cell, or any combination thereof). In some aspects, a polynucleotide (e.g., an antibody expression cassette), a vector, a rAAV particle, or a composition comprising a nucleic acid encoding an anti-IGF-1R antibody can be administered to the eye, behind the eyeball, in the lymphatic vessel, around the orbit, and / or to muscle tissue (e.g., levator and / or promontory muscle). In some aspects, a polynucleotide (e.g., an antibody expression cassette), a vector, a rAAV particle, or a composition comprising a nucleic acid encoding an anti-IGF-1R antibody can be administered intramuscularly, intralymphatically, intradermally, intravenously, intraocularly, behind the eyeball, around the orbit, or any combination thereof. In some aspects, a polynucleotide (e.g., an antibody expression cassette), vector, rAAV particle, or composition comprising a nucleic acid encoding an anti-IGF-1R antibody can be administered intramuscularly to an extraocular muscle. In some aspects, administration is administration to an extraocular muscle. In some aspects, the extraocular muscle is a levator muscle or a procerus muscle. In some aspects, administration is administration to connective tissue. In some aspects, administration is transconjunctival entry into the periorbital space. In some aspects, administration is intralymphatic administration to a preauricular or submandibular lymph node. In some aspects, a polynucleotide (e.g., an antibody expression cassette), vector, rAAV particle, or composition comprising a nucleic acid encoding an anti-IGF-1R antibody can be administered intralymphatically to a preauricular and / or submandibular lymph node.

[0263] In some aspects, polynucleotides (e.g., antibody expression cassettes), vectors, rAAV particles or compositions comprising nucleic acids encoding anti-IGF-1R antibodies are administered to periorbital tissues. In some aspects, polynucleotides (e.g., antibody expression cassettes), vectors, rAAV particles or compositions comprising nucleic acids encoding anti-IGF-1R antibodies are administered to periorbital tissues. In some aspects, polynucleotides (e.g., antibody expression cassettes), vectors, rAAV particles or compositions comprising nucleic acids encoding anti-IGF-1R antibodies are administered intramuscularly to periorbital tissues. In some aspects, polynucleotides (e.g., antibody expression cassettes), vectors, rAAV particles or compositions comprising nucleic acids encoding anti-IGF-1R antibodies are administered intramuscularly to the muscles behind the eyeball. In some aspects, polynucleotides (e.g., antibody expression cassettes), vectors, rAAV particles or compositions comprising nucleic acids encoding anti-IGF-1R antibodies are administered intramuscularly to facial muscles. In some aspects, polynucleotides (e.g., antibody expression cassettes), vectors, rAAV particles or compositions comprising nucleic acids encoding anti-IGF-1R antibodies are administered intramuscularly to periorbital or postorbital connective tissues. In some aspects, polynucleotides (e.g., antibody expression cassettes), vectors, rAAV particles or compositions comprising nucleic acids encoding anti-IGF-1R antibodies are administered intramuscularly to the levator and / or promontory muscles. In some aspects, polynucleotides (e.g., antibody expression cassettes), vectors, rAAV particles or compositions comprising nucleic acids encoding anti-IGF-1R antibodies are administered to fibroblasts in periorbital or postorbital connective tissue. In some aspects, polynucleotides (e.g., antibody expression cassettes), vectors, rAAV particles or compositions comprising nucleic acids encoding anti-IGF-1R antibodies are administered to myofibroblasts in periorbital or postorbital connective tissue. In some aspects, polynucleotides (e.g., antibody expression cassettes), vectors, rAAV particles or compositions comprising nucleic acids encoding anti-IGF-1R antibodies are administered to adipocytes in periorbital or postorbital connective tissue. In some aspects, polynucleotides (e.g., antibody expression cassettes), vectors, rAAV particles or compositions comprising nucleic acids encoding anti-IGF-1R antibodies are administered to muscle cells in periorbital or postorbital connective tissue. In some aspects, nucleic acids encoding proteins or peptides disclosed herein are suitable for delivery to periorbital and / or postorbital tissues. In some aspects, nucleic acids encoding proteins or peptides disclosed herein are suitable for delivery to periorbital tissues. In some aspects, nucleic acids encoding proteins or peptides disclosed herein are suitable for intramuscular delivery to periorbital muscles or postorbital muscles. In some aspects, nucleic acids encoding proteins or peptides disclosed herein are suitable for intramuscular delivery to facial muscles. In some aspects, nucleic acids encoding proteins or peptides disclosed herein are suitable for delivery to periorbital or postorbital connective tissues. In some aspects, administration is through the conjunctiva into the periorbital space. In some aspects, administration is intralymphatic administration to preauricular or submandibular lymph nodes.

[0264] In some aspects, nucleic acids encoding proteins or peptides disclosed herein are suitable for delivery to other delivery sites disclosed herein.

[0265] II.A.1 Antibodies

[0266] Certain aspects of the present disclosure relate to polynucleotides (e.g., antibody expression cassettes), vectors, rAAV particles or compositions comprising nucleic acids encoding antibodies (e.g., monoclonal antibodies) and antigen-binding fragments thereof that specifically bind to insulin-like growth factor 1 receptor (IGF-1R), such as human IGF-1R. In some aspects, the encoded anti-IGF-1R antibody is an anti-insulin-like growth factor-1 receptor (anti-IGF-1R) antibody. In some aspects, the encoded anti-IGF-1R antibody comprises the amino acid sequence of teitutumumab, VRDN-01100 (SEQ ID NO: 113), VRDN-02700 (SEQ ID NO: 116), ganitutumumab (AMG 479), fentolumab, CP-751,871, citumumab (AMG655), IMC-A12, darototumumab, MK0646, RG1507, rotumumab, SCH 717454, AVE-1642a, MEDI-573, BIIB022, rhuMab IGFR, L1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11, L12H12, L13H13, L14H14, L15H1 5. L16H16, L17H17, L18H18, L19H19, L20H20, L21H21, L22H22, L23H23, L24H24, L25H25, L26H26, L27H27, L28H2 8. L29H29, L30H30, L31H31, L32H32, L33H33, L34H34, L35H35, L36H36, L37H37, L38H38, L39H39, L40H40, L41H41, L42H42, L43H43, L44H44, L45H45, L46H46, L47H47, L48H48, L49H49, L50H50, L51H51 or L52H52, or a fragment, variant or derivative thereof.

[0267] In some aspects, the encoded anti-IGF-1R antibody comprises the amino acid sequence of VRDN-01100 or VRDN-02700, or a fragment, variant or derivative thereof.

[0268] In some aspects, the encoded anti-IGF-1R antibody comprises the amino acid sequence of SEQ ID NO: 113 (corresponding to VRDN-01100). In some aspects, the anti-IGFR antibody comprises SEQ ID NO: 116 (corresponding to VRDN-002700).

[0269] In some aspects, the encoded anti-IGF-1R antibody comprises the amino acid sequence of tetumumab or a fragment, variant, or derivative thereof.

[0270] In some aspects, the disclosure relates to a polynucleotide (e.g., an antibody expression cassette), vector, rAAV particle, or composition of the disclosure, comprising a promoter operably linked to a nucleic acid encoding an immunoglobulin, such as an antibody or antigen-binding fragment that binds to IGF-1R.

[0271] In some aspects, the polynucleotides (e.g., antibody expression cassettes), vectors, rAAV particles or compositions of the present disclosure used in the methods disclosed herein encode antibodies (e.g., monoclonal antibodies or antigen-binding fragments thereof) having CDR and / or variable region sequences of tiuximab or antibodies having at least 80% identity (e.g., at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or about 100% identity) with the variable region or CDR sequences of tiuximab. In some aspects, the gene therapy construct encoding the anti-IGF-1R antibody (e.g., tiuximab) is a polycistronic (e.g., bicistronic) construct (e.g., comprising a heavy chain and a light chain). In some aspects, the polycistronic (e.g., bicistronic) construct further comprises a F2A or IRES element.

[0272] In some aspects, the polynucleotides (e.g., antibody expression cassettes), vectors, rAAV particles or compositions disclosed herein comprise nucleic acids encoding antibodies comprising the heavy and light chains of teixumab or an antigen-binding fragment thereof. In some aspects, the polynucleotides (e.g., antibody expression cassettes), vectors, rAAV particles or compositions disclosed herein comprise nucleic acid sequences modified relative to the wild-type (unmodified) teixumab coding sequence.

[0273] In some aspects, the anti-IGF-1R antibody comprises a heavy chain and a light chain. In some aspects, the nucleic acid sequence encoding the heavy chain comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 35-37 (or the HC encoding sequences disclosed in Table 11). In some aspects, the encoded HC comprises SEQ ID NO: 38 (or the HC amino acid sequence in Table 12). In some aspects, the nucleic acid sequence encoding the light chain comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 39-41 (or the LC encoding sequences disclosed in Table 13). In some aspects, the encoded LC comprises SEQ ID NO: 42 (or the LC amino acid sequence in Table 14).

[0274] In some aspects, the nucleic acid sequence encoding the heavy chain variable region comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 25-27 (or the VH encoding sequences disclosed in Table 5). In some aspects, the encoded VH comprises SEQ ID NO: 28 or SEQ ID NO: 91 (or any VH amino acid sequence in Table 6). In some aspects, the nucleic acid sequence encoding the light chain variable region comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 29-31 (or the VL encoding sequences disclosed in Table 7). In some aspects, the encoded VL comprises SEQ ID NO: 32 or SEQ ID NO: 92 (or any VL amino acid sequence in Table 8).

[0275] In some aspects, the heavy chain comprises a heavy chain variable region (VH) comprising a complementarity determining region (CDR) 1, VH CDR2, and VH CDR3. In some aspects, VH CDRs 1-3 correspond to the CDRs of tefixime. In some aspects, the nucleic acid sequence encoding a VH CDR1 comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 7 or 10 (or a VH CDR1 encoding sequence disclosed in Table 3 or Table 5); the nucleic acid sequence encoding a VH CDR2 comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 8, 11 or 14 (or a VH CDR2 encoding sequence disclosed in Table 3 or Table 5); and the nucleic acid sequence encoding a VH CDR3 comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: NO: 9, 12 or 15 (or the VH CDR3 encoding sequences disclosed in Table 3 or Table 5) has a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical.

[0276] In some aspects, the light chain comprises a light chain variable region (VL) comprising a complementarity determining region (CDR) 1, VL CDR2, and VL CDR3. In some aspects, VL CDRs 1-3 correspond to the CDRs of teixumab. In some aspects, the nucleic acid sequence encoding the VL CDR1 comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 16 (or a VL CDR1 encoding sequence disclosed in Table 4 or Table 7); the nucleic acid sequence encoding the VL CDR2 comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 17, 20, or 23 (or a VL CDR2 encoding sequence disclosed in Table 4 or Table 7); and the nucleic acid sequence encoding the VL CDR3 comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: NO:18, 21 or 24 (or the VL CDR3 encoding sequences disclosed in Table 4 or Table 7) have a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical.

[0277] In some aspects, the polynucleotides disclosed herein encode single domain antibodies (e.g., nanobodies) comprising (i) a heavy chain variable region (VH) comprising a complementarity determining region (CDR) 1, VH CDR2 and / or VH CDR3, or (ii) a light chain variable region (VL) comprising CDR1, VL CDR2 and / or VL CDR3. In some aspects, the encoded VH CDR and / or VL CDR are selected from the CDRs of the corresponding tebuconazole.

[0278] In some aspects, the polynucleotides disclosed herein encode the amino acid sequences of: teitutumumab, VRDN-01100 (SEQ ID NO: 113), VRDN-02700 (SEQ ID NO: 116), ganitutumumab (AMG 479), fentolumab, CP-751,871, citumumab (AMG 655), IMC-A12, darototumumab, MK0646, RG1507, rotumumab, SCH 717454, AVE-1642a, MEDI-573, BIIB022, rhuMab IGFR, L1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11, L12H12, L13H13, L14H14, L15H1 5. L16H16, L17H17, L18H18, L19H19, L20H20, L21H21, L22H22, L23H23, L24H24, L25H25, L26H26, L27H27, L28H2 8. L29H29, L30H30, L31H31, L32H32, L33H33, L34H34, L35H35, L36H36, L37H37, L38H38, L39H39, L40H40, L41H41, L42H42, L43H43, L44H44, L45H45, L46H46, L47H47, L48H48, L49H49, L50H50, L51H51 or L52H52, or a fragment, variant or derivative thereof.

[0279] In some aspects, the polynucleotides disclosed herein encode the amino acid sequence of VRDN-01100 or VRDN-02700, or a fragment, variant or derivative thereof.

[0280] In some aspects, the polynucleotides disclosed herein encode the amino acid sequence of SEQ ID NO: 113 (corresponding to VRDN-01100). In some aspects, the anti-IGFR antibody comprises SEQ ID NO: 116 (corresponding to VRDN-002700).

[0281] In some aspects, the polynucleotides disclosed herein encode the amino acid sequence of tetumumab, or a fragment, variant, or derivative thereof.

[0282] In some aspects, the polynucleotides disclosed herein encode antibodies or antigen-binding fragments thereof comprising the six CDRs listed in Tables 1 and 2 (i.e., any set of three VH CDRs listed in Table 1 and any set of three VL CDRs listed in Table 2). In some aspects, the polynucleotides disclosed herein comprise the nucleotide sequences of the six CDRs listed in Tables 3 and 4 (i.e., nucleic acids encoding three VH CDRs as listed in Table 3 and nucleic acids encoding three VLCDRs as listed in Table 4).

[0283] Table 1. Variable heavy chain CDR (VH CDR) amino acid sequence

[0284]

[0285] Table 2. Variable light chain CDR (VL CDR) amino acid sequence

[0286]

[0287] Table 3. Variable heavy chain CDR (VH CDR) nucleic acid sequences

[0288]

[0289]

[0290] Table 4. Variable light chain CDR (VL CDR) nucleic acid sequences

[0291]

[0292] In some aspects, the polynucleotides disclosed herein comprise a nucleic acid sequence listed in Table 5. In some aspects, the polynucleotides disclosed herein encode an antibody variable heavy chain (VH) sequence listed in Table 6 or an antigen-binding fragment thereof.

[0293] Table 5. Variable heavy chain (VH) nucleic acid sequences

[0294]

[0295] Table 6. Variable heavy chain (VH) amino acid sequence

[0296]

[0297] In some aspects, the polynucleotides disclosed herein comprise a nucleic acid sequence listed in Table 7. In some aspects, the polynucleotides disclosed herein encode an antibody variable light chain (VL) or an antigen-binding fragment thereof comprising a sequence listed in Table 8.

[0298] Table 7. Variable light chain (VL) nucleic acid sequences

[0299]

[0300] Table 8. Variable light chain (VL) amino acid sequence

[0301]

[0302] In some aspects, the polynucleotides disclosed herein comprise a nucleic acid selected from Table 5 (eg, a nucleic acid encoding a VH of Table 6) and a nucleic acid selected from Table 7 (eg, a nucleic acid encoding a VL of Table 8).

[0303] In some aspects, the polynucleotides disclosed herein comprise the nucleic acid sequences shown in Table 9.

[0304] Table 9. Light chain constant region nucleic acid sequences

[0305]

[0306] In some aspects, the polynucleotides disclosed herein comprise the nucleic acid sequences shown in Table 10.

[0307] Table 10. Heavy chain constant region nucleic acid sequences

[0308]

[0309]

[0310]

[0311] In some aspects, the polynucleotides disclosed herein comprise the nucleic acid sequences listed in Table 11. In some aspects, the polynucleotides disclosed herein encode antibodies comprising the heavy chains (HCs) or antigen-binding fragments thereof of the antibodies listed in Table 12. In some aspects, the polynucleotides disclosed herein encode the signal peptides listed in Table 12.

[0312] Table 11. Heavy chain (HC) nucleic acid sequence

[0313]

[0314]

[0315]

[0316] Table 12. Heavy chain (HC) amino acid sequence

[0317]

[0318]

[0319] In some aspects, the polynucleotides disclosed herein comprise a nucleic acid sequence listed in Table 13. In some aspects, the polynucleotides disclosed herein encode an antibody comprising a light chain (LC) or an antigen-binding fragment thereof of an antibody listed in Table 14. In some aspects, the polynucleotides disclosed herein encode a signal peptide listed in Table 14.

[0320] Table 13. Light chain (LC) nucleic acid sequences

[0321]

[0322]

[0323] Table 14. Light chain (LC) amino acid sequence

[0324]

[0325] In some aspects, the polynucleotides disclosed herein comprise the nucleic acids listed in Tables 11 and 13. In some aspects, the polynucleotides disclosed herein encode antibodies comprising the HC and LC of the antibodies listed in Tables 12 and 14 (i.e., the HC of the antibody listed in Table 12 and the LC of the same antibody listed in Table 14).

[0326] In some aspects, the therapeutic protein used in the methods disclosed herein is an antibody (e.g., a monoclonal antibody or an antigen-binding fragment thereof) having the VH, VL, HC and / or LC sequences of tebuconazole, as well as antibodies having at least 80% identity, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identity with the corresponding VH, VL, HC and / or LC sequences.

[0327] In some aspects, the polynucleotide also includes a joint sequence, which is operably connected to the nucleic acid sequence encoding the heavy chain and / or the nucleic acid sequence encoding the light chain. In some aspects, the polynucleotide also includes a pause element sequence, which is operably connected to the nucleic acid sequence encoding the heavy chain and / or the nucleic acid sequence encoding the light chain. In some aspects, the pause element sequence has a nucleotide sequence identical to SEQ ID NO: 54 at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%.

[0328] In some aspects, the polynucleotide comprises a nucleic acid sequence encoding an anti-IGF-1R antibody or antigen-binding fragment thereof (e.g., tetumumab) comprising: (i) VH CDR1-3 (e.g., SEQ ID NO: 7-9, 10-12 or 13-15) and VL CDR1-3 (e.g., SEQ ID NO: 16-18, 19-21 or 22-24); (ii) VH (e.g., SEQ ID NO: 26 or 27) and VL (e.g., SEQ ID NO: 30 or 31); (iii) HC (e.g., SEQ ID NO: 36 or 37) and LC (e.g., SEQ ID NO: 40 or 41); or (iv) a construct comprising any one of SEQ ID NO: 68-76, wherein the construct further comprises one or more of an IRES, a furin cleavage site, a 2a site, or a dual promoter (e.g., promoter VH-IRES-VL, etc.).

[0329] II.A.2. Antigen-binding fragments

[0330] In some aspects, the antigen-binding fragment of the antibody described herein (such as, for example, tiuximab) is encoded by a polynucleotide disclosed herein. Exemplary antigen-binding fragments include, but are not limited to, Fab, Fab', F(ab')2, and scFv, wherein Fab, Fab', F(ab')2, or scFv comprises a heavy chain variable region sequence and a light chain variable region sequence of tiuximab as described herein. Fab, Fab', F(ab')2, or scFv can be produced by any technology known to those skilled in the art. In some aspects, the antigen-binding fragment, such as Fab, Fab', F(ab')2, or scFv, further comprises a portion that extends the half-life of the antibody in vivo. This portion is also referred to as a "half-life extension portion". Any portion known to those skilled in the art for extending the half-life of an antigen-binding fragment (such as Fab, Fab', F(ab')2, or scFv) can be used in vivo. For example, the half-life extension portion can include an Fc region, a polymer, albumin, or an albumin-binding protein or compound. Polymers can include natural or synthetic, optionally substituted straight or branched polyalkylene, polyalkenylene, polyoxyalkylene, polysaccharide, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, methoxypolyethylene glycol, lactose, amylose, dextran, glycogen or its derivatives. Substituents can include one or more hydroxyl, methyl or methoxy groups. In some aspects, antigen binding fragments (such as Fab, Fab', F (ab') 2 or scFv) can be modified by adding one or more C-terminal amino acids to connect the half-life extension part. In some aspects, the half-life extension part is polyethylene glycol or human serum albumin. In some aspects, antigen binding fragments (such as Fab, Fab', F (ab') 2 or scFv) are fused to the Fc region.

[0331] In some aspects, the antibody or antigen-binding fragment thereof specifically binds to insulin-like growth factor-1 receptor (IGF-1R), such as human IGF-1R.

[0332] In some aspects, the encoded anti-IGF-1R antibody comprises the amino acid series of teitutumumab, VRDN-01100 (SEQ ID NO: 113), VRDN-02700 (SEQ ID NO: 116), ganitutumumab (AMG 479), fentolumab, CP-751,871, citumumab (AMG 655), IMC-A12, darototumumab, MK0646, RG1507, rotumumab, SCH 717454, AVE-1642a, MEDI-573, BIIB022, rhuMab IGFR, L1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11, L12H12, L13H13, L14H14, L15H 15. L16H16, L17H17, L18H18, L19H19, L20H20, L21H21, L22H22, L23H23, L24H24, L25H25, L26H26, L27H27, L28 H28, L29H29, L30H30, L31H31, L32H32, L33H33, L34H34, L35H35, L36H36, L37H37, L38H38, L39H39, L40H40, L41H41, L42H42, L43H43, L44H44, L45H45, L46H46, L47H47, L48H48, L49H49, L50H50, L51H51 or L52H52 or an antigen-binding fragment thereof.

[0333] In some aspects, the encoded anti-IGF-1R antibody comprises the amino acid sequence of VRDN-01100 (SEQ ID NO: 113) or VRDN-02700 (SEQ ID NO: 116), or an antigen-binding fragment thereof.

[0334] In some aspects, the encoded anti-IGF-1R antibody comprises the amino acid sequence of tefixime or an antigen-binding fragment thereof.

[0335] In some aspects, the antibodies (eg, monoclonal antibodies) or antigen-binding fragments thereof disclosed herein are modified so that they have enhanced half-life and / or reduced toxicity.

[0336] In some aspects, the encoded antibody or its antigen-binding fragment is a human antibody, a humanized antibody or a chimeric antibody. In some aspects, the antibody or its antigen-binding fragment can be selected from any class of immunoglobulins, including IgM, IgG, IgD, IgA and IgE, and selected from any isotype, including IgG1, IgG2, IgG3 and IgG4. In some aspects, the antibody or its antigen-binding fragment is bispecific or multispecific.

[0337] II.A.3 Antibody expression cassette

[0338] In certain aspects, provided herein are antibody expression cassettes comprising a nucleotide sequence encoding an antibody or antigen-binding fragment thereof, or a domain thereof (e.g., a light chain, a heavy chain, a variable light chain region, and / or a variable heavy chain region) described herein that specifically binds to an insulin-like growth factor receptor (IGFR) or an antigen-binding fragment thereof, or any combination thereof, and vectors, e.g., vectors comprising such antibody expression cassettes for expression in cells (e.g., fibroblasts).

[0339] In some aspects, provided herein are antibody expression cassettes comprising a nucleotide sequence encoding an antibody or antigen-binding fragment thereof that specifically binds to its insulin-like growth factor receptor (IGF-1R) antigen-binding fragment or any combination thereof and another class of antibodies or antigen-binding fragments thereof that compete with such antibodies or antigen-binding fragments for binding to its IGF-1R antigen-binding fragment or any combination thereof (e.g., in a dose-dependent manner) or binds to the same epitope as such antibodies or antigen-binding fragments.

[0340] In some aspects, the antibody expression cassette comprises a nucleic acid sequence encoding an antibody that competes for binding to the same epitope as teitutumumab, VRDN-01100 (SEQ ID NO: 113), VRDN-02700 (SEQ ID NO: 116), ganitutumumab (AMG 479), fentolumab, CP-751,871, citumumab (AMG 655), IMC-A12, darototumumab, MK0646, RG1507, rotumumab, SCH 717454, AVE-1642a, MEDI-573, BIIB022, rhuMab IGFR, L1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11, L12H12, L13H13, L14H14, L15H 15. L16H16, L17H17, L18H18, L19H19, L20H20, L21H21, L22H22, L23H23, L24H24, L25H25, L26H26, L27H27, L28 H28, L29H29, L30H30, L31H31, L32H32, L33H33, L34H34, L35H35, L36H36, L37H37, L38H38, L39H39, L40H40, L41H41, L42H42, L43H43, L44H44, L45H45, L46H46, L47H47, L48H48, L49H49, L50H50, L51H51 or L52H52 or an antigen-binding fragment thereof.

[0341] In some aspects, the antibody expression cassette comprises a nucleic acid sequence encoding an antibody that competes for binding to the same epitope as VRDN-01100 (SEQ ID NO: 113) or VRDN-02700 (SEQ ID NO: 116) or an antigen-binding fragment thereof.

[0342] In some aspects, the antibody expression cassette comprises a nucleic acid sequence encoding an antibody that competes with the tefixime antibody or antigen-binding fragment thereof for binding to the same epitope.

[0343] Also provided herein is an antibody expression cassette comprising a nucleotide sequence encoding a polypeptide comprising a sequence of any one of SEQ ID NOs: 7-24, 25-27, 29-31, 33-37, 39-41 or 43-76. In some aspects, an antibody or antigen-binding fragment thereof comprising the polypeptide specifically binds to an insulin-like growth factor receptor (IGFR) antigen-binding fragment thereof or any combination thereof.

[0344] Also provided herein are kits, vectors or host cells comprising (i) a first antibody expression cassette comprising a nucleotide sequence encoding any one of SEQ ID NOs: 68-76 and (ii) a delivery vector.

[0345] In some aspects, provided herein are antibody expression cassettes comprising nucleotide sequences comprising three VH domain CDRs, e.g., nucleotide sequences of VH CDR1, VH CDR2, and VH CDR3 of any one of the antibodies described herein (e.g., see Table 3), e.g., wherein the three VH domain CDRs are in the context of VH. In some aspects, provided herein are polynucleotides comprising nucleotide sequences comprising three VL domain CDRs, e.g., nucleotide sequences of VL CDR1, VLCDR2, and VL CDR3 of any one of the antibodies described herein (e.g., see Table 4), e.g., wherein the three VL domain CDRs are in the context of VL. In some aspects, provided herein is an antibody expression cassette (or polynucleotide combination) comprising a nucleotide sequence comprising an antibody or antigen-binding fragment thereof, the antibody or antigen-binding fragment thereof comprising: (i) three VH domain CDRs, e.g., a nucleotide sequence comprising VH CDR1, VH CDR2, and VH CDR3 of any one of the antibodies described herein (e.g., see Table 3), e.g., wherein the three VH domain CDRs are in the context of VH; and (ii) three VL domain CDRs, e.g., a nucleotide sequence comprising VL CDR1, VL CDR2, and VL CDR3 of any one of the antibodies described herein (e.g., see Table 4), e.g., wherein the three VL domain CDRs are in the context of VL.

[0346] In some aspects, provided herein are antibody expression cassettes comprising nucleotide sequences encoding three VH domain CDRs, e.g., polypeptides containing VH CDR1, VH CDR2, and VH CDR3 of any one of the antibodies described herein (e.g., see Table 1), e.g., wherein the three VH domain CDRs are in the context of VH. In some aspects, provided herein are antibody expression cassettes comprising nucleotide sequences encoding three VL domain CDRs, e.g., polypeptides containing VL CDR1, VLCDR2, and VL CDR3 of any one of the antibodies described herein (e.g., see Table 2), e.g., wherein the three VL domain CDRs are in the context of VL. In some aspects, provided herein is an antibody expression cassette (or combination of polynucleotides) comprising a nucleotide sequence encoding an antibody or antigen-binding fragment thereof comprising (i) three VH domain CDRs, e.g., a polypeptide comprising VH CDR1, VH CDR2, and VH CDR3 of any one of the antibodies described herein (e.g., see Table 1), e.g., wherein the three VH domain CDRs are in the context of VH, and (ii) three VL domain CDRs, e.g., a polypeptide comprising VLCDR1, VL CDR2, and VL CDR3 of any one of the antibodies described herein (e.g., see Table 2), e.g., wherein the three VL domain CDRs are in the context of VL.

[0347] In some aspects, the heavy chain comprises a heavy chain variable region (VH) comprising a complementarity determining region (CDR) 1, VH CDR2, and VH CDR3. In some aspects, the modified VH CDRs 1-3 correspond to the CDRs of tefixime. In some aspects, the nucleic acid sequence encoding VHCDR1 comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 7 or 10; the nucleic acid sequence encoding VHCDR2 comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 8, 11, or 14; the nucleic acid sequence encoding VHCDR3 comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: NO:9, 12 or 15 has a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical.

[0348] In some aspects, the light chain comprises a light chain variable region (VL) comprising a complementarity determining region (CDR) 1, VL CDR2, and VL CDR3. In some aspects, VL CDRs 1-3 correspond to the CDRs of teixumab. In some aspects, the nucleic acid sequence encoding VL CDR1 comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 16; the nucleic acid sequence encoding VL CDR2 comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 17, 21, or 23; the nucleic acid sequence encoding VL CDR3 comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: NO:18, 21 or 24 has a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical.

[0349] Also provided herein is an antibody expression cassette encoding an antibody or its antigen-binding fragment as described herein or its domain, which is optimized, for example, by codon / RNA optimization, replacement with a heterologous signal sequence, and elimination of mRNA instability elements. The optimized nucleic acid encoding an antibody or its antigen-binding fragment as described herein or its domain (e.g., heavy chain, light chain, VH domain, or VL domain) is generated for recombinant expression by introducing codon changes (e.g., due to the degeneracy of the genetic code, codon changes encoding the same amino acid) and / or eliminating inhibitory regions in mRNA, which can be adjusted accordingly by the optimization methods described in U.S. Patent Nos. 5,965,726; 6,174,666; 6,291,664; 6,414,132; and 6,794,498, each of which is incorporated herein by reference as a whole.

[0350] Antibody expression cassettes comprising nucleic acid sequences encoding anti-IGF-1R antibodies or antigen-binding fragments thereof described herein or domains thereof can be generated from nucleic acids of suitable sources using methods well known in the art (e.g., PCR and other molecular cloning methods). For example, genomic DNA obtained from hybridoma cells producing the antibody of interest can be used to perform PCR amplification using synthetic primers that hybridize to the 3' and 5' ends of the known sequence. In some aspects, the hybridoma cell line has a deposit number of DSMACC 2587 (deposited on October 4, 2003). In some aspects, the hybridoma cell line has a deposit number of DSMACC 2594 (deposited on September 5, 2003). This PCR amplification method can be used to obtain nucleic acids comprising sequences encoding light chains and / or heavy chains of antibodies or antigen-binding fragments thereof. This PCR amplification method can be used to obtain nucleic acids comprising sequences encoding variable light chain regions and / or variable heavy chain regions of antibodies or antigen-binding fragments thereof. The amplified nucleic acids can be cloned into vectors for expression in host cells and used for further cloning, such as generating chimeric and humanized antibodies or antigen-binding fragments thereof.

[0351] The antibody expression cassette provided herein can be, for example, in RNA form or DNA form. DNA includes cDNA, genomic DNA and synthetic DNA, and DNA can be double-stranded or single-stranded. If it is single-stranded, DNA can be a coding strand or a non-coding (antisense) strand. In some aspects, the antibody expression cassette is a cDNA or DNA lacking one or more endogenous introns. In some aspects, the antibody expression cassette is a non-naturally occurring antibody expression cassette. In some aspects, the antibody expression cassette is recombinantly produced. In some aspects, the antibody expression cassette is separated. In some aspects, the antibody expression cassette is substantially pure. In some aspects, the antibody expression cassette has been purified from natural components.

[0352] In some aspects, the viral vectors disclosed herein comprise an antibody expression cassette comprising coding regions for two or more polypeptides (eg, a heavy chain and a light chain).

[0353] When needed, the antibody expression cassette includes the coding region of two or more independent polypeptide chains, and each additional coding region beyond the first coding region is preferably connected to an element that promotes protein co-expression in a host cell, such as an internal ribosome entry sequence (IRES) element (see, e.g., U.S. Patent No. 4,937,190), a furin cleavage site, a 2A element, or a promoter. In some aspects, when a single vector comprises the sequence of each subunit of a multi-subunit protein, IRES, furin cleavage site, or a 2A element can be used. For example, in the case where the protein of interest is an immunoglobulin with desired specificity, the first coding region (encoding the heavy chain or light chain of an immunoglobulin) is located downstream of the promoter. The second coding region (encoding the remaining chain of an immunoglobulin) can be located downstream of the first coding region, and IRES, furin cleavage site, or a 2A element can be arranged between the two coding regions, e.g., immediately before the second coding region. In some aspects, incorporation of an IRES, furin cleavage site, or 2A element between the sequences of the first and second genes (encoding the heavy and light chains, respectively) can allow both chains to be expressed in the cell at approximately the same level from the same promoter.

[0354] In some aspects, the protein of interest comprises two or more subunits, such as immunoglobulin (Ig). In some aspects, the delivery vector of the present disclosure may include the coding region of each subunit. For example, a viral vector may include the coding region of an Ig heavy chain (or the variable region of an Ig heavy chain) and the coding region of an Ig light chain (or the variable region of an Ig light chain). In some aspects, the vector includes the first coding region of the heavy chain variable region of an antibody and the second coding region of the light chain variable region of an antibody. In some aspects, two coding regions may be separated, for example, by a 2A self-processing sequence to allow polycistronic transcription of two coding regions.

[0355] The viral vector may include coding regions for two or more proteins of interest. For example, the viral vector may include a coding region for a first protein of interest and a coding region for a second protein of interest. The first protein of interest and the second protein of interest may be the same or different.

[0356] The Kozak consensus sequence, Kozak consensus or Kozak sequence, is known to be a sequence present on eukaryotic mRNA and has a consensus sequence (gcc)gccRccAUGG, where R is a purine (adenine or guanine) three bases upstream of the start codon (AUG), followed by another "G". In some aspects, the vector comprises a nucleotide sequence having at least about 85%, at least about 90%, at least about 95% sequence identity or more sequence identity to the Kozak consensus sequence. In some aspects, the vector comprises a Kozak consensus sequence. In some aspects, after a polynucleotide encoding one or more proteins of interest (e.g., a restriction site downstream of a promoter) is inserted into the vector, the vector comprises a Kozak consensus sequence. For example, the vector may comprise a nucleotide sequence of GCCGCCATG (SEQ ID NO: 77), where ATG is the start codon for the protein of interest. In some aspects, the vector comprises a nucleotide sequence of GCGGCCGCCATG (SEQ ID NO: 78), where ATG is the start codon for the protein of interest.

[0357] In certain aspects, provided herein are compositions comprising a delivery vector (eg, a viral vector) comprising a nucleic acid encoding an anti-IGF-1R antibody or antigen-binding fragment.

[0358] In some aspects, a delivery vector (e.g., a viral vector) comprising a nucleic acid encoding an anti-IGF-1R antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof disclosed herein is secreted from the salivary glands and swallowed. In some aspects, the therapeutic effect of the secreted anti-IGF-1R antibody or antigen-binding fragment thereof is local, systemic, or both.

[0359] In some aspects, the delivery vector (e.g., a delivery vector comprising an antibody or antigen-binding fragment thereof that specifically binds to an insulin-like growth factor receptor (IGFR), such as human IGF-1R) is suitable for delivery to an eye (e.g., one or both eyes) or near an eye (e.g., one or both eyes), such as intraocularly, post-orbitally or peri-orbitally, behind the eyeball, intramuscularly near the eye, delivered to connective tissue near the eye, or any combination thereof. In some aspects, administration is administration to an extraocular muscle. In some aspects, the extraocular muscle is a levator muscle or a procerus muscle. In some aspects, administration is administration to connective tissue. In some aspects, administration is transconjunctival entry into the periorbital space. In some aspects, administration is intralymphatic administration to preauricular or submandibular lymph nodes. In some aspects, delivery or administration is delivery or administration to post-orbital or peri-orbital fibroblasts, adipocytes, myofibroblasts, myocytes, or any combination thereof. In some aspects, delivery or administration is performed by injection. In some aspects, delivery or administration is performed by infusion. In some aspects, delivery or administration is by injection and / or infusion in a single dose. In some aspects, single dose administration comprises multiple injections or infusions.

[0360] In some aspects, the antibody expression cassette comprises a nucleic acid sequence encoding an anti-IGF-1R antibody or antigen-binding fragment thereof comprising (i) a modified VH CDR 1-3 (e.g., SEQ ID NO: 7-9, 10-12, or 13-15) and a VLCDR 1-3 (e.g., SEQ ID NO: 16-18, 19-21, or 22-24) of tiuximab; (ii) a modified VH (e.g., SEQ ID NO: 26 or 27) and a VL (e.g., SEQ ID NO: 30 or 31) of tiuximab; (iii) a modified HC (e.g., SEQ ID NO: 36 or 37) and a LC (e.g., SEQ ID NO: 40 or 41) of tiuximab; or (iv) a modified VH CDR 1-3 (e.g., SEQ ID NO: 7-9, 10-12, or 13-15) and a VLCDR 1-3 (e.g., SEQ ID NO: 16-18, 19-21, or 22-24) of tiuximab; NO:68-76 any one of the sequence, wherein the sequence further comprises IRES, furin protease cleavage site, 2a site or dual promoter (e.g., promoter-VH-IRES-VL, etc.) One or more. In some aspects, the antibody expression cassette further comprises a sequence encoding a signal peptide (e.g., IL-2 or IL-10 signal peptide). In some aspects, the signal peptide is an IL-2 signal peptide or an IL-10 signal peptide. In some aspects, the encoded signal peptide comprises an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NO:119 or 120. In some aspects, the nucleic acid sequence encoding the signal peptide comprises a nucleic acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NO: 121 or 122.

[0361] III. Vector Constructs

[0362] Some aspects of the present disclosure relate to a vector construct or expression construct (e.g., an antibody expression cassette) having a eukaryotic promoter operably linked to a DNA of interest encoding an anti-IGF-1R antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof disclosed herein. In some aspects, the vector construct or expression construct containing a DNA sequence (or a corresponding RNA sequence) that can be used according to the present disclosure can be any eukaryotic expression construct containing a DNA or RNA sequence of interest. For example, a plasmid or viral construct (e.g., an AAV vector) can be cut to provide a linear DNA with joinable ends. These ends are bound to exogenous DNA with complementary, e.g., joinable ends to provide a biologically functional recombinant DNA molecule with a complete replicon and desired phenotypic properties. In some aspects, the vector construct or expression construct is capable of replicating in both eukaryotic and prokaryotic hosts, which constructs are known in the art and commercially available.

[0363] In some aspects, the vector construct or expression construct of the present disclosure encoding an anti-IGF-1R antibody (e.g., tebuconazole) is a polycistronic (e.g., bicistronic) construct (e.g., comprising a heavy chain and a light chain). In some aspects, the polycistronic (e.g., bicistronic) construct further comprises a F2A or IRES element.

[0364] In some aspects, the anti-IGF-1R antibody is teitutumumab, VRDN-01100 (SEQ ID NO: 113), VRDN-02700 (SEQ ID NO: 116), ganitutumumab (AMG 479), fentolumab, CP-751,871, citumumab (AMG655), IMC-A12, darototumumab, MK0646, RG1507, rotumumab, SCH 717454, AVE-1642a, MEDI-573, BIIB022, rhuMab IGFR, L1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11, L12H12, L13H13, L14H14, L15H1 5. L16H16, L17H17, L18H18, L19H19, L20H20, L21H21, L22H22, L23H23, L24H24, L25H25, L26H26, L27H27, L28H 28, L29H29, L30H30, L31H31, L32H32, L33H33, L34H34, L35H35, L36H36, L37H37, L38H38, L39H39, L40H40, L41H41, L42H42, L43H43, L44H44, L45H45, L46H46, L47H47, L48H48, L49H49, L50H50, L51H51 or L52H52, or an antigen-binding fragment thereof.

[0365] In some aspects, the anti-IGF-1R antibody is VRDN-01100 (SEQ ID NO: 113) or VRDN-02700 (SEQ ID NO: 116), or an antigen-binding fragment thereof.

[0366] In some aspects, the anti-IGF-1R antibody is tetumumab or an antigen-binding fragment thereof.

[0367] The exogenous (i.e., donor) DNA used in the present disclosure is obtained from a suitable cell and the vector construct or expression construct is prepared using techniques well known in the art. Similarly, techniques for obtaining expression of exogenous DNA or RNA sequences in genetically altered host cells are well known in the art (see, e.g., Kormal et al., Proc. Natl. Acad. Sci. USA, 84: 2150-2154 (1987); Sambrook et al., Molecular Cloning: a Laboratory Manual, 2nd Ed., 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; each of which is incorporated herein by reference for methods and compositions for eukaryotic expression of the DNA of interest).

[0368] In some respects, vector construct or expression construct contain promoter to promote the expression of interested DNA in secretory cells. In some respects, promoter is a strong eukaryotic promoter, for example, from human cytomegalovirus (CMV), mouse CMV promoter, mouse mammary tumor virus (MMTV), Rous sarcoma virus (RSV) or adenovirus promoter. Exemplary promoters include but are not limited to promoters from human CMV immediate early gene (Boshart et al., Cell 41:521-530 (1985) and promoters from the long terminal repeat sequence (LTR) of RSV (Gorman et al., Proc.Natl.Acad.Sci.USA 79:6777-6781 (1982). In some aspects, the promoter is CMV early enhancer / chicken beta actin (CBA) promoter, CAG promoter, CMV, EF1α, EF1α with CMV enhancer, CMV promoter with CMV enhancer (CMVe / p), CBA promoter with CMV enhancer, CMV promoter with SV40 intron, CBA promoter with CMV enhancer and CAG intron, CMV promoter with truncated 5' LTR In some aspects, the tissue-specific promoter is a muscle-specific promoter. In some aspects, the muscle-specific promoter is a DES promoter, a HSA promoter, a MCK promoter, a HMCK7 promoter, a dMCK promoter, a tMCK promoter, a CK8e promoter, a SPc5-12 promoter, a SP-301 promoter, a MH promoter, a Sk-CRM promoter, or a Sk-CRM4 promoter.

[0369] In some aspects, the promoter comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NO:34-38. In some aspects, the nucleic acid sequence comprising the promoter may comprise an intron. In some aspects, the intron is selected from SV40 introns, MVM introns or human beta globin introns. In some aspects, the CMVp promoter is fused to an SV40 intron. In some aspects, the SV40 intron comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NO:46.

[0370] Alternatively, the promoter used can be a tissue-specific promoter. For example, when the cell is a fibroblast, the tissue-specific promoter can be an insulin-like growth factor binding protein 2 (IGFBP2) promoter, a fibroblast activation protein (FAP) promoter, or a fibroblast-specific protein 1 (FSP1) promoter. When the cell is a myocyte, the tissue-specific promoter can be a muscle creatine kinase (MCK) promoter, a troponin I (TNNI2) promoter, a skeletal α-actin (ASKA) promoter, a DES promoter, a HSA promoter, a MCK promoter, a HMCK7 promoter, a dMCK promoter, a tMCK promoter, a CK8e promoter, a SPc5-12 promoter, a SP-301 promoter, a MH promoter, a Sk-CRM promoter, or a Sk-CRM4 promoter. When the cell is an adipocyte, the tissue-specific promoter can be adiponectin promoter or an adipocyte fatty acid binding protein (AP2) promoter.

[0371] In some aspects, the vector construct or expression construct contains a first promoter and a second promoter. In some aspects, the first promoter and the second promoter are different. In some aspects, the first promoter and the second promoter are identical. In some aspects, the first promoter and the second promoter start transcription in the same direction. In some aspects, the first promoter and the second promoter start transcription in different directions. In some aspects, the first or second promoter is a CMV promoter. In some aspects, the first or second promoter is an EF-1α promoter.

[0372] In some aspects, the nucleic acid sequence encoding the first promoter and the nucleic acid sequence encoding the second promoter are operably connected. In some aspects, the nucleic acid sequence encoding the first promoter and the nucleic acid sequence encoding the second promoter are operably connected through a pause element. In some aspects, the pause element comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:54.

[0373] Given the genome size limitation of AAV, polycistronic vectors (multiple genes or multiple open reading frames) expressing large proteins under the control of a single promoter can be a challenge.

[0374] In some aspects, the polycistronic vector disclosed herein comprises an internal ribosome entry site (IRES) sequence or a 2A peptide. In some aspects, the construct of the present disclosure may also include a proteolytic cleavage site. In some aspects, the proteolytic cleavage site is a furin cleavage site and / or a 2A cleavage site.

[0375] In some aspects, the vector constructs or expression constructs of the present disclosure may also include other components such as markers (e.g., antibiotic resistance genes (e.g., ampicillin resistance genes) or β-galactosidase) to help select cells containing and / or expressing the construct, a replication origin (preferably, a high copy number replication origin) for stable replication of the construct in bacterial cells, a nuclear localization signal, or other elements that promote the production of the DNA construct, the protein encoded thereby, or both. In some aspects, the vector constructs of the present disclosure may contain antibiotic resistance genes, including but not limited to neomycin, kanamycin, puromycin, and / or zeocin. In some aspects, the vector constructs of the present disclosure may contain ColE1, f1, pUC, p15A, or pMB1 replication origins.

[0376] In some aspects, the vector constructs of the present disclosure contain a backbone comprising the ColE1 origin of replication and / or the kanamycin resistance gene of SEQ ID NO:84.

[0377] In some aspects, the vector construct may comprise a ColE1 origin of replication and kanamycin resistance, such as a 5'-

[0378]

[0379] For eukaryotic expression, vector construct or expression construct can minimally comprise a eukaryotic promoter operably connected to the DNA of interest, which in turn is operably connected to a polyadenylation sequence. The polyadenylation signal sequence can be selected from any of the various polyadenylation signal sequences known in the art. In some aspects, the polyadenylation signal sequence is the early polyadenylation signal sequence of SV40. In some aspects, the polyadenylation signal sequence is the bovine growth hormone polyadenylation signal sequence (bGHpA). In some aspects, the polyadenylation signal sequence is the human growth hormone polyadenylation signal sequence (hGHpA). In some aspects, the polyadenylation signal sequence is the SV40 polyadenylation signal sequence (SV40pA). Construct can also include one or more introns, which can increase the expression level of the DNA of interest, particularly when the DNA of interest is a cDNA (e.g., introns not containing naturally occurring sequences). Any of a variety of introns known in the art can be used (e.g., human β-globin intron, which is inserted in a vector construct or expression construct at the 5' position of the DNA of interest). In some aspects, the intron is an SV40 intron. In some aspects, the intron is from an immunoglobulin heavy chain. In some aspects, the intron is a chimera of human β-globin and an immunoglobulin heavy chain gene. In some aspects, the intron comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NO:46, 56 or 82.

[0380] In some aspects, the polynucleotide comprises poly(A). In some aspects, the poly(A) is a synthetic poly(A) or a bovine growth hormone (BGH) poly(A). In some aspects, the polynucleotide comprises a poly(A) sequence comprising a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 52-53.

[0381] When it is necessary to include the coding region of two or more independent polypeptide chains or two or more subunits of a protein of interest in a viral vector, each additional coding region beyond the first coding region is preferably connected to an element that promotes protein co-expression in a host cell, such as an internal ribosome entry sequence (IRES) element (see, e.g., U.S. Patent No. 4,937,190) or a 2A element. In some aspects, when a single vector comprises a sequence encoding each subunit in a multi-subunit protein, IRES, furin cleavage site or 2A element can be used. For example, when the protein of interest is an immunoglobulin with desired specificity, the first coding region (encoding the heavy chain or light chain of the immunoglobulin) is located downstream of the promoter. The second coding region (encoding the remaining chain of the immunoglobulin) can be located downstream of the first coding region, and IRES, furin cleavage site or 2A element can be arranged between the two coding regions, such as immediately before the second coding region. In some aspects, incorporation of an IRES, furin cleavage site, or 2A element between the sequences of the first and second genes (encoding the heavy and light chains, respectively) can allow both chains to be expressed in the cell at approximately the same level from the same promoter.

[0382] In some aspects, the nucleic acid sequence of the vector construct or expression construct comprises a promoter, a heavy chain, an IRES, and a light chain sequence in the 5'-3' direction. In some aspects, the nucleic acid sequence of the construct comprises a promoter, a light chain variable, an IRES, and a heavy chain sequence in the 5'-3' direction.

[0383] In some aspects, nucleic acid sequence vector construct or expression construct comprises proteolytic cleavage site.For example, nucleic acid sequence may comprise sequence in vector construct or expression construct of the disclosure that is adjacent to self-processing cleavage site (such as 2A or 2A-like sequence), and provide the means for removing the remaining extra amino acid after cutting by self-processing cleavage sequence.Exemplary proteolytic cleavage site is described herein and it includes but is not limited to furin cleavage site with consensus sequence RXK (R) R (SEQ ID NO:79).This furin cleavage site can be cut by endogenous subtilisin-like protease (such as furin and other serine proteases in protein secretion pathway).In some aspects, other exemplary "extra proteolytic cleavage site" can be used, as described in Lie et al., Sci Rep 7,2193 (2017).

[0384] In some aspects, the nucleic acid sequence vector construct or expression construct comprises a nucleic acid encoding a signal peptide, which is operably linked to a nucleic acid encoding an antibody or antigen-binding fragment thereof that binds to an insulin-like growth factor-1 receptor. In some aspects, the signal peptide is an endogenous signal peptide of HGH and its variants; an endogenous signal peptide of interferon and its variants, including signal peptides of type I, type II and type III interferon and their variants; endogenous signal peptides of known cytokines and their variants, such as erythropoietin (EPO), insulin, TGF-β1, TNF, IL1-α and IL1-β signal peptides and their variants. In some embodiments, the signal peptide is a modified signal peptide. In some aspects, the signal peptide is an IL-2 signal peptide. In some aspects, the signal peptide is an IL-10 signal peptide. In some aspects, the signal peptide comprises an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 119 or 120. In some aspects, the nucleic acid sequence encoding the signal peptide comprises a nucleic acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NO: 121 or 122.

[0385] In some aspects, the nucleic acid sequence vector construct or expression construct comprises, in the 5'-3' direction, a promoter, a heavy chain, a furin cleavage site, a 2A cleavage site, and a light chain sequence.

[0386] In some aspects, the nucleic acid sequence vector construct or expression construct comprises, in the 5'-3' direction, a promoter, a first signal peptide, a heavy chain, a furin cleavage site, a 2A cleavage site, a second signal peptide, and a light chain sequence.

[0387] In some aspects, the nucleic acid sequence vector construct or expression construct comprises, in the 5'-3' direction, a promoter, a light chain, a furin cleavage site, a 2A cleavage site, and a heavy chain sequence.

[0388] In some aspects, the nucleic acid sequence vector construct or expression construct comprises, in the 5'-3' direction, a promoter, a first signal peptide, a light chain, a furin cleavage site, a 2A cleavage site, a second signal peptide, and a heavy chain sequence.

[0389] In some aspects, the nucleic acid sequence vector construct or expression construct comprises a promoter, a heavy chain sequence of an anti-IGF-1R antibody or antigen-binding fragment thereof, an IRES, and a light chain sequence of an anti-IGF-1R antibody or antigen-binding fragment thereof in the 5'-3' direction.

[0390] In some aspects, the nucleic acid sequence vector construct or expression construct comprises, in the 5'-3' direction, a promoter, a first signal peptide, a heavy chain sequence of an anti-IGF-1R antibody or antigen-binding fragment thereof, an IRES, a second signal peptide, and a light chain sequence of an anti-IGF-1R antibody or antigen-binding fragment thereof.

[0391] In some aspects, the nucleic acid sequence vector construct or expression construct comprises a promoter, an anti-IGF-1R antibody or antigen-binding fragment thereof light chain sequence, an IRES, and an anti-IGF-1R antibody or antigen-binding fragment thereof heavy chain sequence in the 5'-3' direction.

[0392] In some aspects, the nucleic acid sequence vector construct or expression construct comprises, in the 5'-3' direction, a promoter, a first signal peptide, a light chain sequence of an anti-IGF-1R antibody or antigen-binding fragment thereof, an IRES, a second signal peptide, and a heavy chain sequence of an anti-IGF-1R antibody or antigen-binding fragment thereof.

[0393] In some aspects, the vector construct or expression construct comprises, in the 5'-3' direction, a first promoter, a nucleic acid sequence encoding a light chain, a second promoter, and a nucleic acid sequence encoding a heavy chain.

[0394] In some aspects, the vector construct or expression construct comprises in the 5'-3' direction a first promoter, a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding a light chain, a second promoter, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding a heavy chain.

[0395] In some aspects, the vector construct or expression construct comprises, in the 5'-3' direction, a first promoter, a nucleic acid sequence encoding a heavy chain, a second promoter, and a nucleic acid sequence encoding a light chain.

[0396] In some aspects, the vector construct or expression construct comprises in the 5'-3' direction a first promoter, a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding a heavy chain, a second promoter, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding a light chain.

[0397] In some aspects, the vector construct or expression construct comprises, in the 5'-3' direction, a nucleic acid sequence encoding a heavy chain, a first promoter sequence, a second promoter sequence, and a nucleic acid sequence encoding a light chain.

[0398] In some aspects, the vector construct or expression construct comprises in the 5'-3' direction a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding a heavy chain, a first promoter sequence, a second promoter sequence, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding a light chain.

[0399] In some aspects, the vector construct or expression construct comprises, in the 5'-3' direction, a nucleic acid sequence encoding a light chain, a first promoter sequence, a second promoter sequence, and a nucleic acid sequence encoding a heavy chain.

[0400] In some aspects, the vector construct or expression construct comprises, in the 5'-3' direction, a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding a light chain, a first promoter sequence, a second promoter sequence, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding a heavy chain.

[0401] In some aspects, the promoter is selected from CAG promoter, CBA promoter, CMV promoter, EF1α promoter, EF1α promoter with CMV enhancer, CMV promoter with CMV enhancer (CMVe / p), CMV promoter with SV40 intron or tissue-specific promoter. In some aspects, the tissue-specific promoter is selected from DES promoter, HSA promoter, MCK promoter, HMCK7 promoter, dMCK promoter, tMCK promoter, CK8e promoter, SPc5-12 promoter, SP-301 promoter, MH promoter, Sk-CRM promoter and Sk-CRM4 promoter.

[0402] In some aspects, the promoter comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NO:47-51, 83 or 93. In some aspects, the nucleic acid sequence comprising the promoter may comprise an intron. In some aspects, the intron is selected from an SV40 intron, an MVM intron or a human beta globin intron. In some aspects, CMVp is fused to an SV40 intron. In some aspects, the CAG intron comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NO:82. In some aspects, the SV40 intron comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:46.

[0403] In some respects, the first promoter and the second promoter are different. In some respects, the first promoter and the second promoter are identical. In some respects, the first promoter and the second promoter start transcription in the same direction. In some respects, the first promoter and the second promoter start transcription in different directions.

[0404] In some aspects, the nucleic acid sequence encoding the first promoter and the nucleic acid sequence encoding the second promoter are operably connected. In some aspects, the nucleic acid sequence encoding the first promoter and the nucleic acid sequence encoding the second promoter are operably connected through a pause element. In some aspects, the pause element comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:54.

[0405] In some aspects, the signal peptide is selected from the endogenous signal peptide of HGH and its variants; the endogenous signal peptide of interferon and its variants, including the signal peptides and variants of type I, type II and type III interferon; and the endogenous signal peptides and variants of known cytokines, such as erythropoietin (EPO), insulin, TGF-β1, TNF, IL1-α and IL1-β signal peptides and their variants. In some embodiments, the signal peptide is a modified signal peptide. In some aspects, the signal peptide is an IL-2 signal peptide. In some aspects, the signal peptide is an IL-10 signal peptide. In some aspects, the signal peptide comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 119 or 120. In some aspects, the nucleic acid sequence encoding the signal peptide comprises a nucleic acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NO: 121 or 122.

[0406] The vector used to deliver the DNA of interest can be viral or non-viral, or can consist of naked DNA mixed with an adjuvant, such as a viral particle (e.g., AAV particle) or a cationic lipid or liposome. An "adjuvant" is a substance that does not produce the desired effect itself but acts to enhance or otherwise improve the action of the active compound. The precise vector and vector formulation used will depend on several factors, such as the secretory gland used for targeted gene transfer.

[0407] In some aspects, the composition comprises a delivery vector (e.g., a viral vector) comprising a nucleic acid construct or expression construct containing a nucleic acid encoding an anti-IGF-1R antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof. In some aspects, the delivery vector is suitable for delivery to periorbital or postorbital tissue. In some aspects, the tissue is connective tissue, muscle tissue, or adipose tissue.

[0408] In some aspects, the vector construct or expression construct comprises a nucleic acid sequence encoding an anti-IGF-1R antibody or antigen-binding fragment thereof (e.g., tetumumab) comprising: (i) VH CDRs 1-3 (e.g., SEQ ID NOs: 7-9, 10-12, or 13-15) and VL CDRs 1-3 (e.g., SEQ ID NOs: 16-18, 19-21, or 22-24); (ii) VH (e.g., SEQ ID NOs: 26 or 27) and VL (e.g., SEQ ID NOs: 30 or 31); (iii) HC (e.g., SEQ ID NOs: 36 or 37) and LC (e.g., SEQ ID NOs: 40 or 41); or (iv) a construct comprising any one of SEQ ID NOs: 68-76, wherein the construct further comprises one or more of an IRES, a furin cleavage site, a 2a site, or a dual promoter (e.g., promoter VH-IRES-VL, etc.).

[0409] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising, in the 5'-3' direction: a first promoter, a nucleic acid sequence encoding the heavy chain of an anti-IGF-1R antibody or an antigen-binding fragment thereof, an F2A site, a light chain of an anti-IGF-1R antibody or an antigen-binding fragment thereof, and poly(A).

[0410] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising, in the 5'-3' direction, a first promoter, a nucleic acid sequence encoding a first signal peptide, a heavy chain of an anti-IGF-1R antibody or an antigen-binding fragment thereof, an F2A site, a second signal peptide, a light chain of an anti-IGF-1R antibody or an antigen-binding fragment thereof, and poly(A).

[0411] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising the following in the 5'-3' direction: a CMV enhancer, a CBA promoter, a CAG intron, a CBA exon, a nucleic acid encoding an anti-IGF-1R antibody heavy chain or an antigen-binding fragment thereof, a furin cleavage site, a linker, a 2A peptide, a nucleic acid encoding a light chain of an anti-IGF-1R antibody or an antigen-binding fragment thereof, and BGHpA.

[0412] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising the following in the 5'-3' direction: a CMV enhancer, a CBA promoter, a CAG intron, a CBA exon, a nucleic acid encoding a first signal peptide, a heavy chain of an anti-IGF-1R antibody or an antigen-binding fragment thereof, a furin cleavage site, a linker, a 2A peptide, a nucleic acid encoding a second signal peptide, a light chain of an anti-IGF-1R antibody or an antigen-binding fragment thereof, and BGHpA.

[0413] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising, in the 5'-3' direction: a first promoter, a nucleic acid sequence encoding the heavy chain of an anti-IGF-1R antibody or an antigen-binding fragment thereof, IRES2, a light chain of an anti-IGF-1R antibody or an antigen-binding fragment thereof, and poly(A).

[0414] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising, in the 5'-3' direction, a first promoter, a nucleic acid sequence encoding a first signal peptide, a heavy chain of an anti-IGF-1R antibody or an antigen-binding fragment thereof, IRES2, a second signal peptide, a light chain of an anti-IGF-1R antibody or an antigen-binding fragment thereof, and poly(A).

[0415] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising the following in the 5'-3' direction: a CMV enhancer, a CBA promoter, a CAG intron, a CBA exon, a nucleic acid encoding the light chain of an anti-IGF-1R antibody or antigen-binding fragment thereof, an IRES2 element, a nucleic acid encoding the heavy chain of an anti-IGF-1R antibody or antigen-binding fragment thereof, and SynpA.

[0416] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising the following in the 5'-3' direction: a CMV enhancer, a CBA promoter, a CAG intron, a CBA exon, a nucleic acid encoding a first signal peptide, a light chain of an anti-IGF-1R antibody or an antigen-binding fragment thereof, and an IRES2 element, a nucleic acid encoding a second signal peptide, a heavy chain of an anti-IGF-1R antibody or an antigen-binding fragment thereof, and SynpA.

[0417] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising the following in the 5'-3' direction: a first promoter, an intron, a nucleic acid sequence encoding the light chain of an anti-IGF-1R antibody or an antigen-binding fragment thereof, poly(A), a pause element, a second promoter, a 5' LTR, a chimeric intron, a nucleic acid sequence encoding the heavy chain of an anti-IGF-1R antibody or an antigen-binding fragment thereof, and poly(A).

[0418] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising the following in the 5'-3' direction: a first promoter, an intron, a nucleic acid sequence encoding a first signal peptide, a light chain of an anti-IGF-1R antibody or an antigen-binding fragment thereof, poly(A), a pause element, a second promoter, a 5'LTR, a chimeric intron, a nucleic acid sequence encoding a second signal peptide, a heavy chain of an anti-IGF-1R antibody or an antigen-binding fragment thereof, and poly(A).

[0419] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising, in the 5'-3' direction: a CMV enhancer, a CMV promoter, an SV40 intron, a nucleic acid encoding an anti-IGF-1R antibody light chain or an antigen-binding fragment thereof, BGHpA, a pause element, an EF1α promoter, a 5' LTR, a chimeric human β globin and an immunoglobulin heavy chain intron, a nucleic acid encoding a heavy chain of an anti-IGF-1R antibody or an antigen-binding fragment thereof, and SynpA.

[0420] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising, in the 5'-3' direction: a CMV enhancer, a CMV promoter, an SV40 intron, a nucleic acid encoding a first signal peptide, a light chain of an anti-IGF-1R antibody or antigen-binding fragment thereof, BGHpA, a pause element, an EF1α promoter, a 5' LTR, a chimeric human β globin and an immunoglobulin heavy chain intron, a nucleic acid encoding a second signal peptide, a heavy chain of an anti-IGF-1R antibody or antigen-binding fragment thereof, and SynpA.

[0421] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising in the 5'-3' direction: a first promoter, a nucleic acid sequence encoding a heavy chain, poly(A), a pause element, a second promoter, a 5' LTR, a nucleic acid sequence encoding a light chain, and poly(A).

[0422] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising the following in the 5'-3' direction: a first promoter, a first signal peptide encoding a nucleic acid sequence of a heavy chain, poly(A), a pause element, a second promoter, a 5'LTR, a second signal peptide encoding a light chain, and poly(A).

[0423] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising in the 5'-3' direction: a CMV enhancer, a CMV promoter, nucleic acid encoding a heavy chain, BGHpA, a pause element, an EF1α promoter, a 5' LTR, nucleic acid encoding a light chain, and SynpA.

[0424] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising in the 5'-3' direction: a CMV enhancer, a CMV promoter, a nucleic acid encoding a first signal peptide, a heavy chain, BGHpA, a pause element, an EF1α promoter, a 5' LTR, a nucleic acid encoding a second signal peptide, a light chain, and SynpA.

[0425] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising in the 5'-3' direction: a first promoter, a nucleic acid sequence encoding a light chain, poly(A), a pause element, a second promoter, a 5' LTR, a nucleic acid sequence encoding a heavy chain, and poly(A).

[0426] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising the following in the 5'-3' direction: a first promoter, a first signal peptide encoding a nucleic acid sequence, a light chain, poly(A), a pause element, a second promoter, a 5'LTR, a second signal peptide encoding a heavy chain, and poly(A).

[0427] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising in the 5'-3' direction: a CMV enhancer, a CMV promoter, nucleic acid encoding a light chain, BGHpA, a pause element, an EF1α promoter, a 5' LTR, nucleic acid encoding a heavy chain, and SynpA.

[0428] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising the following in the 5'-3' direction: a CMV enhancer, a CMV promoter, a nucleic acid encoding a first signal peptide, a light chain, BGHpA, a pause element, an EF1α promoter, a 5'LTR, a nucleic acid encoding a second signal peptide, a heavy chain, and SynpA.

[0429] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising the following in the 5'-3' direction: poly(A), a nucleic acid sequence encoding a light chain, an intron, a 5'LTR, a first promoter, a second promoter, an intron, a nucleic acid sequence encoding a heavy chain, and poly(A).

[0430] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising the following in the 5'-3' direction: poly(A), a first signal peptide, a nucleic acid sequence encoding a light chain, an intron, a 5'LTR, a first promoter, a second promoter, an intron, a second signal peptide encoding a nucleic acid sequence, a heavy chain, and poly(A).

[0431] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising, in the 5'-3' direction: SYNpA, nucleic acid encoding a light chain, a chimera of a β-globin intron and an immunoglobulin heavy chain intron, a 5' LTR, an EF1α promoter fused to a CMV enhancer, a CMV promoter fused to an SV40 intron, a nucleic acid sequence encoding a heavy chain, and BGHpA.

[0432] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising, in the 5'-3' direction: SYNpA, a nucleic acid encoding a first signal peptide, a light chain, a chimera of a β globin intron and an immunoglobulin heavy chain intron, a 5' LTR, an EF1α promoter fused to a CMV enhancer, a CMV promoter fused to an SV40 intron, a nucleic acid sequence encoding a second signal peptide, a heavy chain, and BGHpA.

[0433] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising the following in the 5'-3' direction: poly(A), a nucleic acid sequence encoding a heavy chain, an intron, a 5' LTR, a first promoter, a second promoter, an intron, a nucleic acid sequence encoding a light chain, and poly(A).

[0434] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising the following in the 5'-3' direction: poly(A), a first signal peptide, a nucleic acid sequence encoding a heavy chain, an intron, a 5'LTR, a first promoter, a second promoter, an intron, a second signal peptide, a nucleic acid sequence encoding a light chain, and poly(A).

[0435] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising, in the 5'-3' direction: SYNpA, nucleic acid encoding a heavy chain, a chimera of a β-globin intron and an immunoglobulin heavy chain intron, a 5' LTR, an EF1α promoter fused to a CMV enhancer, a CMV promoter fused to an SV40 intron, a nucleic acid sequence encoding a light chain, and BGHpA.

[0436] In some aspects, the nucleic acid construct or expression construct comprises a polynucleotide comprising, in the 5'-3' direction: SYNpA, nucleic acid encoding a first signal peptide, a heavy chain, a chimera of a β globin intron and an immunoglobulin heavy chain intron, a 5' LTR, an EF1α promoter fused to a CMV enhancer, a CMV promoter fused to an SV40 intron, a nucleic acid sequence encoding a second signal peptide, a light chain, and BGHpA.

[0437] In some aspects, a vector construct or expression construct (eg, an antibody expression cassette) disclosed herein comprises one or more elements listed in Table 15.

[0438] Table 15. Nucleic acid sequences of exemplary construct elements.

[0439]

[0440]

[0441]

[0442]

[0443]

[0444]

[0445]

[0446] III.A. Delivery Vehicle

[0447] In some aspects, the delivery vehicle is a viral vector, a non-viral vector, a plasmid, a lipid, or a lysosome. In some aspects, the therapeutic effect of the antibody or antigen-binding fragment thereof is local, systemic, or both.

[0448] In certain aspects, a composition comprising a delivery vehicle (e.g., a viral vector, a non-viral vector, a plasmid, a lipid, a protein particle, a bacterial vector, or a lysosome) comprises a nucleic acid encoding or comprising an antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof disclosed herein.

[0449] In some aspects, the delivery vehicle is suitable for delivery to an eye (e.g., one or both eyes) or near an eye (e.g., one or both eyes), such as intraocularly, post-orbitally or peri-orbitally, behind the eyeball, in a muscle near the eye, to connective tissue near the eye, or any combination thereof. In some aspects, delivery or administration is delivery or administration to post-orbital or peri-orbital fibroblasts, adipocytes, myofibroblasts, myocytes, or any combination thereof. In some aspects, delivery or administration is performed by injection. In some aspects, delivery or administration is performed by infusion. In some aspects, delivery or administration is performed by injection and / or infusion in a single dose. In some aspects, single dose administration includes multiple injections or infusions.

[0450] In some aspects, a composition comprising a delivery vector (e.g., a viral vector, a non-viral vector, a plasmid, a lipid, a protein particle, a bacterial vector, or a lysosome) containing a nucleic acid encoding an antibody (e.g., a monoclonal antibody) disclosed herein or an antigen-binding fragment thereof is produced in a cell. In some aspects, the cell is a fibroblast, an adipocyte, a myofibroblast, a muscle cell, or any combination thereof.

[0451] In some aspects, a composition comprising a delivery vector (e.g., a viral vector, a non-viral vector, a plasmid, a lipid, a protein particle, a bacterial vector, or a lysosome) containing a nucleic acid encoding or comprising an antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof is suitable for delivery to connective tissue, muscle tissue, and / or adipose tissue. In some aspects, administration is administration to an extraocular muscle. In some aspects, the extraocular muscle is a levator muscle or a procerus muscle. In some aspects, administration is administration to connective tissue. In some aspects, administration is entry into the periorbital space through the conjunctiva. In some aspects, administration is intralymphatic administration to the preauricular or submandibular lymph nodes.

[0452] In some aspects, the delivery vector comprises a nucleic acid sequence encoding an anti-IGF-1R antibody or antigen-binding fragment thereof (e.g., tetumumab); comprising: (i) VH CDR 1-3 (e.g., SEQ ID NO: 7-9, 10-12, or 13-15) and VL CDR1-3 (e.g., SEQ ID NO: 16-18, 19-21, or 22-24); (ii) VH (e.g., SEQ ID NO: 26 or 27) and VL (e.g., SEQ ID NO: 30 or 31); (iii) HC (e.g., SEQ ID NO: 36 or 37) and LC (e.g., SEQ ID NO: 40 or 41); or (iv) comprising SEQ ID NO: 68-76 any one of the vector construct or expression construct (e.g., antibody expression cassette), wherein the vector construct or expression construct (e.g., antibody expression cassette) further comprises an IRES, a furin cleavage site, a 2a site, a dual promoter (e.g., promoter VH-IRES-VL, etc.) or a signal peptide (e.g., IL-2 or IL-10 signal peptide) One or more.

[0453] III.A.1 Non-viral vectors

[0454] The DNA of interest can be administered using a non-viral vector. "Non-viral vector" as used herein means a naked DNA, a chemical preparation containing naked DNA (e.g., a preparation of DNA and a cationic compound (e.g., dextran sulfate)) and a naked DNA mixed with an adjuvant such as a viral particle (i.e., the DNA of interest is not contained in the viral particle, but the conversion preparation consists of both naked DNA and viral particles (e.g., AAV particles)) (see, e.g., Curiel et al., Am. J. Respir. Cell Mol. Biol. 6: 247-52 (1992)). Therefore, a "non-viral vector" can include a vector consisting of DNA plus viral particles, wherein the viral particles do not contain the DNA of interest in the viral genome.

[0455] In some aspects, the non-viral vector is a bacterial vector. See, e.g., Baban et al., Bioeng Bugs., 1(6): 385-394 (2010).

[0456] In some aspects, the DNA of interest can be complexed with a polycationic substance (e.g., poly-L-lysine or DEAC-dextran), a targeting ligand, and / or a DNA binding protein (e.g., histone). DNA- or RNA-liposome complex formulations include a mixture of lipids that bind to genetic material (DNA or RNA) and facilitate nucleic acid delivery to cells. Liposomes that can be used according to the present disclosure include DOPE (dioleylphosphatidylethanolamine), CUDMEDA (N-(5-cholestenyl-3-β-ol 3-ureidoethane)-N', N'-dimethylethylenediamine).

[0457] Lipids that can be used according to the present disclosure include, but are not limited to, DOPE (dioleylphosphatidylethanolamine), cholesterol, and CUDMEDA (N-(5-cholestenyl-3-β-ol 3-ureidoethane)-N',N'-dimethylethylenediamine). As an example, DNA can be administered in a solution containing one of the following cationic liposome formulations: Lipofectin TM (LTI / BRL), Transfast TM (Promega Corp), Tfx50 TM (Promega Corp), Tfx10 TM (Promega Corp) or Tfx20 TM (Promega Corp). The concentration range of the liposome solution is about 2.5% to 15% volume: volume, preferably about 6% to 12% volume: volume. Further exemplary methods and compositions for formulating nucleic acids (e.g., DNA, including DNA or RNA not contained within a viral particle) for delivery according to the methods of the present disclosure are described in U.S. Pat. Nos. 5,892,071; 5,744,625; 5,925,623; 5,527,928; 5,824,812; 5,869,715.

[0458] Polymer particles can be used in polymer-based gene delivery according to the present disclosure. See, e.g., Putnam et al., PNAS 98(3):1200-1205 (2001).

[0459] The DNA of interest can also be administered as a DNA or RNA chemical coupled to a carrier molecule (e.g., an antibody or a receptor ligand) that facilitates delivery to a host cell to alter the biological properties of the host cell. The term "chemical" refers to the modification of a nucleic acid to allow the nucleic acid compound to be coupled to a carrier molecule (e.g., a protein or lipid or derivative thereof). Exemplary protein carrier molecules include antibodies specific to a target cell or a receptor ligand, i.e., molecules that are capable of interacting with a receptor associated with a target cell.

[0460] In some aspects, the composition comprising a non-viral delivery vector containing a nucleic acid encoding or comprising an antibody (e.g., a monoclonal antibody) disclosed herein or an antigen-binding fragment thereof is suitable for delivery to an eye (e.g., one or both eyes) or near an eye (e.g., one or both eyes), such as intraocular, post-orbital or peri-orbital, behind the eyeball, intramuscular near the eye, connective tissue near the eye, or any combination thereof. In some aspects, periorbital or post-orbital tissue is selected from muscle, connective tissue, and / or adipose tissue. In some aspects, administration is administration to an extraocular muscle. In some aspects, the extraocular muscle is a levator muscle or a procerus muscle. In some aspects, administration is administration to connective tissue. In some aspects, administration is through the conjunctiva into the periorbital space. In some aspects, administration is intralymphatic administration to anterior auricular or submandibular lymph nodes. In some aspects, delivery or administration is delivery or administration to post-orbital or peri-orbital fibroblasts, adipocytes, myofibroblasts, myocytes, or any combination thereof. In some aspects, delivery or administration is performed by injection. In some aspects, delivery or administration is performed by infusion. In some aspects, delivery or administration is by injection and / or infusion in a single dose. In some aspects, single dose administration comprises multiple injections or infusions.

[0461] In some aspects, the composition comprising a non-viral delivery vector comprises a nucleic acid encoding an antibody (e.g., a monoclonal antibody) or its antigen-binding fragment disclosed herein or a therapeutic peptide produced in a target cell. In some aspects, the therapeutic effect of the antibody or its antigen-binding fragment is local, systemic, or both.

[0462] In some aspects, the non-viral vector comprises a nucleic acid sequence encoding an anti-IGF-1R antibody or antigen-binding fragment thereof (e.g., tetumumab) comprising: (i) VH CDR 1-3 (e.g., SEQ ID NO: 7-9, 10-12, or 13-15) and VL CDR1-3 (e.g., SEQ ID NO: 16-18, 19-21, or 22-24); (ii) VH (e.g., SEQ ID NO: 26 or 27) and VL (e.g., SEQ ID NO: 30 or 31); (iii) HC (e.g., SEQ ID NO: 36 or 37) and LC (e.g., SEQ ID NO: 40 or 41); (iv) a VH (e.g., SEQ ID NO: 26 or 27) and a VL (e.g., SEQ ID NO: 30 or 31); NO: 68-76 any one of the vector construct or expression construct (e.g., antibody expression cassette), wherein the vector construct or expression construct (e.g., antibody expression cassette) further comprises an IRES, a furin cleavage site, a 2a site, a dual promoter (e.g., promoter VH-IRES-VL, etc.) or a signal peptide (e.g., IL-2 or IL-10 signal peptide) One or more.

[0463] III.A.2 Viral vectors

[0464] Generally speaking, the viral vectors used in accordance with the present disclosure consist of viral particles derived from naturally occurring viruses that have been genetically altered to render the virus replication-defective and to express a recombinant gene of interest in accordance with the present disclosure. Once the virus delivers its genetic material to a cell, it does not generate additional infectious virus but introduces the exogenous recombinant gene into the cell, preferably into the cell genome.

[0465] Many viral vectors are well known in the art, including, for example, retrovirus, adenovirus, adeno-associated virus (AAV), herpes simplex virus (HSV), cytomegalovirus (CMV), vaccinia and poliovirus vectors. Retroviral vectors are less preferred because retroviruses need to replicate cells and secretory glands are mostly composed of slowly replicated and / or terminally differentiated cells. Adenovirus and AAV are preferred viral vectors because the virus effectively infects slowly replicated and / or terminally differentiated cells. In some aspects, delivery vectors (e.g., viral vectors) are selected from adeno-associated virus (AAV) vectors, adenoviral vectors, lentiviral vectors or retroviral vectors.

[0466] In the case of using a replication-defective virus as a viral vector, infectious viral particles containing DNA or RNA corresponding to the DNA of interest can be produced by introducing the viral construct into a recombinant cell line that provides the missing components necessary for viral replication. In some aspects, transforming the recombinant cell line with a recombinant viral vector will not result in the production of a virus with replication capacity, for example, by homologously recombining the viral sequence of the recombinant cell line into the introduced viral vector. Methods for producing replication-defective viral particles containing nucleic acids of interest are well known in the art, and in, for example, Rosenfeld et al., Science 252:431-434 (1991) and Rosenfeld et al., Cell 68:143-155 (1992) (adenovirus); U.S. Patent No. 5,139,941 (adeno-associated virus); U.S. Patent No. 4,861,719 (retrovirus); and U.S. Patent No. 5,356,806 (vaccinia virus).

[0467] In some aspects, a viral delivery vector comprising a nucleic acid encoding or comprising an antibody (e.g., a monoclonal antibody) disclosed herein or an antigen-binding fragment thereof is suitable for delivery to an eye (e.g., one or both eyes) or near an eye (e.g., one or both eyes), such as intraocular, post-orbital or peri-orbital, behind the eyeball, intramuscular near the eye, connective tissue near the eye, or any combination thereof. In some aspects, periorbital or post-orbital tissue is selected from muscle, connective tissue, and / or adipose tissue. In some aspects, administration is administration to an extraocular muscle. In some aspects, the extraocular muscle is directed to the levator or glabellar muscle. In some aspects, administration is administration to connective tissue. In some aspects, administration is through the conjunctiva into the periorbital space. In some aspects, administration is intralymphatic administration to the preauricular or submandibular lymph nodes. In some aspects, delivery or administration is directed to fibroblasts, adipocytes, myofibroblasts, myocytes, or any combination thereof, post-orbital or peri-orbital. In some aspects, delivery or administration is performed by injection. In some aspects, delivery or administration is performed by infusion. In some aspects, delivery or administration is by injection and / or infusion in a single dose. In some aspects, single dose administration comprises multiple injections or infusions.

[0468] In some aspects, the viral delivery vector comprises a nucleic acid encoding a therapeutic protein, such as an antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof disclosed herein produced in a target cell. In some aspects, the therapeutic effect of the therapeutic antibody or its antigen-binding fragment is local, systemic, or both.

[0469] In some aspects, the viral vector comprises a nucleic acid sequence encoding an anti-IGF-1R antibody or antigen-binding fragment thereof (e.g., tetumumab) comprising: (i) VH CDR 1-3 (e.g., SEQ ID NO: 7-9, 10-12, or 13-15) and VL CDR1-3 (e.g., SEQ ID NO: 16-18, 19-21, or 22-24); (ii) VH (e.g., SEQ ID NO: 26 or 27) and VL (e.g., SEQ ID NO: 30 or 31); (iii) HC (e.g., SEQ ID NO: 36 or 37) and LC (e.g., SEQ ID NO: 40 or 41); (iv) a VH (e.g., SEQ ID NO: 26 or 27) and a VL (e.g., SEQ ID NO: 30 or 31); NO: 68-76 any one of the vector construct or expression construct (e.g., antibody expression cassette), wherein the vector construct or expression construct (e.g., antibody expression cassette) further comprises an IRES, a furin cleavage site, a 2a site, a dual promoter (e.g., promoter VH-IRES-VL, etc.) or a signal peptide (e.g., IL-2 or IL-10 signal peptide) One or more.

[0470] IV. Adeno-associated virus (AAV)-mediated gene therapy

[0471] AAV, a parvovirus belonging to the genus Dependovirus, has several attractive features not found in other viruses. For example, AAV can infect a variety of host cells, including non-dividing cells. In addition, AAV can infect cells from different species. Importantly, AAV is not associated with any human or animal disease and does not appear to alter the physiological properties of host cells after integration. Finally, AAV is stable under a variety of physical and chemical conditions, which helps meet production, storage and transportation requirements.

[0472] The AAV genome is a linear, single-stranded DNA molecule of approximately 4700 nucleotides (the AAV-2 genome consists of 4681 nucleotides) that typically contains an internal non-repetitive segment flanked at each end by inverted terminal repeats (ITRs). The ITRs are approximately 145 nucleotides in length (AAV-1 has an ITR of 143 nucleotides) and have multiple functions, including serving as an origin of replication and as a packaging signal for the viral genome.

[0473] The internal non-repetitive portion of the genome includes two large open reading frames (ORFs), termed the AAV replication (rep) and capsid (cap) regions. These ORFs encode replication and capsid gene products, respectively: replication and capsid gene products (i.e., proteins) allow replication, assembly, and packaging of complete AAV virions. More specifically, at least four families of viral proteins are expressed from the AAV rep region: rep 78, rep 68, rep 52, and rep 40, all of which are named after their apparent molecular weights. The AAV cap region encodes at least three proteins: VP1, VP2, and VP3.

[0474] AAV is a helper-dependent virus that requires co-infection with a helper virus (e.g., adenovirus, herpes virus, or vaccinia virus) to form fully functional AAV virions. In the absence of co-infection with a helper virus, AAV establishes a latent state in which the viral genome is inserted into the host cell chromosome or exists as an episome, but does not produce infectious virions. Subsequent infection with a helper virus "rescues" the integrated genome, allowing it to replicate and be packaged into viral capsids, thereby reconstructing infectious virions. Although AAV can infect cells from different species, the helper virus must be the same species as the host cell. Therefore, for example, human AAV will replicate in canine cells co-infected with canine adenovirus.

[0475] In order to produce recombinant AAV (rAAV) virions containing DNA, a suitable host cell line is transfected with an AAV vector containing DNA but lacking rep and cap. The host cells are then infected with wild-type (wt) AAV and a suitable helper virus to form rAAV virions. In addition, wt AAV genes (called auxiliary function genes, including rep and cap) and helper virus function genes (called accessory function genes) can be provided in one or more plasmids, thereby eliminating the need for wt AAV and helper viruses when producing rAAV virions. The auxiliary and accessory function gene products are expressed in host cells, where they act in trans on rAAV vectors containing heterologous genes. The heterologous genes are then replicated and packaged as if they were wt AAV genomes to form recombinant AAV virions. When the patient's cells are transduced with the produced rAAV virions, the DNA enters and is expressed in the patient's cells. Since the patient's cells lack rep and cap genes and accessory function genes, rAAV virions cannot further replicate and package their genomes. In addition, without the source of rep and cap genes, wt AAV virions cannot be formed in patient cells. See, e.g., U.S. Application Publication No.: 2003 / 0147853.

[0476] In some aspects, the AAV vector of the present disclosure may include or be derived from any natural or recombinant AAV serotype. According to the present disclosure, the AAV serotype may be, but is not limited to, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAV9, AAV10, AAVrh10, AAV11, and AAV12. In some aspects, the AAV serotype is AAV1, AAV2, AAV6, or AAV9. In some aspects, the AAV vector is modified relative to the wild-type AAV serotype sequence. In some aspects, the AAV vector is modified relative to the wild-type AAV1, AAV2, AAV6, AAV8, or AAV9. In some aspects, the AAV vector serotype is AAV1 or a modified AAV vector derived therefrom. In some aspects, the AAV vector serotype is AAV2 or a modified AAV vector derived therefrom. In some aspects, the AAV vector serotype is AAV6 or a modified AAV vector derived therefrom. In some aspects, the AAV vector serotype is AAV8 or a modified AAV vector derived therefrom. In some aspects, the AAV vector serotype is AAV9 or a modified AAV vector derived therefrom. In some aspects, the AAV vector serotype is AAVMYO (see Weinmann et al. Nat. Comm. 11: 5432, 2020).

[0477] In some aspects, the composition comprising an AAV delivery vector contains a nucleic acid encoding or comprising an antibody disclosed herein (e.g., a monoclonal antibody) or its antigen-binding fragment. In some aspects, the AAV delivery vector containing a nucleic acid encoding or comprising an antibody disclosed herein (e.g., a monoclonal antibody) or its antigen-binding fragment is suitable for delivery to the eye (e.g., one or both eyes) or near the eye (e.g., one or both eyes), such as intraocular, post-orbital or peri-orbital, behind the eyeball, near the eye muscle, near the eye connective tissue or any combination thereof. In some aspects, periorbital or post-orbital tissue is selected from muscle, connective tissue and / or adipose tissue. In some aspects, administration is administration to the extraocular muscles. In some aspects, the extraocular muscles are levator muscles or glabellar muscles. In some aspects, administration is administration to connective tissue. In some aspects, administration is to enter the periorbital space through the conjunctiva. In some aspects, administration is intralymphatic administration to the preauricular or submandibular lymph nodes. In some aspects, delivery or administration is directed to fibroblasts, adipocytes, myofibroblasts, myocytes or any combination thereof for post-orbital or peri-orbital. In some aspects, delivery or administration is performed by injection. In some aspects, delivery or administration is performed by infusion. In some aspects, delivery or administration is performed by injection and / or infusion in a single dose. In some aspects, single dose administration includes multiple injections or infusions.

[0478] In some aspects, the AAV delivery vector comprises a nucleic acid encoding an antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof disclosed herein produced in fibroblasts, myofibroblasts, myocytes, and / or adipocytes. In some aspects, the therapeutic effect of the antibody or its antigen-binding fragment is local, systemic, or both.

[0479] In some aspects, the AAV delivery vector comprises a nucleic acid sequence encoding an anti-IGF-1R antibody or antigen-binding fragment thereof (e.g., tetumumab) comprising: (i) VH CDR 1-3 (e.g., SEQ ID NO: 7-9, 10-12, or 13-15) and VLCDR 1-3 (e.g., SEQ ID NO: 16-18, 19-21, or 22-24); (ii) VH (e.g., SEQ ID NO: 26 or 27) and VL (e.g., SEQ ID NO: 30 or 31); (iii) HC (e.g., SEQ ID NO: 36 or 37) and LC (e.g., SEQ ID NO: 40 or 41); (iv) a VH (e.g., SEQ ID NO: 26 or 27) and a VL (e.g., SEQ ID NO: 30 or 31); NO: 68-76 any one of the vector construct or expression construct (e.g., antibody expression cassette), wherein the vector construct or expression construct (e.g., antibody expression cassette) further comprises an IRES, a furin cleavage site, a 2a site, a dual promoter (e.g., promoter VH-IRES-VL, etc.) or a signal peptide (e.g., IL-2 or IL-10 signal peptide) One or more.

[0480] IV. AAV Vector Components

[0481] IV.A.1 Inverted terminal repeats (ITRs)

[0482] The AAV vector of the present disclosure comprises a viral genome having at least one ITR region and a payload region, for example, a polynucleotide (e.g., an antibody expression cassette) comprising a nucleic acid encoding a therapeutic protein, such as an antibody (e.g., a monoclonal antibody) disclosed herein, or an antigen-binding fragment or fusion protein thereof (e.g., an Fc fusion protein), or a therapeutic peptide. In some aspects, the AAV vector has two ITRs. The two ITRs form flanks at the 5' end and 3' end of the payload region. The ITR acts as a replication origin, which comprises a recognition site for replication. The ITR comprises a sequence region, which may be complementary and symmetrically arranged. The ITR incorporated into the AAV vector of the present disclosure may include a naturally occurring polynucleotide sequence or a recombinantly derived polynucleotide sequence.

[0483] The ITR can be derived from the same serotype as the capsid, which is selected from any serotype listed herein or a derivative thereof. The ITR can be a serotype different from the capsid. In some aspects, the AAV vector has multiple ITRs. In a non-limiting example, the AAV vector has a viral genome comprising two ITRs. In some aspects, the ITR is the same serotype as another ITR. In some aspects, the ITR is a different serotype. Non-limiting examples include zero, one or two ITRs with the same serotype as the capsid. In some aspects, the two ITRs of the AAV vector are AAV2 ITRs.

[0484] In some aspects, the length of ITR is about 140-142 nucleotides. The non-limiting examples of ITR length are about 102, about 140, about 141, about 142, about 145 nucleotides and those with at least 95% homology thereto.

[0485] In some aspects, the AAV vector comprises at least one inverted terminal repeat sequence having a length such as, but not limited to, about 75-80, about 75-85, about 75-100, about 80-85, about 80-90, about 80-105, about 85-90, about 85-95, about 85-110, about 90-95, about 90-100, about 90-115, about 95-100, about 95-105, about 95-120, about 100-105, about 100-110, about 100-125, about 105-110, about 105-115, about 105-130, about 110-115, about 110-120, about 110-135, about 115-120, about 115-125, about 115-140. 0, about 120-125, about 120-130, about 120-145, about 125-130, about 125-135, about 125-150, about 130-135, about 130-140, about 130-155, about 135-140, about 135-145, about 135-160, about 140-145, about 140-150, about About 140-165, about 145-150, about 145-155, about 145-170, about 150-155, about 150-160, about 150-175, about 155-160, about 155-165, about 160-165, about 160-170, about 165-170, about 165-175, or about 170-175 nucleotides.

[0486] In some aspects, the length of the first and / or second ITR region for use in an AAV vector can be about 75-80, about 75-85, about 75-100, about 80-85, about 80-90, about 80-105, about 85-90, about 85-95, about 85-110, about 90-95, about 90-100, about 90-115, about 95-100, about 95-105, about 95-120, about 100-105, about 100-110, about 100-125, about 105-110, about 105-115, about 105-130, about 110-115, about 110-120, about 110-135, about 115-120, about 115-125, about 115-140, about 120-125, about 120-130, about 120-145, about 125-130, about 125-135, about 125-150, about 130-135, about 130-140, about 130-155, about 135-140, about 135-145, about 135-160, about 140-145, about 140-150, about 1 about 145-150, about 145-155, about 145-170, about 150-155, about 150-160, about 150-175, about 155-160, about 155-165, about 160-165, about 160-170, about 165-170, about 165-175, and about 170-175 nucleotides.

[0487] In some aspects, the AAV vector comprises a nucleic acid sequence encoding an antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof disclosed herein, which may be located near the 5' end of the flip ITR in the vector. In some aspects, the AAV vector comprises a nucleic acid sequence encoding an antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof disclosed herein, which may be located near the 3' end of the flip ITR in the vector. In some aspects, the AAV vector comprises a nucleic acid sequence encoding an antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof disclosed herein, which may be located near the 5' end of the flop ITR in the vector. In some aspects, the AAV vector comprises a nucleic acid sequence encoding an antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof disclosed herein, which may be located near the 3' end of the flop ITR in the vector. In some aspects, the AAV vector comprises a nucleic acid sequence encoding an antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof disclosed herein, which may be located between the 5' end of the flip ITR and the 3' end of the flop ITR in the vector. In some aspects, the AAV vector comprises a nucleic acid sequence encoding an antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof disclosed herein, which can be located between the 3' end of the flip ITR and the 5' end of the flop ITR in the vector (e.g., located between the 5' end of the flip ITR and the 3' end of the flop ITR or midway between the 3' end of the flop ITR and the 5' end of the flip ITR).

[0488] In some aspects, the AAV vector comprises a nucleic acid sequence encoding an antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof disclosed herein, which can be located within about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25, about 26, about 27, about 28, about 29, about 30 or more than about 30 nucleotides downstream or upstream of the 5' end or 3' end of the ITR (e.g., Flip or Flop ITR) in the vector.

[0489] As another non-limiting example, an AAV vector comprises a nucleic acid sequence encoding an antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof disclosed herein, which can be located within about 1-5, about 1-10, about 1-15, about 1-20, about 1-25, about 1-30, about 5-10, about 5-15, about 5-20, about 5-25, about 5-30, about 10-15, about 10-20, about 10-25, about 10-30, about 15-20, about 15-25, about 15-30, about 20-25, about 20-30, or about 25-30 nucleotides downstream or upstream of the 5' end or 3' end of the ITR (e.g., Flip or Flop ITR) in the vector.

[0490] In some aspects, the AAV vector comprises a nucleic acid sequence encoding an antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof disclosed herein, which can be located in the first about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25% or more than about 25% of the nucleotides upstream of the 5' or 3' end of the ITR (e.g., Flip or Flop ITR) in the vector.

[0491] As another non-limiting example, an AAV vector comprises a nucleic acid sequence encoding an antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof disclosed herein, which can be located in the first about 1-5%, about 1-10%, about 1-15%, about 1-20%, about 1-25%, about 5-10%, about 5-15%, about 5-20%, about 5-25%, about 10-15%, about 10-20%, about 10-25%, about 15-20%, about 15-25%, or about more than 20-25% of the nucleotides downstream of the 5' or 3' end of the ITR (e.g., Flip or Flop ITR) in the vector.

[0492] IV.A.2 Promoter

[0493] In some respects, the payload area of ​​AAV vector comprises at least one element to enhance nucleic acid specificity and / or expression. The limiting examples of the element for enhancing nucleic acid specificity and expression include, for example, promoter, endogenous miRNA, post-transcriptional regulatory element (PRE), polyadenylation (poly A) signal sequence and upstream enhancer (USE), CMV enhancer and intron. In some respects, enhancer is CMV enhancer. In some respects, CMV enhancer comprises and SEQ ID NO:35 at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical nucleotide sequence.

[0494] Expression of the nucleic acids of the present disclosure following delivery to target cells or integration into target cell genomic DNA may require specific promoters, including but not limited to species-specific, inducible, tissue-specific, or cell cycle-specific promoters (Parr et al., Nat. Med. 3:1145-9 (1997); the contents of which are incorporated herein by reference in their entirety).

[0495] In some aspects, a promoter is considered effective when it drives expression of an antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof disclosed herein carried in the payload region of an AAV vector. In some aspects, a promoter is considered effective when it drives expression of a therapeutic molecule of the present disclosure in targeted cells (e.g., fibroblasts, myocytes, adipocytes).

[0496] The promoter can be naturally occurring or non-naturally occurring. The non-limiting examples of promoters include viral promoters and mammalian promoters. In some aspects, the promoter can be a human promoter. In some aspects, the promoter can be truncated. The promoters driving or promoting expression in most tissues include but are not limited to human elongation factor 1a subunit (EF1α), cytomegalovirus (CMV) immediate early enhancer and / or promoter, chicken beta-actin (CBA) and its derivative CAG, beta glucuronidase (GUSB) or ubiquitin C (UBC). In some aspects, the promoter is CMV early enhancer / chicken beta actin (CAG) promoter, CAG, CBA, CMV, EF1α, EF1α with CMV enhancer, CMV promoter (CMVe / p) with CMV enhancer, CMV promoter or tissue-specific promoter with SV40 intron.

[0497] In some aspects, tissue-specific expression elements can be used to restrict expression to certain cell types, such as, but not limited to, a muscle-specific promoter, a B cell promoter, a monocyte promoter, a leukocyte promoter, a macrophage promoter, a pancreatic acinar cell promoter, an endothelial cell promoter, a lung tissue promoter, an astrocyte promoter, or a nervous system promoter that can be used to restrict expression to neurons, astrocytes, or oligodendrocytes.

[0498] Non-limiting examples of muscle-specific promoters include a mammalian muscle creatine kinase (MCK) promoter, a mammalian desmin (DES) promoter, an HSA promoter, an HMCK7 promoter, a dMCK promoter, a tMCK promoter, a CK8e promoter, an SPc5-12 promoter, an SP-301 promoter, an MH promoter, a Sk CRM promoter or a Sk-CRM4 promoter, a mammalian troponin I (TNNI2) promoter, and a mammalian skeletal α-actin (ASKA) promoter (see, e.g., U.S. Patent Publication No. US20110212529, the contents of which are incorporated herein by reference in their entirety). Non-limiting examples of tissue-specific expression elements for neurons include neuron-specific enolase (NSE), platelet-derived growth factor (PDGF), platelet-derived growth factor B chain (PDGF-β), synaptophysin (Syn), methyl CpG binding protein 2 (MeCP2), Ca2+ / calmodulin-dependent protein kinase II (CaMKII), metabotropic glutamate receptor 2 (mGluR2), neurofilament light chain (NFL) or heavy chain (NFH), β-globin minigene ηβ2, proenkephalin (PPE), enkephalin (Enk) and excitatory amino acid transporter 2 (EAAT2) promoter. Non-limiting examples of tissue-specific expression elements for astrocytes include glial fibrillary acid protein (GFAP) and EAAT2 promoter. Non-limiting examples of tissue-specific expression elements for oligodendrocytes include myelin basic protein (MBP) promoter. Non-limiting examples of tissue-specific expression elements for fibroblasts include the insulin-like growth factor binding protein 2 (IGFBP2) promoter, the fibroblast activation protein (FAP) promoter, and the fibroblast-specific protein 1 (FSPl) promoter.

[0499] Non-limiting examples of tissue-specific expression elements for adipocytes include adiponectin promoter and adipocyte fatty acid binding protein (AP2) promoter.

[0500] In some aspects, a promoter can be less than 1 kb. In some aspects, a promoter can have a length of about 15-20, about 10-50, about 20-30, about 30-40, about 40-50, about 50-60, about 50-100, about 60-70, about 70-80, about 80-90, about 90-100, about 100-110, about 100-150, about 110-120, about 120-130, about 130-140, about 140-150, about 150-160, about 150-200, about 160-170, about 170-180, about 180-190, about 190-200, about 200-210, about 200-250, about 210-220, about 220-230, about 230-240, about 240-250 0-250, about 250-260, about 250-300, about 260-270, about 270-280, about 280-290, about 290-300, about 200-300, about 200-400, about 200-500, about 200-600, about 200-700, about 200-800, about 300-400, about 30 In some embodiments, the present invention relates to a nucleic acid sequence of at least one nucleotide of the present invention. In some embodiments, the nucleic acid sequence of the present invention comprises at least one nucleotide of the present invention.

[0501] In some aspects, promoter can be the combination of two or more components of identical or different starting or parent promoter, such as but not limited to CMV, CAG, EF1 α and CBA.In some aspects, promoter is CMV early enhancer / chicken beta actin (CAG) promoter, CAG promoter, CBA promoter, people CMV promoter, mouse CMV promoter, EF1 α promoter, EF1 α promoter with CMV enhancer, CMV promoter with CMV enhancer (CMVe / p), CMV promoter with SV40 intron.In some aspects, promoter comprises and any SEQ ID NO:47-51,83 or 93 any one at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical nucleotide sequence.

[0502] In some aspects, the length that each component in the promoter can have is between about 200-300, about 200-400, about 200-500, about 200-600, about 200-700, about 200-800, about 300-400, about 300-500, about 300-600, about 300-700, about 300-800, about 400-500, about 400-600, about 400-700, about 400-800, about 500-600, about 500-700, about 500-800, about 600-700, about 600-800 or about 700-800 nucleotides. In some aspects, the promoter is a combination of the CMV enhancer sequence of 382 nucleotides and the CBA promoter sequence of 260 nucleotides.

[0503] In some aspects, the AAV vector comprises a ubiquitous promoter. Non-limiting examples of ubiquitous promoters include, for example, human CMV promoter, mouse CMV promoter, CBA promoter (including derivatives CAG, CBh, etc.), EF-1a promoter, PGK promoter, UBC promoter, GUSB promoter (hGBp) and UCOE promoter (promoter of HNRPA2B1-CBX3).

[0504] In some aspects, the promoter is not cell-specific. In some aspects, the promoter is ubiquitin c (UBC) promoter. The size that the UBC promoter can have is 300-350 nucleotides. In some aspects, the UBC promoter is 332 nucleotides. In some aspects, the promoter is β-glucuronidase (GUSB) promoter. The size that the GUSB promoter can have is 350-400 nucleotides. In some aspects, the GUSB promoter is 378 nucleotides. In some aspects, the promoter is neurofilament light chain (NFL) promoter. The size that the NFL promoter can have is 600-700 nucleotides. In some aspects, the NFL promoter is 650 nucleotides. In some aspects, the construct can be AAV-promoter-CMV / globin intron regulatory polynucleotide-RBG, wherein AAV can be self-complementary and AAV can be DJ serotype.

[0505] In some aspects, the AAV vector comprises a Pol III promoter. In some aspects, the AAV vector comprises a PI promoter. In some aspects, the AAV vector comprises a FXN promoter. In some aspects, the promoter is a phosphoglycerate kinase 1 (PGK) promoter. In some aspects, the promoter is a chicken beta-actin (CBA) promoter. In some aspects, the promoter is a CAG promoter, which is a construct comprising a cytomegalovirus (CMV) enhancer fused to a chicken beta-actin (CBA) promoter with a chimeric intron. In some aspects, the promoter is a cytomegalovirus (CMV) promoter. In some aspects, the promoter is a human cytomegalovirus (CMV) promoter. In some aspects, the promoter is a mouse cytomegalovirus (CMV) promoter. In some aspects, the promoter is a CBA promoter. In some aspects, the promoter is an EF1α promoter. In some aspects, the promoter is an EF1α promoter fused to a CMV enhancer. In some aspects, the promoter is a CMV promoter fused to a CMV enhancer. In some aspects, the promoter is a CMV promoter fused to an SV40 intron. In some aspects, the AAV vector comprises a HI promoter. In some aspects, the AAV vector comprises a U6 promoter. In some aspects, the AAV vector comprises an SP6 promoter. In some aspects, the promoter comprises at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of any SEQ ID NO:34-38.

[0506] In one aspect, the promoter is a liver or skeletal muscle promoter. Non-limiting examples of liver promoters include human alpha-1-antitrypsin (hAAT) and thyroxine binding globulin (TBG). Non-limiting examples of skeletal muscle promoters include desmin, MCK or synthetic C5-12. In some aspects, the promoter is an RNA pol III promoter. In some aspects, the RNA pol III promoter is U6. In some aspects, the RNA pol III promoter is HI. In some aspects, the AAV vector comprises two promoters. In some aspects, the promoter is an EF1α promoter and a CMV promoter. Non-limiting examples of fibroblast promoters include insulin-like growth factor binding protein 2 (IGFBP2), fibroblast activation protein (FAP) and fibroblast-specific protein 1 (FSP1).

[0507] Non-limiting examples of adipocyte promoters include adiponectin and adipocyte fatty acid binding protein (AP2).

[0508] In some aspects, the AAV vector comprises an enhancer element, a promoter and / or a 5'UTR intron. The enhancer element, also referred to herein as an "enhancer", can be, but is not limited to, a CMV enhancer, a promoter can be, but is not limited to, EF1α, CMV, CBA, UBC, GUSB, NSE, synaptic protein, MeCP2 and GFAP promoters, and 5'UTR / introns can be, but are not limited to, a chimera between SV40, CBA-MVM (mice parvovirus), human β-globin, immunoglobulin heavy chain, human β-globin and immunoglobulin heavy chain genes. In some aspects, the intron comprises a nucleotide sequence identical to any one of SEQ ID NO:46, 56 or 82 at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. In some aspects, the enhancer is a CMV enhancer. In some aspects, the CMV enhancer comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 48. In some aspects, the enhancer, promoter and / or intron used in combination can be: (1) CMV enhancer, CMV promoter, SV40 5'UTR intron; (2) CMV enhancer, CBA promoter, SV 40 5'UTR intron; (3) CMV enhancer, CBA promoter, CBA-MVM promoter. 5'UTR intron; (4) UBC promoter; (5) GUSB promoter; (6) NSE promoter; (7) synapsin promoter; (8) MeCP2 promoter, (9) GFAP promoter, (10) HI promoter; (11) U6 promoter; (12) CMV promoter, CMV enhancer; (13) EF1α promoter, CMV enhancer; or (14) CMV promoter, SV40 intron; (15) human β-globin and immunoglobulin heavy chain chimera, EF1α promoter, CMV enhancer, CMV promoter, SV40 intron. In some aspects, the promoter is a cytomegalovirus (CMV) promoter. In some aspects, the intron is an SV40 intron, an MVM intron, or a human β-globin intron in a vector. In some aspects, the promoter is a CBA promoter. In some aspects, the promoter is an EF1α promoter. In some aspects, the promoter is a CMV promoter fused to a CMV enhancer. In some aspects, the promoter is a CMV enhancer fused to an EF1α promoter. In some aspects, the promoter is a CMV promoter fused to an SV40 intron. In some aspects, the AAV vector comprises an engineered promoter. In some aspects, the AAV vector comprises a CMV early enhancer / chicken beta actin (CAG) promoter.In some aspects, the AAV vector comprises a promoter from a naturally expressed protein.

[0509] IV.A.3 Untranslated Region (UTR)

[0510] By definition, the wild-type untranslated region (UTR) of a gene is transcribed but not translated. In general, the 5'UTR starts at the transcription start site and ends at the start codon, and the 3'UTR starts immediately after the stop codon and continues to the termination signal of transcription.

[0511] Features commonly found in a large number of expressed genes in a particular target organ can be engineered into UTRs to enhance the stability and production of transcripts. In some aspects, 5'UTRs from mRNAs normally expressed in the liver (e.g., albumin, serum amyloid A, apolipoprotein A / B / E, transferrin, alpha-fetoprotein, erythropoietin, or factor VIII) can be used in the AAV vectors of the present disclosure to enhance expression, for example in brain tissue and particularly in neuronal cells.

[0512] The wild-type 5' untranslated region (UTR) includes features that play a role in translation initiation. The Kozak sequence, which is generally known to be involved in the process by which the ribosome initiates the translation of many genes, is typically included in the 5'UTR. The Kozak sequence has a consensus CCR(A / G)CCAUGG, where R is a purine (adenine or guanine) three bases upstream of the start codon (ATG), followed by another "G". In some aspects, the 5'UTR in the AAV vector of the present disclosure includes a Kozak sequence. In some aspects, the 5'UTR in the AAV vector of the present disclosure does not include a Kozak sequence.

[0513] It is known that the wild-type 3'UTR embeds one or more segments of adenosine and uridine therein. These AU-rich features are particularly common in genes with high turnover rates. Based on their sequence characteristics and functional properties, AU-rich elements (AREs) can be divided into three categories (Chen et al., 1995, the contents of which are incorporated herein by reference in their entirety). Class I AREs, such as but not limited to c-Myc and MyoD, contain several dispersed copies of the AUUUA motif in the U-rich region. Class II AREs, such as but not limited to GM-CSF and IGFR-α, have two or more overlapping UUAUUUA (U / A) (U / A) nine-mers. Class III AREs, such as but not limited to c-Jun and myogenic proteins, are less clearly defined. These U-rich regions do not contain the AUUUA motif. Most proteins known to bind to ARE destabilize messenger RNA, while members of the ELAV family (especially HuR) have been shown to increase the stability of mRNA. HuR binds to all three types of AREs. Engineering a HuR-specific binding site into the 3'UTR of a nucleic acid molecule will result in HuR binding and therefore stabilization of the message in vivo.

[0514] Introducing, removing or modifying 3'UTR AU-rich elements (AREs) can be used to regulate the stability of polynucleotides. When engineering specific polynucleotides (e.g., the payload region of a viral genome), one or more copies of AREs can be introduced to make the polynucleotide less stable and thereby limit translation and reduce the production of the resulting protein. Similarly, AREs can be identified and removed or mutated to increase intracellular stability and thereby increase translation and production of the resulting protein.

[0515] In some aspects, the 3'UTR of the AAV vectors of the present disclosure may include an oligo(dT) sequence for adding a poly-A tail.

[0516] In some aspects, the AAV vectors of the present disclosure can be engineered to include, alter, or remove at least one miRNA binding site, sequence, or seed region.

[0517] Any UTR from any gene known in the art can be incorporated into the AAV vector of the present disclosure. These UTRs or parts thereof can be placed in the same direction as the gene selected from it or the gene that can be changed in direction or position. In some aspects, the UTR used in the AAV vector of the present disclosure can be reversed, shortened, or extended with one or more other 5'UTRs or 3'UTRs known in the art. As used herein, the term "change" associated with UTR means that the UTR has been changed in some way relative to the reference sequence. For example, 3' or 5'UTR can be changed relative to the wild-type or natural UTR by changes in direction or position as taught above, or can be changed by the addition of additional nucleotides, the deletion of nucleotides, the exchange of nucleotides, or transposition. In some aspects, the AAV vector of the present disclosure comprises at least one artificial UTR that is not a variant of the wild-type UTR. In some aspects, the AAV vector of the present disclosure comprises a UTR selected from a transcript family whose proteins share a common function, structure, feature, or property.

[0518] IV.A.4 Polyadenylation sequence

[0519] In some aspects, the AAV vectors of the present disclosure comprise at least one polyadenylation sequence.The AAV vectors of the present disclosure may comprise a polyadenylation sequence between the 3' end of the payload encoding sequence and the 5' end of the 3' ITR.

[0520] In some aspects, the polyadenylation sequence or "poly A sequence" can range in length from absent to about 500 nucleotides.

[0521] In some aspects, the length of the polyadenylation sequence is about 10-100, about 10-90, about 10-80, about 10-70, about 10-60, about 10-55, about 10-50, about 20-100, about 20-90, about 20-80, about 20-70, about 20-60, about 20-55, about 20-50, about 30-100, about 30-90, about 30 In some aspects, the polyadenylation sequence is about 49 nucleotides in length.

[0522] In some aspects, the AAV vector comprises a nucleic acid sequence encoding an antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof disclosed herein, which may be located upstream of a polyadenylation sequence in the vector. In some aspects, the AAV vector comprises a nucleic acid sequence encoding an antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof disclosed herein, which may be located downstream of a promoter, such as, but not limited to, EF1α, CMV, U6, CAG, CBA EF1α with a CMV enhancer, CMV promoter with an SV40 intron, CMV promoter with a CMV enhancer, or CBA promoter with an SV40 intron, MVM intron human β-globin intron, immunoglobulin heavy chain intron, or a chimera of a human β-globin intron and an immunoglobulin heavy chain intron in the vector.

[0523] In some aspects, the AAV vectors of the present disclosure comprise a nucleic acid sequence encoding an antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof disclosed herein, which can be located within about 1-5, about 1-10, about 1-15, about 1-20, about 1-25, about 1-30, about 5-10, about 5-15, about 5-20, about 5-25, about 5-30, about 10-15, about 10-20, about 10-25, about 10-30, about 15-20, about 15-20, about 15-25, about 15-30, about 20-25, about 20-30, or about 25-30 nucleotides downstream of a promoter and / or upstream of a polyadenylation sequence in the vector.

[0524] In some aspects, the AAV vector comprises a rabbit globin polyadenylation (poly A) signal sequence. In some aspects, the AAV vector comprises a human growth hormone polyadenylation (poly A) signal sequence. In some aspects, the AAV vector comprises a bovine growth hormone polyadenylation (poly A) signal sequence. In some aspects, the poly A signal sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical nucleotide sequences with any one of SEQ ID NO:52 or 53. In some aspects, the AAV vector comprises an SV40 polyadenylation signal sequence (SV40-pA), a bovine growth hormone polyadenylation signal sequence (bGHpA) or a human growth hormone polyadenylation signal sequence (hGHpA).

[0525] IV.A.5 intron

[0526] In some aspects, the payload region of the AAV vector of the present disclosure includes at least one element to enhance expression, such as one or more introns or portions thereof. Non-limiting examples of introns include MVM (67-97 bps), F.IX truncated intron 1 (300 bps), β-globin SD / immunoglobulin heavy chain splice acceptor (250 bps), adenovirus splice donor / immunoglobulin splice acceptor (500 bps), SV40 late splice donor / splice acceptor (19S / 16S) (180 bps), and hybrid adenovirus splice donor / IgG splice acceptor (230 bps).

[0527] In some aspects, the length of an intron or an intron portion can be from about 100 to about 500 nucleotides. In some aspects, an intron can have a length of about 80-100, about 80-120, about 80-140, about 80-160, about 80-180, about 80-200, about 80-250, about 80-300, about 80-350, about 80-400, about 80-450, about 80-500, about 200-300, about 200-400, about 200-500, about 300-400, about 300-500, or about 400-500 nucleotides.

[0528] In some aspects, the AAV vector may include a promoter such as, but not limited to, CMV or U6. In some aspects, the promoter of the AAV vector of the present disclosure is a CMV promoter. In some aspects, the promoter of the AAV vector of the present disclosure is a CMV early enhancer / chicken beta actin (CAG) promoter. As another non-limiting example, the promoter of the AAV vector of the present disclosure is a U6 promoter. In some aspects, the AAV vector may include a CMV and U6 promoter. In some aspects, the AAV vector may include a HI promoter. In some aspects, the AAV vector may include a CBA promoter. In some aspects, the AAV vector may include a chimeric intron. In some aspects, the AAV vector may include an SV40 intron. In some aspects, the AAV vector may include an immunoglobulin heavy chain intron. In some aspects, the AAV vector may include a human beta globin intron. In some aspects, the AAV vector may include a chimera of a human beta globin intron and an immunoglobulin heavy chain intron.

[0529] In some aspects, the promoter is CMV early enhancer / chicken beta actin (CAG) promoter, EF1α, human CMV, mouse CMV, EF1α promoter fused to CMV enhancer, CMV promoter fused to SV40 intron, CMV promoter fused to CMV enhancer or tissue-specific promoter. In some aspects, the promoter comprises a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of any SEQ ID NO:47-51.

[0530] In some aspects, the encoded antibody disclosed herein (e.g., monoclonal antibody) or its antigen-binding fragment can be located downstream of a promoter in an expression vector, such as but not limited to CMV, U6, HI, CBA, CAG or a CBA promoter with an intron, such as SV40, MVM intron, human β-globin intron, human immunoglobulin heavy chain intron, chimera of human β-globin intron and human immunoglobulin heavy chain intron or other introns known in the art. In some aspects, the intron is selected from SV40 intron, MVM intron, human β-globin intron, human immunoglobulin heavy chain intron or a chimera of human immunoglobulin heavy chain intron and human β-globin intron. In some aspects, the intron comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any of SEQ ID NOs:46, 56 or 82.

[0531] In addition, the encoded antibody or its Fab may also be located upstream of the polyadenylation sequence in the expression vector. In some respects, the encoded therapeutic protein, for example, an antibody (e.g., monoclonal antibody) or its Fab or fusion protein (e.g., Fc fusion protein) disclosed herein, or a therapeutic peptide may be located downstream of a promoter in a vector and / or upstream of a polyadenylation sequence within about 1-5, about 1-10, about 1-15, about 1-20, about 1-25, about 1-30, about 5-10, about 5-15, about 5-20, about 5-25, about 5-30, about 10-15, about 10-20, about 10-25, about 10-30, about 15-20, about 15-25, about 15-30, about 20-25, about 20-30, or about 25-30 nucleotides.

[0532] IV.A.6 Filling order

[0533] In some aspects, the AAV vector comprises one or more stuffer sequences (also referred to as "filler sequences"). In some aspects, the AAV vector comprises one or more stuffer sequences so that the length of the AAV vector is the optimal size for packaging. In some aspects, the AAV vector comprises at least one stuffer sequence so that the length of the AAV vector is about 2.0-2.5 kb, for example, about 2.3 kb. In some aspects, the AAV vector comprises at least one stuffer sequence so that the length of the AAV vector is about 4.6 kb. In some aspects, the vector backbone comprises a stuffer sequence.

[0534] In some aspects, the AAV vector comprises one or more stuffer sequences to reduce the possibility that the hairpin structure of the vector genome (e.g., a regulatory polynucleotide described herein) can be read as an inverted terminal repeat (ITR) during expression and / or packaging. In some aspects, the AAV vector comprises at least one stuffer sequence so that the length of the AAV vector is about 2.0-2.5 kb, for example, about 2.3 kb. In some aspects, the AAV vector comprises at least one stuffer sequence so that the length of the AAV vector is about 4.6 kb.

[0535] In some aspects, the AAV vector is a single-stranded (ss) AAV vector and comprises one or more stuffer sequences having a length between about 0.1 kb and about 3.8 kb, such as, but not limited to, about 0.1 kb, about 0.2 kb, about 0.3 kb, about 0.4 kb, about 0.5 kb, about 0.6 kb, about 0.7 kb, about 0.8 kb, about 0.9 kb, about 1 kb, about 1.1 kb, about 1.2 kb, about 1.3 kb, about 1.4 kb, about 1.6 kb, about 1.7 kb, about 1.8 kb, about 1.9 kb, about 2.1 kb, about 2.2 kb, about 2.3 kb, about 2.4 kb, about 2.5 kb, about 2.6 kb, about 2.7 kb, about 2.8 kb, about 2.9 kb, about 3. about 2.5 kb, about 2.6 kb, about 2.7 kb, about 2.8 kb, about 2.9 kb, about 3 kb, about 3.1 kb, about 3.2 kb, about 3.3 kb, about 3.4 kb, about 3.5 kb, about 3.6 kb, about 3.7 kb or about 3.8 kb.

[0536] In some aspects, the AAV vector is a self-complementary (sc) AAV vector and comprises one or more stuffer sequences of about 0.1 kb and about 1.5 kb in length, such as but not limited to about 0.1 kb, about 0.2 kb, about 0.3 kb, about 0.4 kb, about 0.5 kb, about 0.6 kb, about 0.7 kb, about 0.8 kb, about 0.9 kb, about 1 kb, about 1.1 kb, about 1.2 kb, about 1.3 kb, about 1.4 kb or about 1.5 kb.

[0537] In some aspects, the AAV vector comprises any portion of a stuffer sequence. The vector can comprise, for example, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95% or about 99% of a stuffer sequence.

[0538] In some aspects, the AAV vector is a single-stranded (ss) AAV vector and comprises one or more stuffing sequences so that the length of the AAV vector is about 4.6kb. In some aspects, the AAV vector comprises at least one stuffing sequence and the stuffing sequence is located at the 3' of the 5'ITR sequence. In some aspects, the AAV vector comprises at least one stuffing sequence and the stuffing sequence is located at the 5' of the promoter sequence. In some aspects, the AAV vector comprises at least one stuffing sequence and the stuffing sequence is located at the 3' of the polyadenylation signal sequence. In some aspects, the AAV vector comprises at least one stuffing sequence and the stuffing sequence is located at the 5' of the 3'ITR sequence. In some aspects, the AAV vector comprises at least one stuffing sequence and the stuffing sequence is located between two intron sequences. In some aspects, the AAV vector comprises at least one stuffing sequence and the stuffing sequence is located within the intron sequence. In some aspects, the AAV vector comprises two stuffing sequences, and the first stuffing sequence is located at the 3' of the 5'ITR sequence and the second stuffing sequence is located at the 3' of the polyadenylation signal sequence. In some aspects, the AAV vector comprises two stuffer sequences, and the first stuffer sequence is located 5' of the promoter sequence and the second stuffer sequence is located 3' of the polyadenylation signal sequence. In some aspects, the AAV vector comprises two stuffer sequences, and the first stuffer sequence is located 3' of the 5' ITR sequence and the second stuffer sequence is located 5' of the 5' ITR sequence.

[0539] In some aspects, the AAV vector is a self-complementary (sc) AAV vector and comprises one or more stuffer sequences so that the length of the AAV vector is about 2.3 kb. In some aspects, the AAV vector comprises at least one stuffer sequence and the stuffer sequence is located at 3' of the 5'ITR sequence. In some aspects, the AAV vector comprises at least one stuffer sequence and the stuffer sequence is located at 5' of the promoter sequence. In some aspects, the AAV vector comprises at least one stuffer sequence and the stuffer sequence is located at 3' of the polyadenylation signal sequence. In some aspects, the AAV vector comprises at least one stuffer sequence and the stuffer sequence is located at 5' of the 3'ITR sequence.

[0540] In some aspects, the AAV vector comprises at least one stuffer sequence and the stuffer sequence is located between two intron sequences. In some aspects, the AAV vector comprises at least one stuffer sequence and the stuffer sequence is located within an intron sequence. In some aspects, the AAV vector comprises two stuffer sequences, and the first stuffer sequence is located at 3' of the 5'ITR sequence and the second stuffer sequence is located at 3' of the polyadenylation signal sequence. In some aspects, the AAV vector comprises two stuffer sequences, and the first stuffer sequence is located at 5' of the promoter sequence and the second stuffer sequence is located at 3' of the polyadenylation signal sequence. In some aspects, the AAV vector comprises two stuffer sequences and the first stuffer sequence is located at 3' of the 5'ITR sequence and the second stuffer sequence is located at 5' of the 5'ITR sequence.

[0541] In some aspects, the AAV vector can include one or more stuffing sequences between one or more regions of the AAV vector. In some aspects, the stuffing region can be located before some regions, such as but not limited to payload region, ITR, promoter region, intron region, enhancer region and / or polyadenylation signal sequence region. In some aspects, the stuffing region can be located after some regions, such as but not limited to payload region, ITR, promoter region, intron region, enhancer region and / or polyadenylation signal sequence region. In some aspects, the stuffing region can be located before and after a region, such as but not limited to payload region, ITR, promoter region, intron region, enhancer region and / or polyadenylation signal sequence region.

[0542] In some aspects, the AAV vector may include one or more stuffer sequences that fork at least one region of the AAV vector. The fork region of the AAV vector may include about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95% or about 99% of the region 5' of the stuffer sequence region.

[0543] In some aspects, the filling sequence may fork at least one region so that about 10% of the region is located at 5' of the filling sequence and about 90% of the region is located at 3' of the filling sequence. In some aspects, the filling sequence may fork at least one region so that about 20% of the region is located at 5' of the filling sequence and about 80% of the region is located at 3' of the filling sequence. In some aspects, the filling sequence may fork at least one region so that about 30% of the region is located at 5' of the filling sequence and about 70% of the region is located at 3' of the filling sequence. In some aspects, the filling sequence may fork at least one region so that about 40% of the region is located at 5' of the filling sequence and about 60% of the region is located at 3' of the filling sequence. In some aspects, the filling sequence may fork at least one region so that about 50% of the region is located at 5' of the filling sequence and about 50% of the region is located at 3' of the filling sequence. In some aspects, the filling sequence may fork at least one region so that about 60% of the region is located at 5' of the filling sequence and about 40% of the region is located at 3' of the filling sequence. In some aspects, the stuffing sequence can be bifurcated at least one region so that about 70% of the region is located at 5' of the stuffing sequence and about 30% of the region is located at 3' of the stuffing sequence. In some aspects, the stuffing sequence can be bifurcated at least one region so that about 80% of the region is located at 5' of the stuffing sequence and about 20% of the region is located at 3' of the stuffing sequence. In some aspects, the stuffing sequence can be bifurcated at least one region so that about 90% of the region is located at 5' of the stuffing sequence and about 10% of the region is located at 3' of the stuffing sequence.

[0544] In some aspects, the AAV vector comprises a stuffer sequence after the 5'ITR. In some aspects, the AAV vector comprises a stuffer sequence after the promoter region. In some aspects, the AAV vector comprises a stuffer sequence after the payload region. In some aspects, the AAV vector comprises a stuffer sequence after the intron region. In some aspects, the AAV vector comprises a stuffer sequence after the enhancer region. In some aspects, the AAV vector comprises a stuffer sequence after the polyadenylation signal sequence region. In some aspects, the AAV vector comprises a stuffer sequence before the promoter region. In some aspects, the AAV vector comprises a stuffer sequence before the payload region. In some aspects, the AAV vector comprises a stuffer sequence before the intron region.

[0545] In some aspects, the AAV vector comprises a stuffer sequence before the enhancer region. In some aspects, the AAV vector comprises a stuffer sequence before the polyadenylation signal sequence region. In some aspects, the AAV vector comprises a stuffer sequence before the 3'ITR. In some aspects, the stuffer sequence can be located between two regions, such as but not limited to the 5'ITR and the promoter region. In some aspects, the stuffer sequence can be located between two regions, such as but not limited to the 5'ITR and the payload region.

[0546] In some aspects, a stuffer sequence can be located between two regions, such as but not limited to a 5'ITR and an intron region. In some aspects, a stuffer sequence can be located between two regions, such as but not limited to a 5'ITR and an enhancer region. In some aspects, a stuffer sequence can be located between two regions, such as but not limited to a 5'ITR and a polyadenylation signal sequence region. In some aspects, a stuffer sequence can be located between two regions, such as but not limited to a promoter region and a payload region.

[0547] In some aspects, the filler sequence can be located between two regions, such as but not limited to a promoter region and an intron region. In some aspects, the filler sequence can be located between two regions, such as but not limited to a promoter region and an enhancer region. In some aspects, the filler sequence can be located between two regions, such as but not limited to a promoter region and a polyadenylation signal sequence region. In some aspects, the filler sequence can be located between two regions, such as but not limited to a promoter region and a 3' ITR.

[0548] In some aspects, a stuffer sequence can be located between two regions, such as, but not limited to, a payload region and an intron region. In some aspects, a stuffer sequence can be located between two regions, such as, but not limited to, a payload region and an enhancer region. In some aspects, a stuffer sequence can be located between two regions, such as, but not limited to, a payload region and a polyadenylation signal sequence region. In some aspects, a stuffer sequence can be located between two regions, such as, but not limited to, a payload region and a 3' ITR.

[0549] In some aspects, the filler sequence can be located between two regions, such as but not limited to an intron region and an enhancer region. In some aspects, the filler sequence can be located between two regions, such as but not limited to an intron region and a polyadenylation signal sequence region. In some aspects, the filler sequence can be located between two regions, such as but not limited to an intron region and a 3'ITR. In some aspects, the filler sequence can be located between two regions, such as but not limited to an enhancer region and a polyadenylation signal sequence region. In some aspects, the filler sequence can be located between two regions, such as but not limited to an enhancer region and a 3'ITR. In some aspects, the filler sequence can be located between two regions, such as but not limited to a polyadenylation signal sequence region and a 3'ITR.

[0550] In some aspects, the AAV vector can include two stuffer sequences. The two stuffer sequences can be located between the two regions described herein.

[0551] IV.A.7 Methods for Producing Recombinant AAV

[0552] The present disclosure also provides a method for generating AAV particles by viral genome replication in a viral replicating cell, the method comprising contacting a viral replicating cell with an AAV polynucleotide or an AAV genome (e.g., an AAV vector of the present disclosure). In the context of the present disclosure, an AAV vector disclosed herein, e.g., an AAV vector comprising at least one polynucleotide encoding an antibody disclosed herein (e.g., a monoclonal antibody) or an antigen-binding fragment thereof is considered to be an AAV payload construct vector.

[0553] In some aspects, AAV particles are produced by a method comprising the following steps: (1) co-transfecting competent bacterial cells with a baculovirus shuttle vector and a viral construct vector and / or an AAV payload construct vector, (2) isolating the resulting viral construct expression vector and the AAV payload construct expression vector and transfecting viral replicating cells separately, (3) isolating and purifying the resulting payload and viral construct particles comprising the viral construct expression vector or the AAV payload construct expression vector, (4) co-infecting viral replicating cells with both the payload and viral construct particles comprising the viral construct expression vector or the AAV payload construct expression vector, and (5) harvesting and purifying viral particles comprising the parvovirus genome.

[0554] In one aspect, the present disclosure provides a method for producing AAV particles, comprising the steps of: (1) simultaneously co-transfecting mammalian cells, such as but not limited to HEK293 cells, with a payload region (e.g., a polynucleotide encoding a therapeutic protein or therapeutic peptide of the present disclosure), a construct expressing rep and cap genes, and an auxiliary construct, and (2) harvesting and purifying AAV particles containing the viral genome.

[0555] In some aspects, AAV particles can be produced in virus replicating cells comprising insect cells. Growth conditions for insect cells in culture and production of heterologous products in insect cells in culture are well known in the art, see, e.g., U.S. Pat. No. 6,204,059.

[0556] The virus replication cell can be selected from any biological organism, including prokaryotic (for example, bacteria) cells and eukaryotic cells, and eukaryotic cells include insect cells, yeast cells and mammalian cells. The virus replication cell can include mammalian cells, such as A549, WEH1, 3T3, 10T1 / 2, BHK, MDCK, COS1, COS 7, BSC 1, BSC 40, BMT 10, VERO, W138, HeLa, HEK293, Saos, C2C12, L cells, HT1080, HepG2 and primary fibroblasts, hepatocytes and myoblasts derived from mammals. The virus replication cell includes cells or cell types derived from mammalian species (including but not limited to people, monkeys, mice, rats, rabbits and hamsters), including but not limited to cells of fibroblasts, hepatocytes, tumor cells, cell line transformed cells, etc.

[0557] The virus production disclosed herein describes processes and methods for producing AAV particles that contact target cells to deliver a payload, such as a recombinant viral construct comprising a polynucleotide sequence encoding a payload, such as an antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof disclosed herein.

[0558] In some aspects, AAV particles can be produced in virus replicating cells comprising mammalian cells. Virus replicating cells commonly used to produce recombinant AAV particles include, but are not limited to, 293 cells, COS cells, HeLa cells, and KB cells.

[0559] In some aspects, AAV particles are produced in mammalian cells in which all three VP proteins are expressed in a stoichiometry close to 1:1:10 (VP1:VP2:VP3). Regulatory mechanisms that allow this controlled expression level include the production of two mRNAs, one for VP1 and another for VP2 and VP3, by differential splicing.

[0560] In some aspects, AAV particles are produced in mammalian cells using a triple transfection method, wherein the payload construct, parvoviral Rep and parvoviral Cap, and a helper construct are contained in three different constructs. The three-component triple transfection method of AAV particle production can be utilized to produce small amounts of virus for assays including transduction efficiency, target tissue (tropism) assessment, and stability.

[0561] In some aspects, the viral construct vector and the AAV payload construct vector can be each incorporated into a baculovirus (also referred to as a baculovirus plasmid) by a transposon donor / acceptor system by standard molecular biology techniques known and performed by those skilled in the art. Transfection of a separate viral replication cell population produces two baculoviruses, one comprising a viral construct expression vector and the other comprising an AAV payload construct expression vector. The two baculoviruses can be used to infect a single viral replication cell population to produce AAV particles.

[0562] Baculovirus expression vectors for producing viral particles in insect cells, including but not limited to Spodoptera frugiperda (Sf9) cells, provide high titer viral particle products. Recombinant baculovirus encoding viral construct expression vectors and AAV payload construct expression vectors initiate productive infection of viral replicating cells. Infectious baculovirus particles released from the primary infection will secondary infect other cells in the culture and infect the entire cell culture population exponentially during the infection cycle, and the number of infection cycles is a function of the primary infection multiple, see, e.g., Urabe, M. et al., J Virol. 2006 Feb; 80(4): 1874-85, the contents of which are incorporated herein by reference in their entirety.

[0563] Producing AAV particles with baculovirus in an insect cell system can solve the known genetic and physical instability of baculovirus. Virus-producing cells infected with baculovirus are harvested into aliquots for cryopreservation in liquid nitrogen; the aliquots retain the viability and infectivity of large-scale virus-producing cell cultures for infection (Wasilko DJ et al., Protein Expr Purif. 2009 Jun; 65(2): 122-32).

[0564] In some aspects, stable viral replicating cells permissive for baculovirus infection are engineered with at least one stably integrated copy of any element required for AAV replication and viral particle production, including but not limited to the entire AAV genome, Rep and Cap genes, Rep gene, Cap gene, each Rep protein as a separate transcription cassette, each VP protein as a separate transcription cassette, AAP (assembly activating protein), or at least one baculovirus helper gene with a native or non-native promoter.

[0565] In some aspects, AAV particle production can be modified to increase the scale of production. Transfection of replicating cells can be performed in large-scale culture format according to any method known in the art.

[0566] In some aspects, the cell culture bioreactor can be used for large-scale virus production. In some cases, the bioreactor comprises a stirred tank reactor.

[0567] IV.A.8 Cell lysis

[0568] The cells of the present disclosure (including but not limited to virus production cells) can be subjected to cell lysis according to any method known in the art. Cell lysis can be performed to obtain one or more agents (e.g., virus particles) present in any cell of the present disclosure.

[0569] Cell lysis methods can be chemical or mechanical. Chemical cell lysis generally includes contacting one or more cells with one or more lysing agents. Mechanical lysis generally includes subjecting one or more cells to one or more lysis conditions and / or one or more lysing forces. In some respects, chemical lysis can be used for lysing cells. As used herein, the term "lysing agent" refers to any reagent that can contribute to the destruction of cells. In some cases, the lysing agent is introduced into a solution and is referred to as a lysing solution or a lysing buffer. As used herein, the term "lysing solution" refers to a solution (usually aqueous) comprising one or more lysing agents. In addition to the lysing agent, the lysing solution can also include one or more buffers, solubilizing agents, surfactants, preservatives, cryoprotectants, enzymes, enzyme inhibitors and / or chelating agents.

[0570] The concentration of salt can be increased or decreased to obtain an effective concentration for rupturing the cell membrane. Lysing agents comprising detergents can include ionic detergents or non-ionic detergents. Detergents can play a role in decomposing or dissolving cell structures, including but not limited to cell membranes, cell walls, lipids, carbohydrates, lipoproteins and glycoproteins.

[0571] In some aspects, mechanical cell lysis is performed. Mechanical cell lysis methods may include the use of one or more lysis conditions and / or one or more lysis forces. As used herein, the term "lysis conditions" refers to a state or situation that promotes cell destruction. Lysis conditions may include certain temperatures, pressures, osmotic purity, salinity, etc. In some aspects, lysis conditions include elevated or reduced temperatures. In some aspects, lysis conditions include temperature changes to promote cell rupture. Cell lysis performed according to these aspects may include freeze-thaw lysis.

[0572] As used herein, the term "lysing force" refers to a physical activity used to destroy cells. Lysing forces may include, but are not limited to, mechanical forces, sonic forces, gravity, light forces, electricity, etc. Cell lysis by mechanical forces is referred to herein as "mechanical lysis." Mechanical forces that may be used in accordance with mechanical lysis may include high shear fluid forces.

[0573] In some aspects, methods for harvesting AAV particles without lysis can be used for efficient and scalable AAV particle production. In a non-limiting example, AAV particles can be produced by culturing AAV particles lacking heparin binding sites in cell culture, thereby allowing the AAV particles to enter the supernatant, collecting the supernatant from the culture; and isolating the AAV particles from the supernatant, as described in U.S. Patent Application 20090275107.

[0574] IV.A.9 AAV purification

[0575] The cell lysate containing the viral particles can be clarified. Clarification refers to the initial step used in purifying viral particles from the cell lysate. Clarification is used to prepare the lysate for further purification by removing larger insoluble fragments. The clarification step can include, but is not limited to, centrifugation and filtration.

[0576] In some aspects, AAV particles can be purified from clarified cell lysates by one or more chromatographic methods. Chromatography refers to any of a number of methods known in the art for separating one or more elements from a mixture. These methods can include, but are not limited to, ion exchange chromatography (e.g., cation exchange chromatography and anion exchange chromatography), immunoaffinity chromatography, and size exclusion chromatography.

[0577] V. Treatment and Methods of Use

[0578] Certain aspects of the present disclosure relate to the use of polynucleotides (e.g., antibody expression cassettes), vectors and rAAVs for treating subjects in need. Some aspects of the present disclosure relate to methods for delivering gene therapy encoding anti-IGF-1R antibodies or antigen-binding fragments thereof to subjects in need. In some aspects, the method includes administering a delivery vector (e.g., a viral vector, a non-viral vector, a plasmid, a lipid, a protein particle, a bacterial vector or a lysosome) to the subject. In some aspects, the methods disclosed herein include delivering or administering a polynucleotide (e.g., an antibody expression cassette), a vector, a rAAV or a composition disclosed herein to an eye (e.g., one or both eyes) or near an eye (e.g., one or both eyes), such as intraocularly, post-orbitally or peri-orbitally, post-ocularly, intramuscularly near the eye (e.g., delivered or administered to the levator and / or procerus), delivered or administered to connective tissue near the eye or any combination thereof. In some aspects, periorbital or post-orbital tissue is selected from muscle, connective tissue and / or adipose tissue. In some aspects, administration is administration to an extraocular muscle. In some aspects, the extraocular muscle is a levator or procerus. In some aspects, administration is administration to connective tissue. In some aspects, administration is transconjunctival into the periorbital space. In some aspects, administration is intralymphatic administration to the preauricular or submandibular lymph nodes. In some aspects, delivery or administration is delivery or administration to retro-orbital or peri-orbital fibroblasts, adipocytes, myofibroblasts, myocytes, or any combination thereof. In some aspects, delivery or administration is by injection. In some aspects, delivery or administration is by infusion. In some aspects, delivery or administration is by injection and / or infusion in a single dose. In some aspects, single dose administration includes multiple injections or infusions.

[0579] In some aspects, the anti-IGF-1R antibody or antigen-binding fragment thereof is expressed in muscle, connective tissue, or adipose tissue. In some aspects, the anti-IGF-1R antibody or antigen-binding fragment thereof is produced in muscle, connective tissue, and adipose tissue.

[0580] In some aspects, the method comprises administering a gene therapy encoding an anti-IGF-1R antibody or an antigen-binding fragment thereof, the gene therapy comprising a nucleic acid sequence encoding an anti-IGF-1R antibody or an antigen-binding fragment thereof (e.g., tetumumab) comprising: (i) VH CDR1-3 (e.g., SEQ ID NO: 7-9, 10-12, or 13-15) and VL CDR1-3 (e.g., SEQ ID NO: 16-18, 19-21, or 22-24); (ii) VH (e.g., SEQ ID NO: 26 or 27) and VL (e.g., SEQ ID NO: 30 or 31); (iii) HC (e.g., SEQ ID NO: 36 or 37) and LC (e.g., SEQ ID NO: 40 or 41); or (iv) a nucleic acid sequence comprising SEQ ID NO: NO: 68-76 any one of the vector construct or expression construct (e.g., antibody expression cassette), wherein the vector construct or expression construct (e.g., antibody expression cassette) further comprises an IRES, a furin cleavage site, a 2a site, a dual promoter (e.g., promoter-VH-IRES-VL, etc.) or a signal peptide (e.g., IL-2 or IL-10 signal peptide) One or more.

[0581] In some aspects, the method comprises administering a gene therapy construct encoding an anti-IGF-1R antibody (e.g., tebuconazole) that is a polycistronic (e.g., bicistronic) construct (e.g., comprising a heavy chain and a light chain). In some aspects, the polycistronic (e.g., bicistronic) construct further comprises a F2A or IRES element.

[0582] In some aspects, the anti-IGF-1R antibody is teitutumumab, VRDN-01100 (SEQ ID NO: 113), VRDN-02700 (SEQ ID NO: 116), ganitutumumab (AMG 479), fentolumab, CP-751,871, citumumab (AMG655), IMC-A12, darototumumab, MK0646, RG1507, rotumumab, SCH 717454, AVE-1642a, MEDI-573, BIIB022, rhuMab IGFR, L1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11, L12H12, L13H13, L14H14, L15 H15, L16H16, L17H17, L18H18, L19H19, L20H20, L21H21, L22H22, L23H23, L24H24, L25H25, L26H26, L27H27, L28H28, L29H29, L30H30, L31H31, L32H32, L33H33, L34H34, L35H35, L36H36, L37H37, L38H38, L39H39, L40H40, L41H41, L42H42, L43H43, L44H44, L45H45, L47H47, L48H48, L49H49, L50H50, L51H51 or L52H52, or an antigen-binding fragment thereof.

[0583] In some aspects, the anti-IGF-1R antibody is VRDN-01100 or VRDN-02700, or an antigen-binding fragment thereof. In some aspects, the anti-IGFR antibody comprises SEQ ID NO: 113 (corresponding to VRDN-01100). In some aspects, the anti-IGFR antibody comprises SEQ ID NO: 116 (corresponding to VRDN-002700).

[0584] In some aspects, the anti-IGF-1R antibody is tetumumab, or an antigen-binding fragment thereof.

[0585] In some aspects, the disclosure relates to methods of delivering gene therapy to connective tissue (e.g., periorbital, retroorbital). In some aspects, gene therapy is administered periorbitally or retrobulbarly (e.g., by injection), and then the antibody or antigen-binding fragment thereof is produced in fibroblasts, myocytes, or adipocytes. In some aspects, the therapeutic effect of the anti-IGF-1R antibody or antigen-binding fragment thereof is local, systemic, or both.

[0586] In some aspects, the disclosure relates to a method of delivering gene therapy to a subject in need thereof, comprising administration by injection to a muscle, intralymphatic, periorbital or retrobulbar tissue, or other delivery sites disclosed herein. In some aspects, administration is administration to an extraocular muscle. In some aspects, the extraocular muscle is a levator muscle or an interocular muscle. In some aspects, administration is administration to connective tissue. In some aspects, administration is transconjunctival into the periorbital space. In some aspects, administration is intralymphatic administration to a preauricular or submandibular lymph node.

[0587] Some aspects of the present disclosure relate to methods of delivering a nucleic acid to cells of a subject, comprising administering an adeno-associated virus (AAV) capsid to fibroblasts, muscle cells, or adipocytes of the subject, the capsid comprising a nucleic acid comprising a promoter operably linked to a polynucleotide encoding an antibody (e.g., a monoclonal antibody) or an antigen-binding fragment thereof disclosed herein, thereby delivering the nucleic acid to the fibroblasts, muscle cells, or adipocytes of the subject.

[0588] In some aspects, the methods disclosed herein can be practiced by administering a gene therapy composition comprising a polynucleotide (e.g., an antibody expression cassette), a vector, a rAAV particle, or a composition of the present disclosure, a cell comprising a polynucleotide (e.g., an antibody expression cassette), a vector, or a rAAV particle of the present disclosure, a cell comprising a nucleic acid encoding an anti-IGF-1Rα antibody or antigen-binding fragment thereof of the present disclosure (the nucleic acid is integrated into its genomic DNA), or a pharmaceutical composition comprising any of the above. Therefore, the methods disclosed herein describing the administration of a polynucleotide (e.g., an antibody expression cassette), a vector, or a rAAV particle of the present disclosure can also be practiced by administering any of these compositions.

[0589] In some aspects, the methods disclosed herein can be practiced by administering a gene therapy composition comprising a nucleic acid encoding an antibody or antigen-binding fragment thereof that binds to insulin-like growth factor 1 receptor (IGF-1R) or an antigen-binding fragment thereof.

[0590] In some aspects, the methods disclosed herein can be practiced by administering a gene therapy composition comprising a nucleic acid encoding an antibody or antigen-binding fragment thereof comprising (i) a heavy chain variable region (VH) comprising a complementarity determining region (CDR) 1, VH CDR2, and VH CDR3 and (ii) a light chain variable region (VL) comprising CDR1, VL CDR2, and VL CDR3. In some aspects, VH CDR1-3 and VL CDR1-3 are from the corresponding CDRs of tebuconazole.

[0591] In some aspects, the methods disclosed herein can be practiced by administering a gene therapy composition comprising a nucleic acid encoding an anti-IGF-1Rα antibody or antigen-binding fragment thereof having an amino acid sequence identical to that of the following proteins: teitutumumab, VRDN-01100 (SEQ ID NO: 113), VRDN-02700 (SEQ ID NO: 116), ganitutumumab (AMG 479), fentolumab, CP-751,871, situmumab (AMG 655), IMC-A12, darotoxin, MK0646, RG1507, rotuximab, SCH717454, AVE-1642a, MEDI-573, BIIB022, rhuMabIGFR, L1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11, L12H12, L13H13, L14H14, L15H15, L16H16, L17H17, L18H18, L19H19, L20H20, L21H21, H38, L39H39, L40H40, L41H41, L42H42, L43H43, L44H44, L45H45, L46H46, L47H47, L48H48, L49H49, L50H50, L51H51 or L52H52, or variants thereof.

[0592] In some aspects, the methods disclosed herein can be implemented by administering a gene therapy composition comprising a nucleic acid encoding an anti-IGF-1R antibody or antigen-binding fragment thereof having an amino acid sequence identical to VRDN-01100 or VRDN-02700 or a variant thereof. In some aspects, the anti-IGFR antibody or antigen-binding fragment thereof comprises an amino acid sequence of SEQ ID NO: 113 (corresponding to VRDN-01100). In some aspects, the anti-IGFR antibody or antigen-binding fragment thereof comprises an amino acid sequence of SEQ ID NO: 116 (corresponding to VRDN-002700).

[0593] In some aspects, the methods disclosed herein can be practiced by administering a gene therapy composition comprising a nucleic acid encoding an anti-IGF-1R antibody or antigen-binding fragment thereof having the same amino acid sequence as telotumumab or a variant thereof.

[0594] Insulin growth factor (IGF) signaling is mediated by ligands IGF1 and IGF2 and receptors IGF-1R, IGF-2R and insulin receptor (IR). Downstream signaling from IGF-1R or IR is mediated by the adapter protein insulin receptor substrate-1 (IRS-1) binding to activated growth factor receptors to activate the phosphoinositide-3 kinase signaling pathway. It is believed that tetumumab causes IGF to activate IGF-1R and prevent downstream phosphorylation. In some aspects, administration of a gene therapy composition comprising an antibody expression cassette, AAV vector genome, or rAAV particle of the present disclosure can cause IGF to activate IGF-1R and prevent downstream phosphorylation.

[0595] Based on the methods disclosed herein, gene therapy compositions comprising an antibody expression cassette, AAV vector genome or rAAV particle of the disclosure for use in treating, as a medicament or for treating a disease or condition in a subject in need thereof are contemplated. In some aspects, the disease or condition to be treated is Graves' orbitopathy.

[0596] Cells isolated from the peripheral blood of patients with Graves' disease are known to express several proinflammatory cytokines, including IL-1β, IL-1 receptor antagonist, IL-6, IL-8, and TNFα, and appear to infiltrate and adhere to orbital tissues through stimulation by TSH (Chen, H., et al., (2014). Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. The Journal of Clinical Endocrinology & Metabolism, 99(9), E1635-E1640). Studies have reported that fibroblasts isolated from Graves' disease patients and treated with teprotumumab in vitro attenuated the expression levels and signaling pathways of IGF-1 and TSH receptors (Pritchard, J., et al., (2003). Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. The Journal of Immunology, 170(12), 6348-6354; Smith, TJ, et al., (2008). Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid, 1...

Claims

1. A recombinant adeno-associated virus (rAAV) particle comprising a capsid and a vector genome, wherein the vector genome comprises an inverted terminal repeat sequence (ITR) and an antibody expression cassette, wherein the antibody expression cassette comprises (a) a promoter, (b) a nucleic acid sequence encoding a heavy chain variable region (VH) of an anti-insulin-like growth factor 1 receptor (anti-IGF-1R) antibody or an antigen-binding fragment thereof, and (c) a nucleic acid sequence encoding a light chain variable region (VL) of an anti-IGF-1R antibody or an antigen-binding fragment thereof.

2. The rAAV particle of claim 1, wherein the nucleic acid sequence encoding the VH of the anti-IGF-1R antibody or antigen-binding fragment thereof comprises: (i) a nucleic acid encoding a VH complementarity determining region (CDR) 1 comprising a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:7 or 10, (ii) a nucleic acid encoding a VH CDR2 comprising a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO:8, 11, or 14, and (iii) a nucleic acid encoding a VH CDR3 comprising a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: NO:9, 12 or 15 having a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical; and the nucleic acid sequence encoding the VL of the anti-IGF-1R antibody or antigen-binding fragment thereof comprises: (i) a nucleic acid sequence comprising a VL CDR1 comprising a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:16, (ii) a nucleic acid sequence comprising a VL CDR2 comprising a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:17 NO:17, 20 or 23 having a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical, and (iii) a nucleic acid sequence comprising a VL CDR3, which comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:18, 21 or 24.

3. A vector comprising an antibody expression cassette, the antibody expression cassette comprising: (a) Promoter; (b) a nucleic acid sequence encoding a heavy chain variable region (VH) of an anti-insulin-like growth factor 1 receptor (anti-IGF-1R) antibody or an antigen-binding fragment thereof, comprising: (i) a nucleic acid encoding a VH complementarity determining region (CDR) 1 comprising a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 7 or 10, (ii) a nucleic acid encoding a VH CDR2 comprising a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 8, 11 or 14, and (iii) a nucleic acid encoding a VH a nucleic acid of a CDR3 comprising a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 9, 12 or 15; (c) a nucleic acid sequence encoding a light chain variable region (VL) of an anti-IGF-1R antibody or antigen-binding fragment thereof, comprising: (i) a nucleic acid sequence comprising a VL CDR1 comprising a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 16, (ii) a nucleic acid sequence comprising a VL CDR2 comprising a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 17, 20, or 23, and (iii) a nucleic acid sequence comprising a VL CDR3 comprising a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: NO:18, 21 or 24 has a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical.

4. The rAAV particle or vector of any of the preceding claims, wherein the antibody expression cassette comprises a signal peptide.

5. The rAAV particle or vector of any of the preceding claims, wherein the antibody expression cassette comprises a linker sequence selected from an internal ribosome entry site (IRES) sequence, a proteolytic cleavage site, or a combination thereof.

6. The rAAV particle or vector of claim 5, wherein the proteolytic cleavage site comprises a furin cleavage site, a 2A cleavage site, or a combination thereof.

7. The rAAV particle or vector of claim 5, wherein the antibody expression cassette comprises a promoter, a nucleic acid sequence encoding VH, an IRES, and a nucleic acid sequence encoding VL in the 5'-3' direction.

8. The rAAV particle or vector of claim 5, wherein the antibody expression cassette comprises, in the 5'-3' direction, a promoter, a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding VH, an IRES, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding VL.

9. The rAAV particle or vector of claim 5, wherein the antibody expression cassette comprises a promoter, a nucleic acid sequence encoding VL, an IRES, and a nucleic acid sequence encoding VH in the 5'-3' direction.

10. The rAAV particle or vector of claim 5 or 6, wherein the antibody expression cassette comprises a promoter, a nucleic acid sequence encoding VH, a proteolytic cleavage site, and a nucleic acid sequence encoding VL in the 5'-3' direction.

11. The rAAV particle or vector of claim 5 or 6, wherein the antibody expression cassette comprises, in the 5'-3' direction, a promoter, a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding VH, a proteolytic cleavage site, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding VL.

12. The rAAV particle or vector of claim 5 or 6, wherein the antibody expression cassette comprises a promoter, a nucleic acid sequence encoding VL, a proteolytic cleavage site, and a nucleic acid sequence encoding VH in the 5'-3' direction.

13. The rAAV particle or vector of claim 5 or 6, wherein the antibody expression cassette comprises, in the 5'-3' direction, a promoter, a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding VL, a proteolytic cleavage site, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding VH.

14. The rAAV particle or vector of any one of claims 4 or 6-10, wherein the IRES comprises a nucleic acid having a sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:

43.

15. The rAAV particle or vector of any one of claims 4-5 and 11-14, wherein the proteolytic cleavage comprises a furin cleavage site comprising a nucleic acid having a sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:

44.

16. The rAAV particle or vector of any one of claims 4-5 and 11-149, wherein the proteolytic cleavage includes a 2A cleavage site comprising a nucleic acid having a sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:

45.

17. The rAAV particle or vector of any of the preceding claims, wherein the signal peptide is an IL-2 or IL-10 signal peptide.

18. The rAAV particle or vector of claim 17, wherein the signal peptide comprises an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 119 or 120.

19. The rAAV particle or vector of claim 17 or 18, wherein the signal peptide is encoded by a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 121 or 122.

20. The rAAV particle or vector of any of the preceding claims, wherein the antibody expression cassette comprises a second promoter.

21. The rAAV particle or vector of claim 20, wherein the antibody expression cassette comprises a promoter (first promoter), a nucleic acid sequence encoding VL, a second promoter, and a nucleic acid sequence encoding VH in the 5'-3' direction.

22. The rAAV particle or vector of claim 20, wherein the antibody expression cassette comprises a promoter (first promoter), a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding VL, a second promoter, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding VH in the 5'-3' direction.

23. The rAAV particle or vector of claim 20, wherein the antibody expression cassette comprises a promoter (first promoter), a nucleic acid sequence encoding VH, a second promoter, and a nucleic acid sequence encoding VL in the 5'-3' direction.

24. The rAAV particle or vector of claim 20, wherein the antibody expression cassette comprises a promoter (first promoter), a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding VH, a second promoter, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding VL in the 5'-3' direction.

25. The rAAV particle or vector of claim 20, wherein the antibody expression cassette comprises, in the 5'-3' direction, a nucleic acid sequence encoding VH, a promoter (first promoter), a second promoter, and a nucleic acid sequence encoding VL.

26. The rAAV particle or vector of claim 20, wherein the antibody expression cassette comprises in the 5'-3' direction a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding VH, a promoter (first promoter), a second promoter, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding VL.

27. The rAAV particle or vector of claim 20, wherein the antibody expression cassette comprises, in the 5'-3' direction, a nucleic acid sequence encoding VL, a promoter (first promoter), a second promoter, and a nucleic acid sequence encoding VH.

28. The rAAV particle or vector of claim 20, wherein the antibody expression cassette comprises, in the 5'-3' direction, a nucleic acid sequence encoding a first signal peptide, a nucleic acid sequence encoding VL, a promoter (first promoter), a second promoter, a nucleic acid sequence encoding a second signal peptide, and a nucleic acid sequence encoding VH.

29. The rAAV particle or vector of any of the preceding claims, wherein the promoter and / or the second promoter is a constitutively active promoter, a cell type-specific promoter, a synthetic promoter, or an inducible promoter.

30. The rAAV particle or vector of any of the preceding claims, wherein the promoter and / or the second promoter is a CBA promoter, a CMV promoter (optionally, a human CMV promoter or a mouse CMV promoter), an EF1α promoter, a CAG promoter or a tissue-specific promoter.

31. The rAAV particle or vector of any of the preceding claims, wherein the promoter comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any of SEQ ID NOs:47-51, 83 or 93.

32. The rAAV particle or vector of any one of claims 1-30, wherein the promoter is a muscle-specific promoter.

33. The rAAV particle or vector of claim 32, wherein the muscle-specific promoter is selected from the group consisting of a desmin (DES) promoter, a human skeletal muscle α-actin (HSA) promoter, a myosin creatine kinase (MCK) promoter, an α-myosin heavy chain myosin creatine kinase 7 (HMCK7) promoter, a double MCK enhancer MCK (dMCK) promoter, a triple MCK enhancer MCK (tMCK) promoter, a double MCK enhancer muscle creatine kinase 8e (CK8e) promoter, an SPc5-12 promoter, an SP-301 promoter, an α-myosin heavy chain (MHC) promoter, a Sk-CRM promoter, or a Sk-CRM4 promoter.

34. The rAAV particle or vector of any of the preceding claims, wherein the antibody expression cassette comprises an intron.

35. The rAAV particle or vector of claim 34, wherein the intron is a CAG intron, an SV40 intron, an MVM intron, or a human β-globin intron, or any combination thereof.

36. The rAAV particle or vector of claim 34 or 35, wherein the intron comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:46 or 82.

37. The rAAV particle or vector of any of the preceding claims, wherein the promoter comprises a first promoter and a second promoter that are different.

38. The rAAV particle or vector of claim 37, wherein the first promoter and the second promoter initiate transcription in the same direction.

39. The rAAV particle or vector of claim 37, wherein the first promoter and the second promoter initiate transcription in different directions.

40. The rAAV particle or vector of claim 37, wherein the antibody expression cassette comprises a pause element between the first promoter and the second promoter.

41. The rAAV particle or vector of claim 40, wherein the pause element comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:

54.

42. The rAAV particle or vector of any of the preceding claims, wherein the anti-IGF-1R antibody is a monoclonal antibody.

43. The rAAV particle or vector of any of the preceding claims, wherein VH CDR1-3 correspond to the CDRs of tefixime.

44. The rAAV particle or vector of any of the preceding claims, wherein VL CDR1-3 correspond to the CDRs of tefixime.

45. The rAAV particle or vector of any one of the preceding claims, wherein the anti-IGF-1R antibody is tefiximab.

46. ​​The rAAV particle or vector of any of the preceding claims, wherein the nucleic acid sequence encoding VH comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 25-27.

47. The rAAV particle or vector of any of the preceding claims, wherein the nucleic acid sequence encoding VL comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 29-31.

48. The rAAV particle or vector of any of the preceding claims, wherein the nucleic acid sequence encoding the heavy chain (HC) comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs:35-37.

49. The rAAV particle or vector of any of the preceding claims, wherein the nucleic acid sequence encoding the light chain (LC) comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs:39-41.

50. The rAAV particle or vector of any of the preceding claims, wherein the anti-IGF-1R antibody is tefiximab.

51. The rAAV particle or vector of any of the preceding claims, wherein the antibody expression cassette comprises a poly(A) sequence.

52. The rAAV particle or vector of claim 51, wherein the poly(A) sequence is selected from bGHpA, hGHpA, SV40pA or synthetic pA.

53. The rAAV particle or vector of claim 51 or 52, wherein the poly(A) comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:52 or 53.

54. The rAAV particle or vector of any of the preceding claims, wherein the antibody expression cassette comprises an open reading frame (ORF) comprising a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any of SEQ ID NOs: 57-67 and 94-97.

55. The AAV particle or vector of any of the preceding claims, wherein the antibody expression cassette comprises a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs:68-76.

56. The vector of any one of claims 3-46, comprising an inverted terminal repeat (ITR).

57. The rAAV or vector of any of the preceding claims, wherein the AAV ITR comprises a pair of ITRs flanking an antibody expression cassette.

58. The rAAV particle or vector of claim 48, wherein the ITRs are of the same serotype as each other.

59. The rAAV particle or vector of claim 49, wherein the ITRs are of the AAV2 serotype.

60. The vector of any one of claims 3-59, wherein the vector is packaged in an AAV capsid.

61. The rAAV particle or vector of any of the preceding claims, wherein the AAV capsid serotype is selected from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVRh8, AAVrh9, AAV9, AAVrh10, AAV10, AAV11, AAV12, and modified forms thereof.

62. The rAAV particle or vector of any of the preceding claims, wherein the AAV capsid serotype is selected from AAV1, AAV2, AAV6, AAV8, AAV9, and modified forms thereof.

63. A host cell comprising the rAAV particle or vector of any one of the preceding claims.

64. A composition comprising the rAAV particle or vector of any of the preceding claims and a carrier.

65. The composition of claim 64, wherein the carrier is water or saline.

66. A method of expressing an anti-IGF-1R antibody or an antigen-binding fragment thereof in a cell, comprising administering to the cell the rAAV particle, vector or composition of any one of the preceding claims, thereby expressing the anti-IGF-1R antibody or an antigen-binding fragment thereof in the cell.

67. The method of claim 66, wherein the cell is a fibroblast, an adipocyte, a myofibroblast, a myocyte, a muscle cell, or any combination thereof.

68. The method of claim 66 or 67, wherein said administering is performed in vitro.

69. The method of claim 66 or 67, wherein said administering is performed in vivo.

70. A method of expressing an anti-IGF-1R antibody or an antigen-binding fragment thereof in a subject in need thereof, comprising administering to the subject the rAAV particle, vector or composition of any of the preceding claims, thereby expressing the anti-IGF-1R antibody or antigen-binding fragment thereof in the subject.

71. The method of claim 70, wherein the subject has a thyroid eye disease selected from active Graves' orbitopathy and chronic Graves' orbitopathy.

72. A method of treating thyroid eye disease in a subject in need thereof, comprising administering to the subject the rAAV particle, vector or composition of any of the preceding claims, thereby expressing an anti-IGF-1R antibody or antigen-binding fragment thereof in the subject and treating the thyroid eye disease.

73. The method of claim 72, wherein the thyroid eye disease is selected from the group consisting of active Graves' orbitopathy and chronic Graves' orbitopathy.

74. The method of any one of claims 72-73, wherein the administration is suitable for delivering the rAAV particles or vectors to an ocular delivery site, a retro-orbital or peri-orbital delivery site, a retrobulbar delivery site, an extraocular muscle delivery site, a connective tissue delivery site, or any combination of their delivery sites.

75. The method of any one of claims 72-74, wherein the administering is by injection or infusion.

76. The method of any one of claims 72-75, wherein the administration is intramuscular (IM), intravenous (IV), intralymphatic, intraocular, retro-orbital, peri-orbital, retrobulbar, or any combination thereof.

77. The method of any one of claims 72-76, wherein the administering is suitable for delivery to retro-orbital or peri-orbital fibroblasts, adipocytes, myofibroblasts, myocytes, or any combination thereof.

78. The method of any one of claims 72-77, wherein the administration is to an extraocular muscle.

79. The method of claim 78, wherein the extraocular muscle is the levator or glabellar muscles.

80. The method of any one of claims 72-77, wherein the administration is to connective tissue.

81. The method of any one of claims 72-77, wherein the administering is through the conjunctiva into the periorbital space.

82. The method of any one of claims 72-77, wherein the administration is intralymphatic administration, including injection or infusion into the preauricular or submandibular lymph nodes.

83. The method of any one of claims 72-82, wherein the administration is a single dose.

84. The method of claim 83, wherein the single dose is multiple injections and / or infusions.